var title_f10_57_11152="Herpes keratitis fluorescein stain";
var content_f10_57_11152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fluorescein staining patterns in a case of herpes keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fine branching elements distinguish this from the linear or geographic pattern of a traumatic corneal abrasion, although the clinical presentations may be quite similar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11152=[""].join("\n");
var outline_f10_57_11152=null;
var title_f10_57_11153="Throwing phases";
var content_f10_57_11153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Phases of throwing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Throwing athletes suffer from a unique form of shoulder impingement. It involves the superior and posterior labrum and rotator cuff, and occurs during the cocking phase of throwing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11153=[""].join("\n");
var outline_f10_57_11153=null;
var title_f10_57_11154="Patient information: Preserving fertility after cancer treatment in men (The Basics)";
var content_f10_57_11154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83956\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"         Male reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/42/40610\">",
"         Patient information: Infertility in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/51/31538\">",
"         Patient information: Testicular cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/4/24645\">",
"         Patient information: Testicular cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preserving-fertility-after-cancer-treatment-in-men-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H197558060\">",
"      <span class=\"h1\">",
"       What is fertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fertility is the term doctors use to describe a man&rsquo;s ability to father a child. &ldquo;Preserving fertility after cancer treatment&rdquo; involves doing things before or during cancer treatment to raise a man&rsquo;s chances of being able to father a child later on.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197558075\">",
"      <span class=\"h1\">",
"       Which cancer treatments can cause fertility problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer treatments that can cause fertility problems include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation involves getting high doses of X-rays.",
"       </li>",
"       <li>",
"        Surgery &ndash; If both testicles (male sex organs) are removed, a man no longer makes sperm (",
"        <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"         figure 1",
"        </a>",
"        ). Then he is not able to father a child. (If only 1 testicle is removed, a man might still be able to father a child.) Also, surgery near the testicles and penis sometimes damages nearby nerves. Nerve damage can make it hard for men to ejaculate. If ejaculation doesn&rsquo;t happen, sperm can&rsquo;t exit the penis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Both chemotherapy and radiation can damage the testicles. As a result, the testicles make no sperm, too little sperm, or unhealthy sperm. This is a problem because a man needs to have a normal number of healthy sperm to get a woman pregnant.",
"     </p>",
"     <p>",
"      Not everyone who gets chemotherapy or radiation will have fertility problems. With chemotherapy, it depends on the medicine and dose a person gets. With radiation, it depends on the dose and part of the body treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197558113\">",
"      <span class=\"h1\">",
"       What should I do if I want to father a child someday?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should let your doctor know",
"      <strong>",
"       BEFORE",
"      </strong>",
"      you start your cancer treatment. In some cases, treatment that has a lower chance of affecting future fertility might be available.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197558128\">",
"      <span class=\"h1\">",
"       Are there other ways to preserve fertility?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The main things that can be done to help men preserve their fertility are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Sperm banking &ndash; This involves collecting and freezing your sperm before you start cancer treatment. To collect your sperm, you will need to ejaculate. If you can&rsquo;t ejaculate, or if there is no sperm in your semen, your doctor can do a procedure to remove sperm from your testicle. After the sperm is collected, it is frozen and stored until needed.",
"       </li>",
"       <li>",
"        Shielding your testicles during radiation treatment &ndash; This involves wearing a special shield on the outside of your body during radiation treatment. The shield covers and protects your testicles, so they aren&rsquo;t damaged by the radiation.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197558143\">",
"      <span class=\"h1\">",
"       How do I decide which option is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best way to preserve your fertility depends on your cancer, treatment, age, and individual situation. Talk with your doctor about your choices. To make your decision, you might want to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The benefits and downsides of the choices",
"       </li>",
"       <li>",
"        How well your doctor thinks they will work",
"       </li>",
"       <li>",
"        How much they cost &ndash; For example, it costs money to collect, freeze, and store sperm. Health insurance sometimes pays for these things.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197558160\">",
"      <span class=\"h1\">",
"       What if I still can&rsquo;t father a child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you still can&rsquo;t father a child after cancer treatment, you have other options. You and your partner can try to have a baby using another man&rsquo;s sperm from a sperm bank. In addition, adoption might be an option.",
"     </p>",
"     <p>",
"      Couples can have a tough time making these decisions. You might find it helpful to talk to a counselor or go to a support group for people who are facing the same issues.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197558175\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/51/31538?source=see_link\">",
"       Patient information: Testicular cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=see_link\">",
"       Patient information: Infertility in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24645?source=see_link\">",
"       Patient information: Testicular cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/57/11154?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83956 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11154=[""].join("\n");
var outline_f10_57_11154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558060\">",
"      What is fertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558075\">",
"      Which cancer treatments can cause fertility problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558113\">",
"      What should I do if I want to father a child someday?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558128\">",
"      Are there other ways to preserve fertility?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558143\">",
"      How do I decide which option is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558160\">",
"      What if I still can&rsquo;t father a child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197558175\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"      Male reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=related_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24645?source=related_link\">",
"      Patient information: Testicular cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/51/31538?source=related_link\">",
"      Patient information: Testicular cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_57_11155="Delirium";
var content_f10_57_11155=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Delirium (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/57/11155/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11155/contributors\" id=\"au4265\">",
"       Joseph Francis, Jr, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11155/contributors\" id=\"au7251\">",
"       G Bryan Young, MD, FRCPC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/57/11155/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11155/contributors\" id=\"se7072\">",
"       Michael J Aminoff, MD, DSc",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11155/contributors\" id=\"se1605\">",
"       Kenneth E Schmader, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/57/11155/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11155/contributors\" id=\"de4290\">",
"       Janet L Wilterdink, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/57/11155?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DELIRIUM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Delirium is a sudden and severe change in brain function that causes a person to appear confused, disoriented, or to have difficulties maintaining focus, thinking clearly, and remembering recent events, typically with a fluctuating course. Delirium can be triggered by a serious medical illness such as an infection, certain medications, and other causes, such as drug withdrawal or intoxication. Older patients, over 65 years, are at highest risk for developing delirium. People with previous brain disease or brain damage are also at risk. Some patients become agitated, while others may be quietly confused.",
"    </p>",
"    <p>",
"     Delirium is very common in intensive care units and on cancer wards, but can be found on any ward throughout the hospital and in nursing homes and can appear in private homes, especially in high risk patients (see below).",
"    </p>",
"    <p>",
"     Delirium is distinct from dementia because it develops suddenly, over hours to days, rather than months to years. And unlike dementia, delirium is usually temporary, resolving when the underlying cause is addressed promptly. Delirium also differs from the psychosis of psychiatric disease, in which orientation, concentration and attention are usually less impaired. However, these features are not always reliable",
"    </p>",
"    <p>",
"     The goal of treatment is to address the cause of delirium when possible and to keep the person safe.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DELIRIUM CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     It is not clear why or how delirium develops. There are many potential causes, with the most common including infections, medications, and organ failure (such as severe lung or liver disease). The underlying infection or condition is not necessarily a brain problem.",
"    </p>",
"    <p>",
"     As examples:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A urinary tract infection or dehydration can cause delirium in certain people.",
"      </li>",
"      <li>",
"       The time after surgery (called the postoperative period) is a common time for delirium to develop, especially in older people. This may be related to pain or the use of anesthesia or pain medications.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain underlying conditions increase the risk of delirium:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Advanced age",
"      </li>",
"      <li>",
"       Underlying brain diseases such as dementia, stroke, or Parkinson disease, particularly when there are current problems with memory",
"      </li>",
"      <li>",
"       Use of multiple medications (particularly psychiatric drugs and sedatives), or multiple medical problems",
"      </li>",
"      <li>",
"       Frailty, malnutrition, immobility",
"      </li>",
"      <li>",
"       Advanced cancer",
"      </li>",
"      <li>",
"       Undertreated pain",
"      </li>",
"      <li>",
"       Immobilization, including physical restraints",
"      </li>",
"      <li>",
"       Use of bladder catheters",
"      </li>",
"      <li>",
"       Limb fractures",
"      </li>",
"      <li>",
"       Interventions, including diagnostic tests",
"      </li>",
"      <li>",
"       Poor eyesight or hearing",
"      </li>",
"      <li>",
"       Sleep deprivation",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      How common is delirium?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nearly 30 percent of older patients experience delirium at some time during hospitalization; the incidence is higher in intensive care units. Among older patients who have had surgery, the risk of delirium varies from 10 to greater than 50 percent",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DELIRIUM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Delirium is not a disease, but rather a group of symptoms. The key features include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       There are abnormal changes in the person's level of consciousness and thinking. The person may be sleepy (hypoactive delirium) or agitated (hyperactive delirium), or alternate between these states. The changes may be subtle initially.",
"      </li>",
"      <li>",
"       The person often has difficulty maintaining focus.",
"       <span class=\"nowrap\">",
"        He/she",
"       </span>",
"       may change the subject frequently in a conversation, have difficulty retaining new information, mention strange ideas, be disoriented, or even have visual hallucinations.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These changes develop over a short period of time (hours to days) and tend to become intermittently worse, especially in the afternoon and evening. This sudden change helps to differentiate delirium from dementia, which worsens slowly over months to years. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"      \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      DELIRIUM EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     Delirium may be difficult to recognize because changes in behavior may be attributed to the person's age, history of dementia, or other mental disorders. In addition, the symptoms can come and go, such that a person has no or few symptoms early in the day but progressively worsens late in the day or in the evening.",
"    </p>",
"    <p>",
"     If a caregiver or family member suspects that their relative has delirium, it is important that the person is evaluated promptly to identify the underlying cause and begin treatment if possible. Some life-threatening conditions can cause delirium, so it is important to be evaluated quickly. If the person is hospitalized, the evaluation may be done by the attending physician or team. If the person is at home, the patient should see their primary care provider or go to the emergency department.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Laboratory testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     urine tests may be performed to determine the cause of the person's delirium.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the cause of a person's delirium cannot be determined based upon the history, physical examination, and laboratory testing, a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the head may be recommended. This test can help to determine if an abnormal growth, bleeding, infection, or inflammation is present in the brain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Lumbar puncture",
"     </span>",
"     &nbsp;&mdash;&nbsp;During a lumbar puncture, or spinal tap, a clinician uses a needle to remove a sample of spinal fluid from the area around the spinal cord in the low back. Several tests are done on the fluid to determine if a bacterial infection (such as meningitis) could be causing delirium, and if so, which antibiotic treatment is best.",
"    </p>",
"    <p>",
"     Lumbar puncture is not recommended for every person with delirium. It may be performed if other tests are unable to determine the cause.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      EEG testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electroencephalography (EEG) measures the electrical activity in the brain. It may be performed in a person with delirium to search for abnormal electrical activity that is commonly associated with seizures and epilepsy. It is not recommended for all people with delirium, but it may be performed if other tests are unable to determine the cause.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      DELIRIUM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no specific treatment for delirium. Instead, treatment focuses on several basic principles:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Avoid factors known to cause or aggravate delirium, such as certain medications",
"      </li>",
"      <li>",
"       Identify and treat the underlying illness",
"      </li>",
"      <li>",
"       Provide supportive and restorative care",
"      </li>",
"      <li>",
"       Control dangerous and disruptive behaviors to avoid harm to the patient or others",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In people with a first episode of delirium, the initial treatment is often provided in a hospital setting. This allows the healthcare provider to monitor the patient, begin treatment of the underlying problem, and develop a long-term care plan with the patient",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     family.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Supportive care",
"     </span>",
"     &nbsp;&mdash;&nbsp;The goal of supportive care is to maintain the patient's health, prevent additional complications, and to avoid those factors that can aggravate delirium. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Making sure the person gets enough to eat and drink (or providing nutrition through an IV, if needed).",
"      </li>",
"      <li>",
"       Treating pain and avoiding discomfort, including avoiding constipation. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"        \"Patient information: Constipation in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Minimizing the use of restraints and bladder catheters, which can be uncomfortable, particularly to confused patients.",
"      </li>",
"      <li>",
"       Encouraging movement and assistance in doing so.",
"      </li>",
"      <li>",
"       Having someone help during meals and having the person sit upright to minimize the risk of inhaling food, drinks,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       saliva, which can lead to pneumonia.",
"      </li>",
"      <li>",
"       Maintaining a regular",
"       <span class=\"nowrap\">",
"        night-day/sleep-wake",
"       </span>",
"       cycle when possible and avoiding sleep deprivation, and maintaining a reassuring and familiar environment with one or two visiting family members or familiar",
"       <span class=\"nowrap\">",
"        objects/pictures",
"       </span>",
"       from home.",
"      </li>",
"      <li>",
"       Avoiding overstimulation (eg, multiple visitors, loud noise), which can worsen delirium, but also avoiding understimulation (darkened room, complete silence).",
"      </li>",
"      <li>",
"       Making hearing aids and eyeglasses available at the hospital if the patient uses these at home.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Managing behaviors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people with delirium have disruptive behaviors, potentially causing them to harm themselves or others. The person may say or do things that are obscene or offensive, but such behaviors do not reflect the person's true beliefs. The person may also be at risk for falling, wandering off, or inadvertently removing intravenous lines.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Sitter",
"     </span>",
"     &nbsp;&mdash;&nbsp;Allowing a family member or other caregiver to stay with the patient at the bedside may help to manage the patient's behavior. This person can provide reassurance, answer questions, and notify staff if the person needs assistance. In some cases, the hospital is able to provide a sitter if a family member is unavailable. However, a familiar and trusted family member or friend can provide additional reassurance to the patient.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications to control difficult behavior are only to be considered as a last resort, if the patient&rsquo;s agitation is so extreme as to be a potential source of harm. Some classes of drugs, especially sedatives such as lorazepam (Ativan&reg;) and diazepam (Valium&reg;), can build up in the bloodstream and cause the person to become more confused. Antipsychotic medications, such as haloperidol (Haldol&reg;), may be considered, but only in small doses and for short periods of time. If necessary, these medications should be stopped frequently, with direction or approval by the physician, so that the patient can be reevaluated. Antipsychotic medications are not recommended for long-term treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Restraints",
"     </span>",
"     &nbsp;&mdash;&nbsp;The use of restraints (to tie a person to their bed or chair) is almost never appropriate, as restraints can increase agitation and create additional problems by preventing the person from moving around as needed. Preventing movement also potentially allows skin sores (called pressure ulcers) to develop from sitting or lying in the same position for long periods.",
"    </p>",
"    <p>",
"     However, in the rare situation where the patient is at high risk for harm and restraints are applied, hospital staff should monitor the patient at least every two hours, untying the restraints and changing the patient's position. The restraints should be removed as soon as possible.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      DELIRIUM RECOVERY",
"     </span>",
"    </p>",
"    <p>",
"     Delirium has an enormous impact upon the health of older people. Patients with delirium experience prolonged hospitalizations, a decreased ability to function independently, and are at high risk for requiring care in a long-term care facility (eg, nursing home).",
"    </p>",
"    <p>",
"     Delirium can be frightening for the patient, as well as for the caregiver or family. Caregivers may feel exhausted and frustrated because of the time and other resources required to take care of a person with delirium.",
"    </p>",
"    <p>",
"     Delirium can sometimes resolve within hours to days. In other cases, it takes weeks or months to fully resolve. For this reason, it is important for caregivers to discuss the patient's short and long-term needs with a healthcare provider. Even patients that appear to have recovered from delirium may have trouble remembering medications and self-care instructions. Once the person is released from the hospital, additional assistance from family members or a home health nurse may be needed to assure a safe transition to home. In some cases, a rehabilitation or subacute care facility may be needed until the person has recovered and is able to care for",
"     <span class=\"nowrap\">",
"      him/herself.",
"     </span>",
"     If the person is unlikely to be able to care for",
"     <span class=\"nowrap\">",
"      him/herself",
"     </span>",
"     again, then ongoing formal home-based services, or an assisted living facility or nursing home may be required.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287367929\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248134230\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/54/8034?source=see_link\">",
"      Patient information: Delirium (confusion) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=see_link\">",
"      Patient information: Disseminated intravascular coagulation (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248134238\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"      Anticholinergic poisoning",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=see_link\">",
"      Dementia and delirium in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=see_link\">",
"      Evaluation of abnormal behavior in the emergency department",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=see_link\">",
"      Management of comorbid problems associated with Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/58/33706?source=see_link\">",
"      Medical consultation for patients with hip fracture",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5831?source=see_link\">",
"      Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10394?source=see_link\">",
"      Perioperative care of the surgical patient with neurologic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11322?source=see_link\">",
"      Psychiatric illness in dialysis patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/MEDLINEPLUS/ency/article/000740.htm\">",
"      www.nlm.nih.gov/MEDLINEPLUS/ency/article/000740.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/pdq/supportivecare/delirium/Patient\">",
"      www.cancer.gov/cancertopics/pdq/supportivecare/delirium/Patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/health/delirium/DS01064\">",
"      www.mayoclinic.com/health/delirium/DS01064",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/57/11155/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/57/11155?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11155/abstract/1\">",
"      McNicoll L, Pisani MA, Zhang Y, et al. Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc 2003; 51:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11155/abstract/2\">",
"      Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc 2008; 56:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11155/abstract/3\">",
"      Inouye SK, Zhang Y, Jones RN, et al. Risk factors for delirium at discharge: development and validation of a predictive model. Arch Intern Med 2007; 167:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11155/abstract/4\">",
"      Pisani MA, Murphy TE, Van Ness PH, et al. Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med 2007; 167:1629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_57_11155=[""].join("\n");
var outline_f10_57_11155=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DELIRIUM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DELIRIUM CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DELIRIUM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           DELIRIUM EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           DELIRIUM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           DELIRIUM RECOVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_57_11156="APL bone marrow aspirate II";
var content_f10_57_11156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bone marrow aspirate from a patient with acute promyelocytic leukemia (APL)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with acute promyelocytic leukemia. The cytoplasm of these promyelocytes contains densely-packed bright pink, reddish-blue or dark purple granules. Note the cell on the bottom left with a single Auer rod.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11156=[""].join("\n");
var outline_f10_57_11156=null;
var title_f10_57_11157="Taking infundibulopelvic ligamt";
var content_f10_57_11157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Creation of a window in the posterior peritoneum during gynecologic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAdoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio7ieG2haW5ljhiXq8jBVH4mgCSioYbq3nYLDPFIxQSAI4J2nIDcdjg8+1TUAFFFFABRRRQAUUUUAFFQS3trDdwWstzClzPnyoWkAeTAydq9TgdcUtxdW9tj7TPFDlWYeY4XhRljz2A5PpQBNRSKwZQykEEZBHehmCKWYhR6k4oAWiiigAoopgmiM5hEiecFDmPcNwUkgHHpkHn2oAfRRRQAUUUxJo3lkiSRGkjxvQMCVz0yO2aAH0UUUAFAIPTmquqX0Gmadc3124S3t4zI7E44ArnpPFGnaff3UTSxRwW1gLt0+YOpO58En5Pu84zn8KAOrorL0/XbG/XTjaymT7db/aYSg3rswDksOB14555xVyC9tp7u5toZ4nuLYqJo1cFoywyu4dRkc80AWKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV8VxbfEWh315Zz3mlW6XCyJFA05jnby/KkMagscKsq5AON/411VUNd1a10TTZL6/crCjKgAxlmZgqqM8ZJIHOAOpIGTQBwOqCWLULy60XR7+Cxns7eEeVbTQGPN3MZH2RgSd9xVcMQ+TjJNQWKeIryygguZ9ZEcVpqrLIkc1uzuk0Itd24l87S5UMxLAHO7mupTx1ps0EbWtveXM7mYG3hVGdDFtLgtu2cB1OQxBzxk8VHf+NYS1kNHt5buKa6tIJbgqBFEJyhAOWDbtjq3AIGRnGaAOb1G61fTI2+03OrpbXC6Q8smJHfzZZ5VuEjwCQdojyiD5cjAGa6jRJtSg8H6nN9nvrqSNrl7CCdmS4liBYxKxf5gx6AtzgrnnNX/ABHq1lYyW9vdWU1/MVa7WGGJZDGsRUmX5iB8pZcY+Yn7oOKqaF4in1rxNqFtaxAaVaRxlZ/Lz5zPGkgYNu4GHHG055OR0oA47T5tdWSWKZ9afRDc2zzvHbXaTLG0c29YzITMf3iwBiuCAzEBc1p3kOtyvrM+k3WuCG20+I2MUqlTK7eaHOHXc0gXbgMeu3cK1b3xmF1SGGztJGsiLsNdyABHaBTuCYO7hgQSVwccZq/Y+K9PuYocmQXD3ENr5QQ5MkkSyggdSuwls+it6GgDktQbVDYXJsJ9bXTEvFNulxDeedOvk/MhZF89E34YMQeQR90gVa8PXOst4rsnvINVaO4jUyxzGZFsB9nBKMdvkzfOCNykPufphTi5c+OwdGtbmwtHuZ5BaPMyD91As0qoNxJViSCxAAJHGQAauN4/0KO8uoZZ2SOAT/vjtKuYc+YoUEvkbW6qAcHaTQBk+JbO9g8U6/qltbajNjTLCGIQPIqnM9wspGzliiMrlV+b05YVz1za63e6Vcxzw6jdrCupxW7yWsyM0b2q7BiQs/LsyjcSSRj2Honh3XbjVtV1e2nsZbJbMw7Em2+YQ6bsnazD9frzUC+MrGV3S1s9RuJftUllGqQbfOmjaQOqMxCkL5TktkDtnPFAGHpzawmvWyONUW5W8VShST7ILLyB3xs3bvffu4+7XP6bd6zqfhuG4sm1a887TQ14bmGRle486Ly/KDrg/J52dnHCk8816BH4x0mS2uZ1ebZb28NxKDGQVWSSSMAj+8HicEdsVHaeJdJtbxNMgtpbW1jmks0lESpAsscbSNGMHIwiM2cbeCM54oA4++vPEZ1bU5rGLVYGa31BDb+TcSKrKp8h1dv3eWKgqI174JJrr/CkN/a6tqVvdSX0tp9ntpo3umZ/3rB/NCsf91CVHAz0GadoHiZ9Z16a1jspreyFjDeQyTqFeUSO4DABjhcKOCA3XIqq3jKK0v8AUI9S8qG2tbmeMyAMT5cUEcpOBnJ+c+nQY5oAwtC+26FJCDHrPkrrd+17GLeaVTFJJcvCygKdyndGSVzgkbsVlSLrjwxXkkWuJrsmgwLbPHBMFN4JJSFmKjaACV3B+ME8dK7w+MLRBKs9jqEN1HNFb/ZmjQyM8gJQDDFeQO54745qDUPHml6fpEOp3cdxFZs0qSs5iUwNE5SRWBcFirKwwm4nHGeKAMrRW11vGrnUbm8iAvLgGH7LO0Elth/JAf8A1KnHlsSMPncp603xtc6yPEkX9mRajEYHtPLaGK4ljuFab96CEIiXC5yX3HHQDg1v3Xi+zg1GSzWzv5nW5+xB4412tP5fmCMEsOSvOfujuRVO6+Ieh2tvDNM8yqYTPMG2K1tGHZGLgsM4ZHGE3H5DgEc0AYN0PFENtPd2DapJqEz6vGI5NxRVSaT7NtRvlU7VXax+8D1IxW54FtxFrXiCeCPUxaTG3MUmoJMHciMhv9aN3B/Ltxirs3jCyjvJbZba8crLNbLLsAjknjjaQxA5znYjHOMcYznitHwxqx1zQLHUjaS2n2qFJfKkIJG5QeCOo568fQUAalFFFAHGfFOVH0jStLlhEyatqltZspbbgbjIT+Hl15d45WXxF4k17TbeVre517UItFRRkFreABpm3KMjjcMNgHPGa9C8VTRXnxS8P29zG32PRbG41ieRj8iMcRxn6jEprlPhmz3Gp6l4g1jZ/wASWCQbppPLUXVwfOlIJwANpjTJyQQwyRQB33g63gfXNVnsWA0+xVNJtYkG1YxF98Y7kOSM+1S+AWS9i1bWFT/kIX0jJKf+WsKHZGfpheKmuyPDvgi7m05ALlYHliEjB987/d3MPvZdgM1peG7H+zNA0+zK7WhhVWH+1jLfrmgDSooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKQ5wcHB9aAFooooAKKKKACiiigAooooAKKKKACs/XtJt9b05rO7MioXSRHjIDRujBlYZBGQQDggg9CCCRWhRQBgW/hiCOeCae9u7iaGOeNWcRJlZQgbIRFHHljHHc5zVK28DWNsLdLe91CO3iktZmgDRlZZLdUVHbKZyViQHBAO3oK6yigDG1zQItVuIbgXl3ZXMcUluZbYoC8TlSyHcrDGUU5ABGOCMnMui6HaaNJdNYh1S4MeYyRtQRxrGoXjptQdc1qUUAcv/AMIXZeeW+23/AJANyY7bdH5cRnz5m35N3ViRknHbjirNr4U0621uy1RDO1xaWi2iKzjYQoIVyMffCs659HIx0xv0UAchH4C0+G1htre+1GK3VLdJI1aMifyHDRlsoSDkAHbtyOtTN4JsCl9B9puxp9553mWg8sIDLneVfZ5g5ZiBvwCeBgADqaKAMnRNEXS7q9uWvbu9ubvZ5slz5efkGBgIqgce1VW8K2os4Ibe6vLeaC9uL+G5jKGSOSZ5WcDcpUr++cYKnjHcA10FFAHIz+AtPki8uG91C3jeCOC4WJo/9ICSvKpcshOd8khJXbncc9qvSeFNPlkRpWndVvpdQKFhhnkhkhZTx93bK3HXOOe1dBRQBhaB4ah0a7Nwt9e3cn2WOzT7SUISKMsVA2quT8x5OSeM1S1bwXp98L+RzPLJctPIY2lCIWlhWIjcFJUYRcEZIOTz0rqqKAOM0Pwndmee88QXjy3b3cFygjlV8eUm1QzCKMHOTkBB25NLqHw9067t72Fb7UbdbyK7guDE0RLx3EskrrlkO3DSvjbg4xndgV2VFAGH/wAI1Z/a/tHm3G/+0f7TxuGPN8rysdPu7ecdc9+1Z48DWMUiyWd7fWs+10kkTynMiNK8oUh42A2tK+CADhuprrKKAME+FrEzxSM9w3l38uohSwwZJIZImU8fd2yNjvnHPar2g6YujaTbafHc3FzDbIsUbT7NwRQAq/Kqg4A64z6k1oUUAFFFU9Y1CHSdIvtRut32ezge4k29dqKWOPwFAHkHjXVHttA+KPiZdzBAuj2rHk7UCxyKo/66ySY962dG8O/2b4P8JeFLqETzX0gvNRdF8tGKYlkY4xgmQx8DGefesGy0cS6B8NvD2pBvtGp3769f+fLjzXQGZ19yZJUO30U+lekaJs1PxjrWpqztHaKmmRYOUJX55CP9rc20/wC4KAE8alL680PQzIQb268+WMD78MOHbnt83lfnXU1ytiTqHxE1SZov3Ol2sVpGzj/lrJ+8cr7bTEPqK6qgAooooAKKKxvEnibR/DUEcms30cDS58mEAvLMR1Ecags556KDQBs1U1XU7DSLJ7zVr21sbRMBp7mVYkXPTLMQBXE/2r4u8T27TafDH4R0fAY3moIs16yYBJWLJji+rl+DyoIxVjRvBGkW97HfS2tzruqxtxqetymZlyckxBgQnXgRqo7ZoA3oNfS+No+j27X1rOqyC5U7Y9hzkA4J3dDhgoIP3u1WrR9VcubqK0QYIUKzEg5OD7jGPTvU32WSQf6TcyNznbFmJfbod364NTwQRQAiCKOME5IRQMn8KAFhEgjUTMryd2VdoP4ZP86fRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFIxwCcE47CgBaKzNQ1dLO+gszBK9xcxSPBjAV3QAmMseFYg5APUBj/CaxNUe713StN8Q+D7sm4iPmi2kO1LyPkPBJkfI2c4P8LDnjNAHXUVnaBrNprumpe2DsU3NHJG42vDIpw8bqeVZSCCDWjQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxHxguCfCUelRrK8ut3tvpYWPqySODKCew8pZea7euF8Tyfb/AImeGrEGWSHTLW51aeGMZ+c7YoSfX70+B7UAZ/xm8O3c+g6RrHh8BdT8NXAvbcZ+9GFIdMdwRtyOuAQOSKsfCTxboer+D5Zra9YT2ZMmqNdKImSZ/wB47t22kkkEcYrY8cj+0rTSdIFu00Wp3sQnU5Uxwx/vWZh6ZRUI/wBvmvGfEKnW/DPiwK0LW/ifW7gCWBAAbeBo7SI7gOSZzA3uC3uaAPZvhuftXh3+1zI0h1eaTUAz9RHIxMa/8BTav4V1XOfaq2mWq2Wm2lqn3YIkiH0UAf0qzQAUhIUEsQAOST2qG/vLbT7Ke8v547e1gQySyysFVFHUknoK8n8TNe+ObzydQnuNO8Nxn5tJQ+VPeqwwr3T5/cRNniJvmYA5BJ2gA17rxrqHiy5n0/4diJraIslzrs6nyIsEgiAHiVgQfm+6Oo34K1Y8N+HdO0m8kvbFJdZ124AM+qXTeYzY44Y4wOpCrtTg7cdKs29vHHbR2soEVrHHhLCGPy4406guD93p96Tk84VWrXgt7m9QgLGsDZPzKfLOT/dOGlPByzFQcggGgBFt57uZZDM9xKjMMo22NevG/GfxjAPGCT1rR0zTFsWdlkJZ+XAGAzf3iTlmOMDLMenGKvRqUjVSxYgY3HGT+XFOoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK53xLq7aXewR6nbp/wj92ht5rwOQbeVsgeZ6RtkAPnhsZxkEdFUdxDFc28sFxEksEqlJI5FDK6kYIIPBBHagDxTx9/aehyadp/iCfdp6Sr/ZWvYZnjuFY+Stwcja4B278ESqXU7Sa3PCviOdFl1w2jW8TzfZvEGlod7afdggG4Ud42G0tgcqQ/PzGtO6tIvDls+ha+n27wXe/6PBNPljY7uFglbr5ecBJOqnCk/dY8TqX9o/Crxjb6ndG4vNAmiW1kuUG5pYVJKrMP+e0QLFX/AI4w44ZVBAPQ9b0y50XWZPFHhyJrhZ1X+1LCLn7VGo4mjA6zKOw++oA6ha6rTL+01TT7e+064jubS4QPFLGcqynvXPWOpz6V4gFhfzrNpWpMZNLu+MKxG425I46ZZPVQRztyc2/iHgLV7zWo5Cvha+k83UYQMiynYgG5Udo2J/eAdCd/TeQAd5RTY3WRFeNgyMAVZTkEHuKdQAUUUUAFFFFABXN694ttdOv/AOzNPt7jWNcIz/Z9jtZ4xjIaZiQsKnsXI3fwhjxUXibWL6bV4fDfh0+Xqk8P2i4vWTelhbltu/B4aRiGEanjKsxyEKto+F/DmneGdNNnpcTDzJDNPPKxea5lb70srnl3Pcn6DAAFAGTPb+Ob+MtHqHh7RSQAIltJdQZT3PmmSEfh5f41FJJ4+02RppI/D2vWwUkwWyS6fPnP8Jd5UY4z8rFBn+ICuzooAxPDPifT/EIuY7UzW9/aFVu7C6j8q4tWYZAdD2POGGVbBKsRzW3XNeLvDr6k0Wq6PPHY+JLFGFpdsDsZTyYZgPvxMQMjqOGXDAGpfBniQeI9Pnae0k0/VLKY2t/YykFreZQCQD/EjAhlfjcrA8ZwADoKKKKACiiigAooooAKKDnHGM+9FABRRRQAUUUUAFcN4LmTVvHvjXVklaSO2ng0eH5cLthj3vj1IlmkU/7tdyeBXEfBdJW+G+k31zKJbnVPM1SZgAP3lxI0zD8C+PwoAi8aeI7fSY/E2shIDJ4c0x/LmaRhi4kXf5TL05C25B/265XwRpDwap4a0KOVZYdIt44rnABic28eWZV7Fp7g5J72vrUXjrVLO38D6bPrQt4LbxDrQv7sTYLtaQ7rlVx3Yx28UWP9vFdZ8LdPnEuranqCob1pBYNLGNqyGJmaZgvYG5kuSPYigDv6gv7y20+ynvL6eK3tIEMks0rBVRQMkknoBU9eSeLdVt/GXiN9MjUXegaPcqkgQGRb3UVBYQlBxIkS4ZkzguRnAjagBJtRvfGGqLqt7usPDloBc6ZaTAJJcFefts+4ERRg48sMCeC23dsx0VjayGaOO0jaObHmKACsnzcFgGzszzmWTMjfOAORTtI024v5A0o/eJJ5jytiRIpBjJB6Sz8Y342R4AUfKQ3YWVnDZRskCY3Nvdics7YA3MTyTgDk+goAp6bpEdsi+cFdgdwQZKK3Hzc8s3A+diTnpjOK1KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjuYIbq3lt7mKOaCVDHJHIoZXUjBUg8EEcYrzp4E8OSL4V8TK9/4Q1HEFhe3L7mt3J+W1lbOeoBjk65wpO4KT6TVTV9Ns9Y0250/U7eO5srhDHLE44YH+X1HIPIoA8n0i3tfDdtcfDjxnctHo78+H9TlcIXiBDLH5h4WeFsFfUBSBxWzo/wATfDkVrd6V4v8AEGipqFm5tpZDMnlXiEcSqMkYYfeXnawYdsm79it42t/CvjeCLVtPlfGm3l7Gsi3BHIilyMCdQDg/xqCRzuAl1P4d6PbWHmeEtL0rSNXgl8+CZLVArtgho5MLny3UlSB0zkcgUAcj4Q1i78BeJ7nw7qh/4pme4MmmESCRbG1YgQsHJy0TOTGRj903lgkrIhr2avCTpka6MLKALb6cLlobAXwEg0a6bCyadc462soJRTyuHUDnyieq+FnihQ8fhvUJbgzL5wsmujulURNiS1kbvLDkDdk74yjgnLYAPTKKKKACq2p31tpem3d/fSiG0tYXnmkPREUFmP4AGrNcP8YWa48Jw6LE8qy67f22l5j6+U7gzg+3kpNQBL8K9PkTw82uagmNY8QONTvCykMm9R5cPPaOPZGP90nGSa7GVxHGzs6oFGSzdB7mlACgAdBTZ4YriCSG4jSWGRSjxuoZWUjBBB6gigDGk1n7HLBbajLb/at6JMLbc5XzHKwuUwSqOVZckkBsjLYJGZqviJ4LzTjp8ltdQ6hdLDDJFMXHlyQSMsgH3WPmQ4ABxgk8da5PxPBBBHHq9vdGSPSUmjNyGbz303IW6hZsbhJAwSVSQXPlAfeZyef8b6hYeHtSt7SNyv8AZstxehQwGFFnqUw2gY/57RgAAcnA6CgD3eRPNG1wrRMpV42XO7OP068e9cj4s07VIb6DWvDIQ61aDbNaOVRdUtAcmLOeHQsSjHAViQcLIxrRXU2s9c06GSSeSy1WH9wHiI8mVF3Hc7H+NSMJjIKMeRu23vEGlvqdpGLa5e0vbeTzra4XJCSAEDcuRvUgkFSeQeoOCABfD+t2Gv6ct7pk3mR7jHIjArJDIPvRyIeUdehUgEVpVwd5ol8mqt4i0KCKx8U+RH/aViHY2moqMgI0hUAuNpCSgbl4DDadp6nw9rdrrth9ptRLFIjGK4tp12TW0oxmORezDIPcEEMpKkEgGnRXmehfF3S9a8T2FhaWk66fewuVuZv3ckMq72w8Z5EbIoZZASCWUdTx2Pg/xJaeKtHGoWUNzbgSNFJBdIFljYYOGAJHKlWBBOQwoA26KKKACiiigAooooAKKKKAOS+Kc0//AAh81hZXTWt5qs8GmxSofnTzpFR2T/aWMyOP92vOvhBH4hhtvG/gyWI2A03EEM6AmKG4mDEmHv5ZBSYKeVMhHAxXoHi1kuPG/hG0mlSOG0+16w5foRDEIce3/H3u/wCA1Q+E8pl0mDUZVaS68S+brtwzy7vKDmNYUA9BFsUf9cz3oA0PiFpmhQ+EEudW0y3vk0bZcWEMinm4X5YVGOpZiq46HPNbvhbSzovh3TtOeZ7iW3hVJJ5PvSvj5nb3Y5J9zWR4mk/tLxX4f0OKUKsbtq12nXdFCQI1PpmZ43B/6YtW9reqWmiaReanqMvlWdpE00rYyQoGeAOST0AHJPAoA5L4m+JL2xOn+H/Dpc6/q7Ha8ahja2y482fn5QQCFXdxuYE5ANUvDmmw2llHDYWqW1iI/IjFuxTzY+pWEnlY8nLTE75CM/3cYnhyymu73VPEOvJH9t1UlpoZG+VIkGEtC2TiGLkykDDyMw5xhvRNBjNzI9xOWkYYBYrtDMPVewHZe2efmzgA2LOIQW0caqiqoACRrtVR2AHYCpqKKACiiigAooooAKKKKACiiigAooooAKr397bWECzXkyQxNJHCGc4BeR1RF+pZlA9zViqOuaZb63ot/pd7v+y3sEltLsOG2upU4PY4PBoAyLjxvoUdnfzw3guZLKyfUJbeFf3whRnRiEODkNG6leoK4IzgUmneLra88Vz6G8D28qK/lPI4/evGVLqAOMeXLbyA5ORIcgFGFeHRanJ4a8V2uqay0KyQPMuo7ysSyqGWDUF2bgNrOba+VQm5vMb1rejiudKSyaygup9R0SZ7BExud5bEO0ShccyXOnyygtzz5fcCgD3miq+nXtvqWn2t9YyrPaXMSzQyr0dGAKsPYgg1YoAKKKKACiiigAooooAKKKKACiiigClrOmWms6ZcafqMQmtZ12uuSCMHIYEcqwIBDDkEAjBFcx4a1m90jVo/C/imZprxgx03UnAA1CNRnDY4Eyj7yj7wG4cZA7SsvxJoVl4h0xrK/VwAwlimibbLBKvKyRt/CwPQ/UHIJBAMfxfpAWK4v7axF7BND9n1PT1TcLy2wQcL3kUE4xywyvJ27fKdZ0qfTDbzw6lJd6bcRebY6rCPMlmSNS0MqnPzXduu4Y63EG9fmKFa9f8AD2s3C3x0LXyi61DGZElRdsd9ECB50Y7EEgOnVCR1UqzZnibSrWwW++2RH/hGdQO+9CNsNlPuDC6QjlRu+ZmBBVwJP77AAv8AgPxRF4j00pLLbHVbVI/tSQPujcOu5Joj/FFIvzK3pkHDKwHT15jZeBbrwdoltqHh69n1TVrCSSZlljjT7Xau2+S0RUCqozl4x0V+AVRmFegaHqtnrmkWmp6ZMJrO6jEkb4IOD2IPIIPBB5BBBoAvVxHji6A8c/Dyxx/rdSubjPceXY3A/wDagrt6818ctKfjJ8OHjb/RbcX/ANqIIAQywhYd3+8yuB7igD0qmTSpDGZJW2oOSx6Aep9B70+uf8R6WWQ31i+tC+jUpGunXYU/M3LeVM3kMRknLqSB07CgDk/PEes3nm3H29PO8zekPM+F+UFeF3mJjDnBEitEwPyNjyP7Xc+IfiDpGjQafdTDTLfVNGgvp4tsc9/DbsijaxxtEcathsfPJIcAYrrdS1CCPxZoX9uTHw9eSSJA0zA2Md7tYMVaNiVjljJcq6NLHINy7wzoo4HRdZlmaLx7YabKdMs/ENzq080dtEWa1knKYdw6tlEluCUIYgtG2ArlqAPfpYP7S+FNl/Z8t1etDaQTW88ykyz7NpWTHXLABh0b5hgq3I2PCHiOHWITbyyqb6AKHx0kyisWUj5T97t2KtwHXPP2sp0TU/Elh4lWKDQJ45b59RuJR5QWVwmyR2AXcQOAQcD5BwoL8M1/4sa9nvfAvhbWbm2hzbWM95HHZr5bsTLNtnk8yRzgEFlAd2LybtsaqAe7Xkc8kBFrMsMwIKsybx9COOPoQfeuOv7aPXdUlu9A1E6L4psXFtOXi3pOind5csZ2+bEckqwKsAzbWXcwOLa/FK60PS7ib4k+GNU8PSwq0izQp9ttpEBAUGWIEI5Jxh9o6HPOBm3ms+ENd1VtV1rTPEnhm/RCkd/fW01vEPMXy/M85C0SHaSodmUjedpyc0Ac3qGl+J7G48QQapoF9aNqV5E0epaYkd+ttAZ3mkWPO1wczSHmMgEEgHIxPpcOqQfEfSJpLm5tLK+1JJNGsJYvs4wYCbl5EyWcpbRpECcAPKcAY3H1JLtNN236z6trrTpGzGycSQ71xExVAwCglixXkfKe64rxjxrcaTDqh1S30Pxw+rRwymS/u5bqBI4m+87yp8yxJsb92GjXBbpwSAfStFYnga4F14K0Cdbu4vRJYQMLq5TZLPmNf3jrk4ZupGT1rboAKKKKACiiigAooooA8a+J0k01942u9IKyamum2Hhu23nAinu528zHvsnt2/4DXonhi2tI73UmsoxHBa+VpkIUfKI4UyAPo0jr/wAB9q4WyLahqVipCyjV/Fl5eT5GSkdiGiRh/wADtbcZ9GwetdXaahd6F8MTqs9mw1U2j3zWTjaxu5syeTjsTK+z8aAJvCI/tDW/EWusyPHNcjT7VlHIhttyMD7+e1z+G2uV8fah/wAJF4ytNAgZpNL0WSK+1JYn2tcXRyba2BB4xtMznGFVUJIrqbme1+Hnw4DurTx6VZqiov37mbAVVH+3JIQPq1cDoumzWdjFaLi81G5zcXVygDpNPJ+8lmwAPvcMAf8AlmsK4x5goA6G3SWZsQmJ5CoKbGMUaIMBcH+FFBBXuBh8F3QDvYZbOytLWNGhhgfbHCoOAxPQL615uNRsdMuYILmOK+mmdsW5lUhtm4kt2cgklnY+Wp4BLDLdb4fgmu9R/tHUoZ5rjYTFK67IYM8FIkbD9P42X5uemdtAHTUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5x8Q4JdQ+I/gXTH1HU7XT7mPUDcQ2N9NamYpHGULNEyk7Tnv3rXk+HukPjN/4myO/wDwkV+f5zUAeefHLRJbW+vL6ya4jjv7c3UghKne0KeXcxgOCC0tm7EDjmzU9RVL4eahcalo1xCjyT6lb20cqLC4d577TzGC+7JBNxbyWanDHjePU12virwJbaVpMutaI+sXur6V/pltDe6pc3SS7QfMiCSOy5kiMkWcceZmvDfAuoW/gX4qaXZWbw3WnTaolp5jTgyvHNHi0n/1h3KYZ1JIRRk88qKAPoT4V6lFLp9xp1usws4VjvtOMqlSbG5DSQrj+HYRLEF7LEvqK7mvBL3wxpdxrMei6vBPJa6Tqz2i/YJp7crbXbI8W8qQG2SSwL97kNI23Kknsm+DHhNiNx1sqOinWLkj/wBDoA9JorzA/A7wbn7msD/uLXH/AMXSH4GeCz96LVm+uq3HH/j9AHqFFeZp8EfBKAgWeoHIx82pXB/9np0fwT8Eowb7Hfn2bUZyP/Q6APSqK8/h+D/gyJSBptyxIwWa/nJ/PfVk/CrwcQAdJk49L24H/s9AHb0VxC/CvweudumTj6X9x/8AHKxNf8F/DHQEV9ZiitSWCqj6hcF2J6AKHJOeegoA9SorgfghLFL4EP2VZ47NNS1BLeKfd5kUQu5diNuJIIGBgk131ABRRRQBheL/AA7H4i0+JEuZLHUbWQXFjfRKC9tMOAwB+8pBKsp4ZSR3zXm3in4vXvhIzaL4n8Mtca1Hbo7yW06fY5w4YBwW/eCPKsrfIdp45yufZq5vxj4fuNVS3v8ARbsWHiCwJe0uSMo4P3oZh1aJ8DI6ghWHKigDkPhF460jUPC1qglktSky28tncOXfTnk4ihZsf6tirCN2xnKrycZ275h4I8QzalJLt8M6xOiXMYT5bG8c7RPkcCOUkB89JCrfxuw8/wDFVnNrTz+LfDOkSr4p06TZ4l8OT3LA3sSwlRGU+ZJPlO6NguGBJHzYFek+DfFGi+NtBQW9zFqsN7FK08RgDJCjEH7PMBlVcLIqlWOW2scYBwAdfXjXxThkudR1rUreZ0udOW3mtY0AfdJYRzXhL5IxGXngQ4ycgcDqNeTWdd8IXEHhWQx3P2jzDpmuajOqwxQKMlJ8sHlmjGcKvMigMWXEjLr22g2s2lQRxXV/MmoQfYle6tizCJi0lw8gwNrzYbLkBc+UAvGGAOj0LXLTW9E0nVLMkW+pRJLCHKhhuQvtIz94AEEDOCD6GtC4hiubeWC4iSWCVSkkcihldSMEEHggjtXhcHiC78IeJNFtp2lfQNV1xLu3eNk2xSXf2lXt2Od2wGWCcYTALMCQGTPvFAHjXjXQdK0p7zTNTtLWDw1qIZZLa1leCJEK7QdsoNssgbEgZWhcGNcb+VbzPwfot/feIT8ObaK2s7uwgls9RvrKAIVtNxSQzCQbZDKBCyBVJHmgsxCstfUetaeNT0+S3MtzC/3ke3uXgYMOnzJ2z2IIPcHpXj3hq6l8GfEO2Gs6e+mxX9nDp1xIscSwuUfbayjygF+Us8LkBR+8tjsjDlVAOui+Gehaf4WtNMvNX197DTI1aGafWJoxCIyHRyFZU+QorLuUhdoxgDFL4E1vxNeRX0U1k2q6akobTNauSlp9tgI53xqCwZW4DBFV1wwAHXS8fyedaS2ytaTm1tJtSbT7m2MgujEAYucgBVl2MQMkkL0Gc+Zad8RtT1LTEls3un8Q31wr3kShxbWdtu2QLBnKs0peE5XcSZG3FdqoAD0vVPG9vpc8Njq+j6omo3MvkWtrDCJxeNtLfu3U7ccHO8pjBJwvzVl+FNC13wtLrEVhpOnr4fmZJrPSo79j9mc7jNs3R4AYlcRghQQSMbjXSX9vqF34Vl+22NpdazbBpreMn93JPExMMnUFdxVGxn5dxXJxk70W/wApPN2+ZtG7b0z3x7UAeTN4Ra1Np4u+GUc2n3Il33egzEwQXSKSkkOw5WGQHfgj5S+Sc53DzubxDpeu6lJBoF34l1/WbVGZfD2uW806vOjFMupkWNQCdpJB2kFuor6fAA6cVxNxoGjeLrDVIWs5NK1S3v333Vr+7uba5CrtmSQDq0Zjb0Kthh1FAHZW+/7PF5iLG+0bkU5CnHIB9KkrgvB3jORdZn8JeLZFh8S2WxRc+UYrfUUcMY5Ij0DsFbMfYq+3IU472gAooooAKKKKACory4js7Se5nbbDCjSOfRQMk/kKlrlvimXb4d+ILeHInvLR7KIjqJJv3S/+POKAPMvC0WoWcmkWNsyCSy8JQQs0Zy8N7qNwm93b03RBwPZvUV6b4wH9oaz4a0YSOolvP7RnVR96G2w457fv2tvqMiuV8Op/aHj3Xb6zzJby61Hp7iNAqLb2VoW9Odt1KVJ9QB0FYvjbVvE2sfF260HwjLbWsVpY21vfalM4D2Qmd3dYgeryKsJHBx5fSgBPif42t9U8a23hfS7efU5dND3UkEEgjjmuwuI43lPyosQYzMTnayxY5Bqr4b8F6trWpajdeI9VbUfNlF21nZq8NpbAhzGmQRJISshPlEqNrLu+8K6jwboOieHdIs9O06KfW5J4CqSRx4SYqyvKzydPmcrnceQqqcnOe9e703ScRu8MEtxKT5actJK3zHgckmgCh4W8OW+lQCU2sME7gfu0AIjxnAJH3mGTz0HRQB16Kq9lc/a42k8maEBioEybS2O+OuP8KsUAFFVrya4ie2W2thOHlCykyBfKTBJfnryAMDufQGrNABRRRQAUUUUAFFFFABRRRQAUUUUAeYfE3UH0v4k+BLuK1ku3jh1IiFJEjyfKj5LOQAB36nngGrbeOPEMdvHLP4a0+NiMywf2uxlt/k3kSDyMZVTk7S3RgNxFU/ibBNdfEv4fRWyuz/6eHCEA+W8SRucnj5VctjvtFa9xZwPJJeQf6syl5cKQSrTIwbnnOyWb04kIwaAK1n8R5tgOo+GryFtwR/s95bSiNsZZGLSIdy5G4KG296+d/iNYi4uojp8t1p8UcsukLvswjRJCTcWZIfa6bUeSIODz9lOCRmvpdPDXnRaXfXkSyT2cDtsC/MWLREAKehZItrc9z1rzf4r6FqFrCbqSH7VPJEkSuy+YZbiziF1CQpH/AC0Ivoj1yZ1yD0oA6LUHi8R2Gi67cWeNO8TaILbUZrYPI9sdm9ApjzgDzZ+SCNyJyp5q/Y+OPEF1pxVdFtYbq3WSC4nu7raGuIR++EcaglhwxX5lJAJwMGua+F+sR6v8INbjE1vBJpt5NcCQTbRDFIwukkVlT5cJKcfJwVxt4xXT+Fbe1bxteebaymHVoIdYtnaVZUFxB+4lZWUkDcjW7AgncHbOORQBPa33iu/nmtv7TsxKrhRJZ6Y6RgeYUbLSu2SArMMcFQOeRmnqWq+J9P06aeW6vzdqFSK3FnEwmkZYTgADOAZXB54ETGvTaQgHGQCRyPagDzD/AISTxPbiNVvtMeRY0ku1u7Zv9GDCTOTGwGFaGZW9Nmec4qnL4g8a6vcXNmZLXRH5WKa2RZ4l+Zo/3kj4w4dHBRQMhThs4B9QvdNtL2MJPCpAkST5flJKPvXOOozng8HJ9a5A6K+mN9pv8iy0+3ikeTJYFFVCyhRyxD20bZP/AD0bHfIBzF1pOs2ttE2qa54htvtsqQxeZfhWVmBbnaNoCp5qt6tCjD75xd07wzpV1cg3a6jC1zLDcyLJfykwpNGwEQIbgiaNhj/a967XTLRL/RL3TbqQSzwyzWzysoLKSDtY543GN1JPfcfXFZ8duRezibbEGe3dvM5b/j9kaPj3yfxNAHMaf4R0R7DZfnU5ygtY5mk1CVg0hnaFwBuBwWTr6YxS+HtG0q0uY307TYopFnhkikVC8pDraSZDvllQnzFPP8R966S1t0vpNRWzZhdebE+SQcBL6dgSPTIb8K19Rhi03SES1cx+XPEWKtgu25eD/vcD6GgDmvgdaix8DSWe4s9tquowuS24kreSjk9+3NegVwnwfDroWtLKQZBruolsdMm4djj8Sa7ugAooooAKKKKAOZ8V+HJb+7ttZ0OZLPxFZLthmbIjuYs5NvOByYz2OCUJ3L3VvF9K/tW4XxV4v02C4+y31wBe6NZShEkDTeUGt5EIAuVEazeZkh/PC4BANe3+P9ZfQPBes6lDsNzBbP8AZ1c8STEbYk+rOVH41z+j2j+DfhfBGI3uZrGFWVYWGbkxALF0xzIEjB4Jy/I5NACWUsPijTotC8QTt/aaxi+03U4F8pplXGy5iyPklTeA6HpuwQUfByJNdubTS7rR9Rs5oNZtWFteSwElpY5X+R7Xc29muWBC/NiNkfcf3Q38nrnhCw8DeFtN1fQ5bi10uxv2hvoYLl1YAEQm7h8xmUTo6M/yKA6O0bBlJz318tz4g+xoJ7C28aaUGu9Kv1G62voyArsnU+U4ISSMEtGSpyf3UjADb3wlYR+BNQ0vXYoLc6n511qUlvEoigR3UuA7AIPKTYquwDERbwuRgaXw38R3d/Yw6T4jaOPxFDbJcFfum5gOAJgPUE7JAPuuDwFZM2NEudP1/Sb251BDaXUjrbapZXYiYwMBg2r5XDId5IP8Qk3KcMK5O68P6jq2oxTSyXVj4hlna704vL5h0eBSQNxDEOHyxkTPzmRI87Yt6gHrNef/ABL8JXeuQyT2emaTquVKTWV0zwfaIiu0pvG4CTBfZJhWQnAYKXDbvhvxBPcXB0rxDbR6dr0e790rZiu0H/La3Y/eXpuX7yEgNwVZujoA8FsvHk1l4q03TtY+2RazpAENtBewvBdatay/LIu5v3ckyskRwhKyvF+7bD4X0aw8IeGdWng1e1zdw7Uj2O5dGMTKfnB53h4kLbud0fIzmuk13RdM8QadJYa3YW1/ZyfehuIw657EZ6H3HIrz+X4ca7oSEeAvGmp6fajO3TdSAvbdVxgJGz/PGMjrlsZ6UAd1rmt22lzWNmzltR1CXybWBF3ux43SFcj5EB3McjA4HzMoM+gaedK0WysWmaeSCJUeZuDI/wDE2MnGTk47Zrza8/4TnS/F76/D4KsNUnmsxaSeRrpOwBgR5QkjURhsEsuCCQhyMHdvW+seP9Ssj5XhXSdHuG4DX+qGfZ7mOKP5vpvWgDq77TzfRqkl5dQuApJtpPL5Gee/Bz0Oegrmfhg7rY+IIb27a81G11e4ivLtmH75gEKNgcKRCYVKgAAqcCs3SfAGutbuuv8AjPUJGmujc3I0qJLH7Se2+QZlyAFX5XA2ogAGOdKH4V+CY9zS+HbK6ndmkkuLpTNLK7HLO7sSzMSeSTk0AR+JIfCGoyarDr+r6WsuoLDbpm8WOSMR7miKZbiRXkkcMuDyPTNcn4d+M1jpl7d6H44urRb3TZltZdVtZFeC4yjOkxReUDKBnG4Bsg7flz6TbeEfDtqjLb6HpqKwwQLZOf0pYvCXh6Ly/L0PTVMZJQi2TI/SgB+ieKNB15N2i61p1+MZIt7lJCB7gHIrYrnNW8D+F9WjVNQ0DTZgG3j/AEdVOcYzkAdqyp/hloMbPJokmpaFcMhUy6ZePDn0yuSpxweR2oA7iivJdS8H+NtLijFj4p1bxDbHIkgluEs5l9Ckqrz9GGKyv7G8UX0C22oeGPEF4kTDi/8AEkRSQrt5OwdGAIPH8RoA9U1rxXoWiFl1PVLWGVesIbfJ/wB8Llv0rzb4geNZdZ021tbS3n0Sxa4t706jqUYWUiGUTDyLXl5CTEvJAX5ua09I8F69LMAV0rwtYfMpGkr5t7IhIwrTuPk4ByVzyatazd6B4EDNpGnS6v4jmfaY4ibm8lfCkhmOSudyk5wAGLYxQBgfBR/I8X+KtGtZtQnttNu5p3l1Bds0hukt3VyMDhnjuGBwMhgcVhfC3Qx498R+I/E88ayWL69cvDeyDcLu3CiKOJFyCoVFB8zrkgDo1XvBGuapY+Gvi14j16ztbbxFbTSNO1u+9CYrRTDGD0IUEDPcsfWtj4WadqWi+EtC0nTree3FtBDHeIrR4WUqvmv3LZad2B9LcDvggHop8P2yyqbaW4todxd4YWAEhON2SQSAdoyAR3PU1b07TLLTgVs7eONmyWbq7c92PJ/E1lQ2OvXNo32jVFs2mAYpHCJHhzI7FQ5OPuFFzg8qT3rRsdNs9Ndpt8jTyfK008pZmJI9eBk44AHagCO81/T7W5a2MrzXajJt4I2lkA9dqgnFNutbWG1LLbyG7lMiWVpKywyXjrGX2oGIxwrdcdCelc9r3xAtre9tdL0GAalrFyzjyS/lpbKCyCWZj9yMuAAcEtn5Q1QaJaXenzG/1e9WfXLvdD9tuItpVD8whtoByqZHO4hmKgnOFCgG/GsOj+ZqFzbh9f1GOJZ4beZ5BLKiYCRByNqAljnCjks2Mk1sWAuls4RfvE91t/eGFSEz6DPOO3v7dKztEt3Wd5zbOodNpuLps3EpzxkDhVxzjjkn5R32aACiiigAooooAKKKKACiiigAooooA82+I0rQ/EDwi8ThJ/smp+UcgHf5AIx78E/hXW2thaX1qqgeTJDI0ZEZwSiyhdpBz8reSoz6DjFcf8TE8z4kfDX5iqx3t0zcZ6wFR39WFaFhdNa6b54YxsbZro+WNpZlEMzKR3JaSYkdcM1AHWaxcLa2DRJKUuJo3jt+SSXEbN19cKTz6Vzfj2Y6p4a1GKwhaTUbOWO6sOQVluITFNECR0DMUHOMjPTNTtcy/aDJqMpDwTYjT+FFEzxs5Pb93NEST7Hsaokrb21tHPktawxyThWBKlEDHPH960K8dd3HSgDyr9ny4s9O+Jfi/wAOWa239lajaR6hYqiBQLY4khyuBuLRXSgk5OYzk4xXQ6S39g+HLG4ZczeFroJKIZN/7iHdbTOy5LDNviXaQBuVMZJGeGX7N4I+IGg61cmZbDw5qE2gajMxZjBburtZuw/55+XPtDHoI1H19Ruo7K2+J2qWT7Xh1eGDUI97HZJvAtp9v3lPyLDnCgkMfmHBoA9WyN2MjJ5xS15foE9zcaFZW0tzdNf6Yz6OZGQmRJUY23nOe/mLLBNgnoMj26KSTxKtrFNbxEO6CdoXKsVP71zCfT70SZH900AdcTgZPSsDW9R26rYWsZZlWXdMgwQ4JSLYc9h9oR/+A+9QmDWmeRJ0E9v8w8ppAAy7pxgnqdyGIexAPrXORadrFjfEXVlcXKQRQS+ZEok850jhZwuSOd1oFGcczKexoA0rC7fT7CC9imDmSEXE0IOQzC1Kkbu+DB1roWTTLyQzHaZXlUFhkFmgl2gfRXOPxrnNH0fWV0lobi1t4nmtmjVJJAwtywRNuAMHpLIfdyo9atICLi1tYQ8ErzvcDchUlZLkzEA+6Rvke4z1oA0Q9tp1m9pp8bGUWszLJn5mMbYO5u5LOTn1JPes3URGtlrAhUyvFeB8TE53xWyOvJ90Xn3NQwGa4hmkYN5ktuFjcKPkW6nYkkHnhQhI9qsttaO1kXMsE8ss4lDfe82URofdRHIT9FFAFT4Uuraf4hCZwuvX45/67E/1rt68/wDgyhTSfEJbrJrt5N9Q7Bx+jCvQKACiiigAoorJ8Va5B4d0G61K4jeYxgLFBHgyTysdqRID1ZmIUD1NAHLeJriHxN44sfDMjhdMsHivr4kqVuZwTJBagHnI8tpmx2jQHh62ZxpureIE062idn0oJJNJFtEUTAq0cDcg5yEk2r2jXcQGUNmaTZz+DvB017qIhvfEt7MbidgSqzXs5VFjQnO1BiOMf7KAnvWhZaPZ+GNMGqX0s9xcWVtNLcSKGfzZHIeaQIMksxXAHOFwq4HFAHFfFW3F9YaT4D0+UtJNCIpVDEbw6NFGGHt+8nPU7bZ8c4Iq+I/DtroWlR33hiB9LijnYixsyTGZUnEEbwEjENwwkILH92wLLKroSw2PDUusajfya7fyQzX6yyWOn2skq+THIzjz2QjlxEqBMjDExTn7rrjoPHHlWHhq7iispYYYYo44pYyoHzSDcFGc5XaGOR9M80Ac5HbT+LtO0vxNYW1ldavZFLm3lAIs9ZhUExlhyY3BdigcFoZN2Ny5LX/DvifT49Na5t5LnUvEl3Ipu7eW2eK43K4DQCP5hH5QbhN21d6u7YkMjZln8MobTwwv9i2/9mauI4HmjErpFeSKqu3mbWJV9+7E6BZEIGMqCGx7LXb6/aLV9DvEtfELn+z1uL+ERw6iy5xaXyL/AKi8jJbBGFYtlMq5jUA1dc0qC+urS/8AFl0bdLi5lMFr9omF7FKhIU221BIzgKMLAI1wWJ88EMdDTvFHiPwzoLX/AIv0+6vtGi3SNqWyGC8hj4Iae2Vtu0Dccxtv6AxA5NdD4eu11HQ2i0i+c6zaHyLltWiElxBISGdZUQqAT1GwhCNpTKban0G803XJruSziuL21hudwvLj5oWuE/dsIQx42lOSihNxOCTvwAWPDXirQvE0Hm6Dqtre4RZGjjf95GrDKl4zhkyP7wFbVebeMND0XxJZS6h4o1G1utMj8z7JOqLDBbSLJtXDo4naQnKkJIFbGNoJFZp0HW7f7ZdeHPEvivSrS6mjjgOqut6gLbVUpFMkku0seQ7xEZOcAUAet0V5gZfH1oY7ddasJ7hljaOK800GdwQC5YRSBcrgjA2pkr+85IGBrd98QuZoPEzWdrG/lZTRo98km5V8pRIfnkZtwVV+TqxlIABAPZNR1C206FZLuTYHbYiqpd3bBO1VAJY4BOADwCegNcxqPxA0uwmeO4jltlEhjSW+eOzSTC5LL5rKxQZA3AYz0zXn+p+EoW1gQLqviLVvFVzGIby4/tVh9kibDNCBGI4++cFQoGGKsSscmvo/w38J+F0spdYsLe81BnMsNvKTKkbLyZGZ8ltgOTK/Tcdu3cqUAXn+Jm+B5beXwvgYRRJriqpfvhygVh16Z459q1LDxhqN4iS2+nWl9CWEZbTbxboKcbixK4xgAjaevGDk4rC8Uat4ZWOGefWdGsWuY0hv5IbkXDWyKCxjgUKQrMzYL4BwAcZC44PUtc+FNpZXEGn3WkWtlYwk2VtDHKDPIVAM0hCg7h0VSeoLH+EqAeoP8SrONtsqW9uxMjYup/s+1F6ffALE+gHHON2CaW4+JmmKwEdxYjzGiEQe5QMQw6lc9fRfQZJHSvOtP13R20S0trL4qre6xhm+0ahFHcwo23dhmdBgLzg5VmzgdeOlTw1rkOhprGueK7OFVw0Is9EtZGQMQEUHa25zuKnaMEtxxQB1Fv44a+e1eztlFtJEJWkckCTqX8rOC4RVLZVTuHQL1ro7vXbGwgD6lcwW77gpTzA2MuVH6g/k39014fbadr0EE2t3It7qfd5MGozXM63s8hbi2hVDtAHQ7Nqllb+Ebq1rvw34rttMtJHs9F0+csryiETXskUSo2/Lt919pwHUElsAdSaAO+utSW/kRYbjUZrWEx+Y0SiBOBl97nnG3krx1UdTxh3Ou2Nj9ttfCNsY4Ed3urm3ty7uV3iUhj1K7cAknldo6Vy/iqXxHdDSbC+1XTrC0uZ3gZTGZpTEoPmt5hIxLHHGSTg5Z8dq5nWvB2n3Vvreh6Xcavplvc2s99p8sc03mExFC8F1ESSw/eB0I5KOepXkAn1+WS6+AHi7VmaG2t/EGtRG18hGO+2EtvbA7cbjuWBnwAchveneFfHiT2sFtZ6/4e0prmIllsYXjLFY0RVZ2UBcukoD9iSQMDnR8YatfeLPhL4EvPD1vH517qltPb2gkEKRLAjuyeZ/CqeSx3ccDiq8eh6/q+uakNEKQtcPJHei1XbACww4RmUEqxiZORgMp7PmgDc1Lx3bafKl7fa3eXmqxRzfY7SzcNBczEkoFjQEyY8/ys5A/cO3YGq1+njXxlqTC4u08OaTvEq7lE2oBDL5iYCArCMRwj5stuUnviuu8F/DXwv4Zt7a4fyZ763jKyyI5SHzMHewjBxnHHOTgfXPYQLpmuaKqaZOgtFI8qW1CjyyuCNmQQD+HGeKAOO8H6Bp/h3T2tvD9g1sh4nIJ/0lxxvkkQOzN143DGeldPpOn3KiWLa9km7InihRGlHbJLOx/wCBDNacGj2MJjPkGUxEGMzu0pQjuC5OD71foAhtITb26RGaWYr/AMtJSCzfXAFTUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5b8W5baHxn4KbULyCwtH/ALQie7nkEaRlrRwCWJAGDz1rPn8f+Gbe/kZ/E+j3ZjmMv7iR7hI0y5kB8tD/AASzfNnAESE9Ti58a7Eahr/gyBigXzryUl13DCWzuRjsSARntmt46FBa6Rq0LSRTBI/sKvKBvK+WgVSw6febjGTvyTQBztt4m8KzWgj0/wAeaNE7hYnivGWNTEF2n5XKurGMR8527kyF5IKz+MtAtrmGKXxbozSzyL5S6dIb55JXbLJsjBYKWzjOciZwMEA10eoeDNLk8QC9v8C12BLdCwHlzPM7sY8D5S+8q394YHrTPEfhTTtN0q3fQ9K0+1WznF6DgRqrxhmjz0437RgEcHHagDitL1vTdQ8ZQ6dHoN1b+HtS0xNNnOrxgLdGPEkYzljxA8xw5BO5cgYqtreg618L9T0mTw1aWGsaBLcCxs4tTmcSaW8zKAol5LQu4Xgg7Wx9R0fxg02MafpepQFrgaFOs62Vv8oKxoWlUqOpMQ2AcYDn1rrvFGjx+KfAd5p0hkZp7fMMsgG8SL80cvy8Z3KrDGPwoA4O81HX7vXXl0LVo9Hi1Wza6kgW3WeRLuBhbyqGYEEFjEpOOkZIxzmf/hDrzX724XXPFHiCaytbv7O8a3BgS5OyNk3LGBgh2P3eCB6jNcN4k1W4tvDN9qkNrcQ6hbLB4mNvaXLQnMgMF/CrqcqqSLuYA5y/rXK6mmua0LS88Qal4chTUY5fsbGLzpN6qrJH5kvzFjk5OflwBkkgUAe1f8K00G1XTdOmhWaSdFtrqTz5UkkYQOfM3bs7iVk+oP8As1Su/h3pFva6lPaWl2s2kXomt872doNod0XLfvFIdwAehUDtXkFlpWpBYo7i50XC/ZvLlm0tGZRLv5LMowfuEAlQVkPzZFdh4UufHu3bHqWnxJpsrRXFn5kkKoRgowcZRgwJzngFWFAHQ6v4K1HQb/T7nwJ4i1NG1RDsga7LwNMpEiyBWyNrIHBXoAcjpW9NrnibRmg0/wAU2VnrUdyZbcSWRMFyy8HocKzFGA2oRypPSuL0vxytte2uj60sEPkXLSw/aGSJdsoYOIZk/dSfJI4C4XBBGQVr0+zvIvE3hG0vLRjc6rY+XOY5P3Mvmxt0deSm/a31B4JHNAGPoGvWniq9aLw7qiqx3yPFcjyZrZgoRITCRnCqzyZ/vbSeCK1rqC8ub1mgsJYNLlR7FYypV8qRFGQg+7Hh5nz/AHUQjqK5HVdA0zxFa6VOfs97HFcLbCdLkI6gMyQyEr8wYjbGwzySufu4q8mqeItFt7mwtNVjuLmFkmVtWVpAiMWDRu64JK7HK4GW2f7QoA6P4ZSB5vGCDpH4guU/8ciP9a7WvPPg5Ot2njK5VShl8Q3BdCclXEUKsPcZU4PcYPevQ6ACiiigAryjxhqdxr3jWOy0xQ7aRMILPzIi8Tak8e4yuOAUt4m3nnlpFA+YCvQfFmsJoHhvUdUdGk+ywtIsa8l2x8qgdyTgVyHw30gaL4dl1zVSBeeTIS8oxsyxknYcZxJNuYHuiwj+GgDf2/2x4wQErJZaIN24P967dSMEDj5Y2JIPeRT2qbxne3EdjDpumyPFqWpv9mhlVQ3kLjLzc8fIoLYPU4HUip/B9lLZeH7YXhBvp83Ny23BMsh3MPwztGecKKxtBtV8SX2q65cOywyh9OsHiykiQK+JGB6gvIn5IpHWgC94W0+23pdWkCw6fawix02NSSqwLjLj/eKgDOflRSD8xpusn+0vEFrYq7CG3+eRQmRIzA5XPoEDgj1kT1GekjRY0VI1CooAVVGAAOwqhoum/wBnxStK/nXU8zzSynuWI4HoAoVeMfdB60AWFEVrayyhfIDZlfew4J5OSTj9cV5G/gF7z4h+Jo7e5u7a31TSrae7cBPLW5BMarJCDtlR0V9yMrKPmwQWFew3MEVzBJBcxRzQSKVeORQysD1BB4IrnNAMN74u1+9KQCeEx2aHyf3nlhd2d/dSzMMdMp1oA8i1oraa0+l+JZYF1uCHHnF/OmmtSXYK0TNuvbRtrBoCWmjKnBk3LIOvh8WalcG10u/s7W5vr52it7l7hV0m6UhgSsnJk4yBbhTICpySAZaivJLXU/jPqGlG1iurOS1t7e7jkhR4m2iaUo4ZSc/vEbggHGDmsLX/AA3qOha7qmj6DYafqWk3KLcxaZfSHy59wkLQmNgUdgUBR9yOMqpZkQAAHbeDYYtQ1z+1Nsms+WWT+2rv9zFGxABisYcECLsXB+YbQXlIJXrNTvnisbp5GfT1jlESyuiytIpxzEqkksSdqgjO4fdPAPjng7xGrSxXOizLPcaYGt28Oa/fhbm0IX5hazsfmPJU+aC2ON6IRmvq9zf/ABB8Vx+G/EVxe+FbdkJuFvCtvPd7sj7NZjcysgBxJKCzPkj5UIWgDrPFnxE8L6FYXOl2Fleazqk4ZJbCyYtK7gbXV5gcFxgKyqzOOPlrD0zVvF2pRC9g8D6lBMsHl2ImkjhjsU2kDyoG24bbgbixbqMKPlHqXhbwhoXha3WLQ9OityE8vzTl5WUHIUyNliBngE4Fb1AHkHh/TPiW1oYha+H/AA/Dj5GtmMlyfmLHzDIJAxJLEnJJLEk55qxY/CIXMy3niXWJL3U95L3McYMhTsglk3yIOvCMo5OAM16vRQByVn8OfCdtdJdHRLW5vF6XN0vnS/i7ZNdGunWSxhFs7cIBgDyxjH5VaooA5fWfh/4R1p1fVPDml3DqchjbqD+YxXOXHwc0G2Dv4WvdX8NXJACvpt44Qf8AbNiV9e3evS6KAPE7L4cePdGuLN9O8WxXKWSmC0WeMuII8BchWyN20bcjtn1NW7nRvidY3yahBNpeskyF5bSZxbEMY/L3xyKOy5ABGMsTjNew0UAeJaT4he+8caJZa54ev9Nk0e1nnjtLoK5RXe3thKJM4kUCSdmbqB1Hcy3C3PhvXPDUNjpl43k3U5htEw01wiJeooYk8KfMjIY9sfQeheOvDA8R2ELW8kUGp2jM9tLIm5CGUrJFIOpjdSVYA56EcqK8pl0Hxr4e1K41q5TRbFYIvskV69zNetmWRE85gwBzGgwqnA2lgck5oA5qO4vtS+Hfg11kh0W9m8W30hXzFRbQn7UzRkt8vBJGDwRgd67PT9e8V6RaONW8K6/ql05QmK0uopYGJmV2ZDHgg+WS2WIywwcbga4vStJ0yL4XaNFq9l/a+nW/iWI3UIDy+eZU8h3QjBc+aXYY+lddp2n/AGeMw6b45uorN3+zQzXdmrTqCfIUbsruwpjyxwceSx+7yAdta6/HBFNJB4J1RJI7tTEEsgpkRyMz5PRgGfKn5sgjuM2G8WXglhsrm0XTtTdiEt5QX37B823pvTJHzJkgdRniqMVzrfnWbaRrljMJJw/2a8ieHzRIgndVPzEnaGK9gGIP3OdqLXZhqF1pfijShbRBwbe8yJLa5TJIPqjDaMqw6kYJ4oAmi1+4lj2+QpljbZK9sfOQP/c28OOvXbxVhtfW2XbfLBHcAbmQTBePX59p7elacttZ38aSSw29yhGVZkVwR14NSWtvFaW6QQLtiQYVck4H40AU7XWLS6kkjhMrSR/fURsdvpnAPXt644qyLxGmjjEc+XzgmFgowO5IwKsUUAFFFFABRRRQAUUUUAFFFFABRRRQB5/8RQf+Ey8FFVDNvv8AapHU/Y5K1bfzb/zY4l8uU6hFczFiQoVAm4j1+ZGXA7j0ql43BXx34DmQbpFuL1QucZzaSHr/AMBA/GvNfjB46ls5bjTrV5Y9SlFrFdR2AWSdbjYziCF+RG+WyZMHYoyBkrkA9H8UeIIo/wCyW1PU9N0ItdyNHDf3EZaZVyscgXcARuKvw3A255yB598RPHxvdUEdoZUgQx3NrbJDvvZlhYSGTym2rBGWCYebJIU4TByfNVl125uLi81HXJ4zPbFRJYGTaVQBQWmQmSeLtuaUAEPyMDPSw+GX0awvItItZd15bac93A4aaSdiWMjud2x+udnysQARg80AZura54is9Phsru31KWK/srm9tUfVGAZWZWk8026QgfM+SWyoXI4FQ/DTVhaaMmrPdzDWoA0seryvIVwh2LFcA9bR0VFVv+Wbg5IypruvF+lC8+Idzbypc3rWWhTyT+XFKU8zzlKHaepIXB5OdgK4I4j+FXh/Rtch1bwzryCeVyur2rrc5miSUeXKiyRngB4wNufuuoOepAK4s7HUbgptnjsdSl3LEWIZLLWIfucnBxdKGOOmR61i/DfwRqfiPwrf+MNctle/0+IxaTZyIvl+bEcTSlTwS7Jtz14Potes/Efwk0Okx33h0JDcadpcljbW7MAnybJINpPIdZIk2n3NaPwgvYbvQdShtVK2kWoSSQK3JEdwqXQB+huCPwoA4/wbBPrvhR30u6t5bJoGizJGQkhSRXjLsW/1ZicsYzj75xg5qby4rHVNT+z32pRC0tftOVMTeQjCbe3ljIwTKHCsCGwNuOaLRU0zxJrekTMsmZWjiYsVEETMr/Mqg7g7SKmOMiMc4ralt4x4juLtI1hRdMu0kQsrCUecMfN7FCRycLxgYoA4nxpoFrq+v232SdleTTpmtjcWqzwRNbMphkORlAS5LYXJMmCCOayfsV/oGjaX4h8NiewgdlH9nXlwUNmx/dlFkOW8oSjbtkypXGCvOfW2VJPEfhWSJXkLpOnnbGw37s7ty4+UEqBluvGO1Y2gW/2v4Wail1MyzWU93FIwZcnZO7hS2Pu5x+HXnJoA86h+Jq6cYLPxF4ak0yxuBML6ZrbyCzF9plBHyb/NQdD1z35r03wv4l0rxJNYvLd21011GiSt/q2aSN8wSqpPQ88DPJHauY17wydSTVtHkt1Fvc3V9aWUZ+RYUa3S5Q55I/eq5JXrk+tefa1oC2Np4f1Hw1YxsmsR2jXFqsgjto5GwhYOD8rmYr8yEFWUZBXIoA9++GNv9kuvGUG/eI9cZVOMfL9mt9o/AYH4Vv8AjF4ovCmryTy+TGtrIfM8zy9p2nB3ZGOcVxHwCvr3UtC8R3erRPFqD63Ms6OAGVliiTB28Z+Ucjr17133iTVF0Tw7qurNEZlsLWW6MYO0uEQttz2zjFAHn0uv39poiyaTqI+y2GhW+ojAWbz5CzhlZ2ydp2YOMHPcU7TL9tG8TXWpX97Cttea1cWc89yqL5caQs0aeYeQMqoAJx6ck57WfxNp1s9wt1KyNDcNb7UUysxVFdiFQEgAMMkjjqakbxHpayWi/aHK3SxtDKIX8pvM+4PMxsBbIABIJJHrQBwV14s1uXwyNShvEhkt/Dr6yyrCpE0qZO05Bwhxg4wfQirU+rTX/jnRIrnUQk0GuXEA0wbAUiWyudkrcbzu4bOduGHGRmqXhbxDMusS3Ov6pdIgmvLo28e+RMhxEsSBd29Y0Tc4GQryZ7V3q+INNXU1gOopJ9oEXlBYyUQuMqDIBtBfI2gkE8YzmgDzHQPEF1ElldxamialcaRorx6eSrG8Z9wdQGy/Rj8wPHViQDWpq3i24v8AR7/T3urc3X9n6x9rhTAkiMTbYsjqvynPPXrW7c+NLCC/1LUGu3l0ywsjKkUMbE3BDgSMucBth2rxnBbnFdla3Ed1bxzwkmNxlSylT+R5FAHA6Z4hvjrtrafbU877Wlr/AGXsXd9m8gN9oz97rzuztx8uN3NYWn+ONYn8N2t/aahb6k9xptpcXkiKgTTZZHjVwSoOAEZ2w+dvl5Py8V6Zp8st5qt5PulW1h/0eNCMK7Dl39x0UH2asy1jAntPD+hBrbR9LiSKeWNySoVQEgVjk5wAWOcgY6FgaAOSj1LWtQvNPks76xvNQjttRFpLDMkySlfs7IshQBd2SVJUDHXGeKsy+LNQ1G20vWdPgaSzudQmSxtmVkeRY7C5Y7unLSoRggjABHOCOsv55dS8Q22n2VxJHDZMtzevE4BJ/wCWcR5z8xyx4xhcHGRWb401aQX9rptnLcxiAf2hfS25+ZIEORGSOQZGAXjnbuI6UATeDrltTaG9TxKNVC2+JoI1jVI5H2nkKMjbsYBWyw3HJNXbFZLnxHfXdpMiQxOlrcK8ZYybEZsIdwC4aVSTg52kYHWpLFpdG8MibVJ5ZLhEaaZpCXIdiW2DHUAttGOwFSIzaP4caW5f97FE0shPIDnLN+GSfwoA8r+JMCab8I7vV7d/s+sW2oyy2c8cSyyeY90U8pdwwBIPkYEFcMchhxVK1sfFen6d9gm0HU73RpCqvpt/Y2kgKc5iRoJWiVO3FumR3XjGh8UJ7ot4J8P2EC32rw6lBqF3bAkQ5Xc+15FDFNz7ivyMSFY4wpI67wV8Qode1e40TWNOm0TX4C3+iTNvScKSCYpCq78AA4Kg4IOCOaAJPhLp+sab4Xlh1yxTTQ13LJZ6ctx5/wBjtzjZEX5zg7jgEgAgDAAA7WiigAooooAKKKKACiiigAooooAKwPH2mNrXgrW9OR1Rri1kRWJwFOODntW/SOodGVwCrDBB7igD5gu9WufFXw+8c6Hbzi0hs7uDV7GQx+U0MUsiXLn5eQA0vBHOPeuQn8W6poGuWFprGr6kdPF01vIs0cN4bfazRyR5kTc7JIqfNuJMbqeDiuy8RwWfw7+IC2OrKbLQNTsbrTTdNGSjQEGSEBwDh0kJQ5/h8v8ADlvGsLXeq6bNrKwl3uLW7uTMRG0Lzw2pmOz3EZLHqpNAHaxt4ht9OGoW8DX0AVw1lb2/l3dpIFYSr5bOUkZVeQBAUDRvlOnHoPgDxzp+tWSC6uYr9JpI0aR2BaOQBYmDxH5o8sIzg95G7DNZngaG6Fg1pdMX1fTJPsLnzMm8t4zmCbI6yeWV+YdcHGcFah1nwNpNx4gTXrSI2t9cq8Fw8MgiN2siFWUtyqy4I4b5H7Y5NAHpMnh21jiSTSZbi0ZPmjW3kyhz/sk4I7/551tPkLW6q5naRchmljKknP0x+Vcj8OPEbXGhR2WqTPJf2P7ieR7cwuACQhkjPKEgH24znkCu3VgyhlIIPQigBaKKKACiiigAooooAKKKKACiiigAooooA8i/aAvbqxbwq+n2cl9cyXVzCtvGCS261kBPDKcDqeegPB6V51ZaFqUWspea6kl9rFzcpJbTx27SYleMSSSI5ABHyqCQEICbQCucesfFuOObXvB6TRmSPzrxmG/YAPssgyTkcc8jvVTTdAvLae8aO5kihTUWK2254lkPlqpyWPzArxl2cYA27COQDIsNBjt/Dd1PJZtbzx2EatGzmPz2ml83G30zgDPzKdw+Y8m7caTcHVSl3LGYLTUdPs7aRA7CQRJlvNTOAw3Eh8jGBjBGTq3ujxTWGo2pjBLXtrZQER4CGIph/p93jPO3OK39Nvhq2rfOjhLfUZ0TZKzJIqRgbmB44Y8DoCPWgDHhFu3ibxffAxQHyraJriJhGWwhcM5OAVOQq8nqc8GuJ+JVjY6LoNxd6Zd3dlrGmb5bGdrhjPbkhXMeWY/K6k5Qgg7SeQOPWNPXTbZtVQ3KSS3ckk7JLuEhRQFIAc5KqeARhRnivGPE0Mfj7x7aaVolxE8UEBgMrRLJ5anb5vIGV2JtAySGeQDkA0AbPwz+Jur6xZeGv+EoisdQ0nXB9mi1S1jaIw3YBzBPHyAxOArKQD7dK1fhDqHleMvE+hy8TWiRxthcZaJ3Uknv+7e3GfQVU8S+E4LLxBfeGrCIWun+IbIT6cyIMWmo2iDay5PDFFU5x/yz681T8BakH+NcN28UUY17w+J8pkA3KSBbgAHngoBz6UAdFrEE0fxc3FZmtb2CGFlVA6t8soww7AFlbJ/uitOCxuZbXXltls5bySBMRtvRSd0o+YtyM9c4H403VbzyviUI422P9kVUYDP7wlsA8EDjNPsJtMg8O65NcRtPDYXrB1d2J3KRIF3HkjdITz2OO1AGtBdJeeIdJ+xlPL+zzTsCG/1ZYKpUg7c5xwc8ciuP8KQef4B1K3G3N/LqFxkALGQbgqPl/D+Z713ltZWo1i4uX0428kNqtus+75GjJLMiqOBggZ4rn9MsYLLw5JY28f8Aodta4CQHAYSSsw259vX1oA0bh7aPXI7UOQbm4k2qRhSy2+CvHYDmvOks4r/wNbWojVZbW3g/dXNrvaMrdHY7KAABwSrjJC5LDmvVbWE2msztI0YEiyTfJ8ox8g+YZ5bg/Nx2rkdRtTcfDY3JuZhFH5c0CRN5ZXbLnBYclW4yD2GKAI/ghG1vbeL7dpmm8nX50LtGELHy4snA6DOce3YV3HifS/7c8N6tpPneR9vtJbXzdu7ZvQruxkZxnOMiuV+FwjTU/HccXCjxBKxHoWhhJ/M5rvKAOB17w5qNjqNxqmiiW7vbmS5BRYYyiRzRwqVO+VOd1uhDAnGSNp61QbwhBHLpdvqOu6atzYQ6fctDPGJJYFtXjLGJi48uNymCdvVjknpXouo3tvpthc3t5IIra3jaWRz2UDJrzrw7oN9riR61qdtsfXZ1urvzGAeG0j5trbA5IOdzA4wWYHpQB0dl4S+ytZH7bu+zJfJ/qsbvtMgf+9xtxj39qzdN+H8Wm3lpMlzZTqn2RpftVmXcyQRxoGjYSAJkRIcENgjIrvK5v7PPq3i0Tzxsmm6WCsKuhHm3DDlwe4VTgcdWyDxQBmXHgIT6XBZtqJAi029sN4h6m4kicPjd/D5WMd89RiuytVnW3jW7kjlnA+d4oyik+yksR+ZpbmeK2t5Z53CQxqXdj0AAyTWL4UiuZkutWvS6zagwdISwIihXIjAx3IO4/wC9jtQBb169ltrZIbPab+6byrcHHDd2PsoyT16dDVO4aLwxoUVvYxie7dvLgRuDcTtyWbA4ycsTwBz0FWNKP268m1RifKwYbfnI2A/M/wDwIjv/AHao6EDrWrS65MG+yR5t9PR1I+XOHmwT1Y/KOAdoPUNQBoaTZpoekObibzZvmnuZ2wDJIeWPb2Az0AAqhp1vf3/2STU95RpTeNGxwIsf6qMYA6cMc55yMkYq5q3+naja6aCDF/r7hSmQyKeF545bGQe2frV3VrtrHTbi5SIyvGmVQfxHsKAKl+32zVraxQuEhxczsvTg/IpPYk847hTUeuFLq9s7CQp5IP2q43NjEaHI+oLYBz2zWjZWkduZJfLRbmch52Uk7mxjqecDsKybeB9TsdZniaJXvQ8EMinjYqlVJx33FqAPLfCuvyR+HNZ8SNdK+pXusXexniSURxxgoHToxRYhv2g5bt945s22hyWXh+LVbi5eW6u7lHtdwWUWU0Ts0YkZT95mEgkwCN77chUBrn9B0HxqdGtfDtv4RsNPtNFlikMkV7F5dzdxnd5pBUllc7SVOxgpxk8YzPGNp4qvPGGn6B4hfwxosmuIZtS1TRVuIXKxDcYnPmYlYqMDcvGeMUAer/BHxhqHjPws+o6hZ6kiyTSvDc3cMUSSRmRtiRhDlgqhQWIGTnk16JXlPg+1i8MfEL+y9NjWCwvonDQIpQHaivFKynpJtDqxwC3yk5Ir1agAooooAKKKKACiiigAooooAKKKKAMvxJc6ZY6TLea0kDWltiX98oYbx93aD/Fngd8mvkXxqs2uXniLVLiJZtUluHjnjeUI1igaPcm3ocLhWcHhkbtXsfxK8TzeIfEbeH/D5eQaaDNNOi5jjkAI8xmPA8vquMkybeymuN8a6c1h8NLO3tPMgsfsAnS3eM/I7sr7ZnIwJS2dobO4k7qAPU/AXh9bXWNTF5+8SQD7PjKm328PHnPzckNntnI4Kk9T9ia3Mpnjt5ojkPkZDof42Ud89RjB6jBzXM6c4jkMgDp/G0UhKhD1B4zgDPOM7c90Ix1EFw+zzlK+SCOPutFnnnHHpyPlPt3AMO702WW+s7yzlNvqdoP3W5t5eP8AijDf8tYjnOD8ynkc8V0Ph24knhUy2wtnUbZEjkDIH7gqD8p79uvODxTJrNLu3/dqrITkoxKqDj73HMbe6+/rVYpcQylx5zTKM7gALgD0ZRxKvXkc9hzzQB01FR28qTwrJG4dT/EBjnvx25qSgAooooAKKKKACiiigAooooAKzdY1q10kIbqK/k3gkfZLCe56evlI2PxrSrndR8G6PqV0Z9QGo3BMnm+VJqVyYQ3PSLzNg68ALQBxnii8ufEniLwxf2vhXXLjTtJuZ5rn7Tbx2xw0DKpUTOhJDEc4GPUVQsfG0VlJb2cUWji7Rp55Y5dbtoWZ2Y4HlxNM/wB3BJHftWh4i8FeGbTxr4GsoNC01LVp7t3j8hSJGWAlS2fvEHnnNd3JZ2lkdQnuLO3jtZERN0WS7KAVwQBxjOBj1oA8rTxhq0ktgl1pth5zXEl7HLb29/eGYgHHlf6PEvCkD7xB9quaNf8Ai77Q8Om6O9uscREbNpSxbVkbf1e9Y5zk8p+FejL9ng8Q2tqBtSCzxEGPC5YKACe5Ax15xV/T41827mwd0kpG49wOB+HWgDwnxLpXxA1UKL+NpnaQx+UL63RpUVDuUIttuI53Fd5zgVi/C/xIPhZruuWfjbTLuQXk6THxBalrmERSH5A5xuRclzzznjHFe86aFup9LuG2tNunmOAM85XPXjjAqtL4UtJb6+EwV0vLQ2ssBT9y8W8kZUnlxuIzjHtQBT8dT2ms+DP7c0SWO/l0qZdQtmtmDZeI5ZD+G4FevauVis7SH4meD9Qt7ozRSXF6bf5dojhuLYSrHj/eViM/3jXGaloj/DDVbLU/COpSNpVyjf2hYT75k8tSFLjAAcZJyOHHOwEZFKuuiz8D+GdbjtJZrjTNRW2kSOcPnZKSAJBwVMciqCe3pjFAHeLAdV+Kt9eQeQ621wi7ZVZtvkwsCwx6SSpXR+H0s7Lw5rlxqMZlhn1CaW4R1ySSwUAj8FrnfhZp7RaTqesXAeKe/mkbMjrI0gQsXYEEghm4+XBwqk111kI5dMCgjbNex+YuMZ4Q4/QUAdA1om+6kTcJLhArEsSOAQMDt17Vh+EzDqVjd3Ua3ELtL9mMhVoy4h+UEA9iQ3PfNdLWTdXq3egvcpPNZKxwJFTLrh8dPfH60ARXGmvBrl7rJu3aJrLyfsxTKqVJbcD156YqpcW8b+BEikKrG0CMdq8DJB4FbWstt0q7x1MTKPqRj+tZ2rP/AGZoljA7BlDxQOxGcgdT/wCO0Acp8KJC3iz4koD8i67kD0Jgiz/KvSK8x+EL7/FPxGYkktrKvkjGQ0CEfpx+FdZ4316bRdNii02JLjW7+T7Np9u5OHlP8TY6IoyzH0HuKAOf8WyP4x12Tw1YKJtN00rcauGyFnbG6K1DepIDN1woAPJrudMe7k062fUooob1o1M0cTFkR8cgE9QD3rjPA2nS2d8LCwupm07TDJ9suHHzaheycuxJ6quT9DgdFrr9Yv002xecrvkJCRRjrJIeFUfU0AF6800iwWFzDHMkiNOD8zCPPIA7E4wCau1l+H9Nawt5JLlhJf3T+dcydcsf4Qf7q9B7fWrWpzzW9lI9rF5twfliQ9Cx6Z9u5oAytWH9sakmlIM2kJWa9JHDDqkfvkjJ9h71c16Z/Ijs4GZZ7xvKVlXOxerNzxwM1JounLptkItwkmdjLPLjHmSN95v89gKhsv8AS9Zu7plcJb/6NFuPBPV2A+uBn2oAzPFzsbaw8Pac6wz6i3k/dLCO3UDzD7HbwM9zXSWsEVrbRW9tGsUESCONFGAqgYAHsBWLosJu9a1DVpFkAOLS3DHjy1OSy47M3rn7tb1AEEFskNxcTBnaSYgsWbIAAwAB2H+NUbDUpL7Wb2C3WM2VoBE8n8Rm6lR7AYznuRUuu3zafpzyxIZLhyI4YxjLu3AAz+f4VJo9l/Z2nQ229pGQZd26uxOWP4kmgCLXrhobAxxBDPcEQRK5wCzcc98dalle30fSSxDC3tYuijJwo6AetLbvFeS+cqKywsVjk65OMEj+X51EL9pNaaxgQFIYxJPIc/KT91R7nk/hQBgQiWCDTI7i4ltru8uW1C5AJVgqjcUYdhgIp7deteYeMraG813wN4u1CaMabbak3mTSsoE6FspOO4UDjBA4XOMYNdX41iufEfiafQIrlYIZVCajdRj/AI97MAOYd5XAeXqc52qPesjW9Ol1iHxRbW+lqkWo2NsltCzK0MLRM8RQKFGPlYNx6qOlAGR4i+J8D/GK0u9LVr3w/okTWupX8BdoozKwBOBwQhUDcMjLdhXv8brLGkkbBkcBlYHIIPQ18reCdHsdP8N22l39pa6hBaFra/t5LeMXVtJLIRHIvmDYEKcs5L4I2qFPNdP8P/G0/wAPtQm8O+I28zwzbTNbxX4dXOntu+VJlX5kQgr8xGFJwcc4APoSimxSJNEkkTq8bgMrqchgehB7inUAFFFFABRRRQAUUVHcTRW0Ek1xKkUMYLPJIwVVA6kk9BQBJXl3xK8cBZ/7B0WZ/Nkm+y3NzCwUiUjItomPHmkY3HoinJ5wKzfH/wATmmY6b4Z+1FnUkPAn+kXY/u26noODmVsAAHaGOK5n4YaG+qy6bd6ksDRalG4S1hJe3Ftuy6o3JPbc2d5fqcAUAb3hHw1dx6JqWm6lKba6wJriWPAWzdzgxQH+4IxjccknccZJrX8cQ/bo5nZxHaXOjTTM74eNSPnEgiONxHUknuBjrXSeGrJBpuoLZyBZEuDEDclHKlFwFOPugZyAckEknrVT+zpdQ/sa4juVlja1mt7xpgD567SgPJ4AYk8DkcUAYuhXCTaFpVyhAheygmRm+UAbFAZSPuDJ24P3CcN8rDG4V861e1mjZreRgDHzEwcHIKEH91IOoH3WzlT1ri/h7LKfC1lEktxPPbSSW5mMfluzq7KMoeDlcAHo65U8gV2tnllZoI2LKmDCnznYDgmPP+sjz1RuV5AwcUAX7RpLVVdmMkStzcLHsKeokUfcPqQCpwSQM1vKLa+h2sFcZ3j1HoykfXqD61jW/CJNDIxbO1GRic4P3BnqP9huRzg1uST29nAjSFYoyQBhSACfbtz60ALawSQBlad5Y+Nm8fMv1Pf+f1qegHIyOlFABRRRQAUUUUAFFFFABRRRQAUUUUAcH45nFt498EzurMkP2+VgvXAtz0z9cVstaldM0extXufLlmWWT7ScuY+XZWPryBiua+JtpPf+OPh/bWzFN15cNMQ+3MKxZdcjnJ+WutmxceKkZpR5VjbFyA33Xc4+b/gIyM/WgComof8AFV3VvGsbyPLHAGKk4VYzI4z68jv3rbZBZabKFbAjRm3enU5rnfCkt5K0MslnKEvZJ72SZsARAnaiDOSSQAeCOPyrX8SSKbFLTDs95KsChO2eSTjnGAc0AR6RAhvI54yAsdokYAHXd8xOfyq3pt297PdtgLFBK0AXqWIxls/0ohuY0tb2aF5JlhdxsZdm0qMFF4HHHXn60mkA2ujQtdvGrBDLK33VXPzHJ9vX2oA5PVdSa8iEtzaLZI1o00YnTJjkim5I4zkL8w+teMyaX9i0T4reD5Uk+z2t1DqFkrPn/RpXG4hz04Jz6HNe/Xln9svdGS8liu1eKdXkUBQ6sg6Y7Y715d8WrBIPEOu3C8wX3h+402VEHzhokE6PnucEjHsaAPSpIBbWMumaQnm2tnp5t0JmJZSU+Q+jZGOev1zVfRB9ssdC8tybeaY3O4Nz+7QAD3GRTtIW2ktNMSZpE+0wxvHMm1DIsUI+YkckHcetWfDemQ6ZqMGn6YzNpenWSwoHk3kOzbs5PU7e/vQB0d28sdrM8EYkmVCUQnG5scDP1rNu53Wx0s3saxzzzRK8a8hXIyR78g1W8TzlLu0g2nbNDcAt2U7ABn8TU8qx29/olm7gsqvtUjO7agGfbGaAJfEhjbTRbSTxQvdSpDEZSQGcnO3juQDWb42trjUYbfT7T5pJCZSmcZ2lSMnt/Wtm8t7mW/sZI5YltYi7TRsmWc4wpU9sHNYOtN5njPTIEnlgkZDK5jb70UZ3Yb0VmYDnrtoA5HwLqdpovij4s6lqUwhs7XUo5ZXPZRbp+Z9u9a2iadq+tzXniWedbXVLyFI9PtLhcnTLZupK8/vnHJ+gXoDXKaL4fm1r4oeNpo5vN0mx1C3uTp4wgu7vyFKNI3eNRghe5APYA+v6Pp/2CGQySeddzN5k8xGC7f0A6AdhQBJpVhb6Vp0NnagrDCuAWOSTnJJPqSST9ayrB01W8/te4KrYQZSz3nAPYy/j0Ge31qfU9+qXZ0yPItVAa7kB6jtEPc9T7fWszVo/7d8RwaMIVOlafsub0MPlkfrFEB3AxuIIx92gDrKKKKAKuq3TWenTzohd0X5VAzljwP1Iql5TaV4eEUSsZwm0CM5YyMeSPXkk/hVHT76TXV04usZjZmum2N91VYhB75PX6VuXVotzPbSSM22Bi4TsWxgE/TmgB1jbLZ2cNvHjbGoXIGMnufxPNT1l61dyxS2FtbSiOa6nC5ChmCAZYgfQAZIIGauahdx2FjcXc5xFBG0jfQDNAENzp6XOp2t3M5ZbYMY4scBzxv8ArjgfWrrDcpGSMjGQcGsnwpBPFo0Ut5Isl3dE3MrJkLufnAB6ADAx7Vdjlum1GaNrcJZog2ylhmRz1wAegHrg59uaAINSvrPQNJaeZWS2hGFjiQuzH0VRySa4i81jVbSyisdCsp5Ne1VjeXE0g3xWULMAWLfdLhcbI89QSeOqfEG8Go+MNO8PWlut9fi2a6SJWOLY7wPOm+ZQFAB287i2ccZy/W9QsvDWk3MLXf7oTh9RmKs0l3JIdrQIoUkyuMbQv4YHNAFHxKNO0XwZeaQksi6ClvKNS1ZzvlZgcbQxB3zMTxw2TwAO0ul6LfXOhX2vatbvp1w0IFjaA4ktIAVJeTbhfOcKC5HQALkgGqvw3srnXfEV7c69p/2CDRpEWx0guHFvIyZ8+Ujh5iuOeQmcDnJrtPD1pGdD1LRl3rFbyzWqh23EI3K89+GoA8w+JGjroGtLrNq94mg6nt+0/wBnFo5Uwd6yIykMzo3zqo6rvABph8NXV5oV5cSW+k3CrZsbKRzmOZZW8xi4VAW3JzwWXcclc5Nd94ws3vvhVPFB5iywW6OjqSrqYmBLKRkg4U15paLN4K8RqdV3TeFwHntnWHfHatKAxk2HJKEdV6xscgFDkAFTwlf+IPh1qF3Y+HvO8QeGbTyxLpcl2ktzZb13YQqSFxz97ap6YU8n2jwT460DxnamTRLwNcIMzWcy+XcQ4wDvjPIwTjIyM96808MqfEFj4nV47e1tbpzp1p9me3VrNSMDLIPmbDlgQWHJA45rkPEHhdrnxnpWgeGGWIWNpHMzKJHuAIsIjK5YGMsMtuUxjOQcnFAH1DRXit74k8XeBdseqX8F9YL5eJ9TgZYwpbaq/aEyUZj/AH0k6ZLc11WneP8AU7iBJm8H6jd2z523OkXUF5C30Ysh9vu9qAPQKK88vfifDbP5T6HfW03f7fd2luq+5PnE4+gNcjrvxC1fULYSyTf2VpUjqofT8lpAeCouZFADEbiNkeeANwNAHo/jPxzpHhaNkuZRPfbdwtYmG5R2aQniNP8Aab8M9K8O8T65r3jaE3d3PFFpDIt3aptJRo9w+7Fn5nGCAznluigGr+jeCJdT0q4udasXke4hkuLK1k3KYlZ9sby5y0kjMSxLEnp0rs7bTkKKLszRizu4Ibd4rMTGY4AJRedu5QdxPQgnr1AMW58K6VDprR/a5WcafLfXV3dMAzSrhY2cr/y0Vu3QD5QK7PwXYNZ3Bs7R4LlLWyjMuxWjT7RIAWYZ4GV6BenTrWj4itLe38MXaaVHFDHJEkSSJtDASSfMfn46nPPU+9XLBI5k1JIWuhbCWOJd7GIALgfIe4469zmgCvo0Vq9rei7l2LFq0h3SFfmfIwCcYOcgfpTLu3W2sDPf2ssq219vJt9qnyww2/KCcoMjK+2a1NWvDai6gljiIeGSeBioxuQZIIPU55zT9KjS5t5vNFti7iSR/K4d9yYLMPfnGKAPN/DyLB4l8UaTcTReS18bi183LGJZxny5ecGN2XKkcqfQ4rpDE6yskgkiljcEl3+ZX6Dc3ZscCQfKw4YZrmru0isPiBf3UeVstStyGSZGLwywEI52/wDLSJkKlvTAYc110DLsSK/ZgYl/d3AO94FPZj/y0iP97oRw2DzQBbtrjFyXmdre4G1XuFUfNkYCzJ/7N0PGD2rSugZnX7RGY5hkRSq2F5H97+hBHHQ1ThhEciRXabH6QTRcowI6KT0B/uNkemcVJFDJbRtHGkZhbIMTjEUnqBnPln/ZOR6UAT6TG1tcPEflRl3KvI6eg5X/AL5IHP3RWtWXZsUlKxM6NjLW1wfmHurdx155+orUHT0oAKKKKACiiigAooooAKKKKACiiigDgPiVPdaT4g8La/Do+q6ra6e9yk0WmxLLKvmxhVOwkZGQec8fjXP2Xj0yxanJffD7xwRfykMVsFUtEBhVP70EcA8e5r1+igDyzRPFt3ZXd9cv4F8ZkzsqxILO3VYoUGEQDzvqT7ntTv8AhLb+bxJ/ad14H8YtFBD5VpCLaD5S333P7/GTwPp9a9RooA821rxld6nZJZf8IR4yjSeVFc/ZoAdoO48+dgZxjJ96uaz4q1G80y4to/BHig+avlsGjtcFSQGH+v8A7pNd7RQB5rL4l1L+3tOki8DeJ47Cyt5EULFbZ3NtULjz8YCjrWB8VfEYufDM15P4W8R6ctqXmku5oIURVMTx/ORIxx84BwCa9prG8Z+H7fxX4X1LQr2WaG3voTC8kJG9Qe4yCO1AHmfhLWtRg07TJbzwb4nVrXS4rRPs0UW04IOU/e5HAA9/0rU8LeI7rSo7+a58F+KI57u5aUxxWkRVF6IoxL6dT6k16XZW62lnb2yMzLDGsYZupAGMn8qmoA8p8TeKtSv5Eez8FeKt8aBY3e1jGzc6l+PM5yi1dk8YsNZGpHwX40aZYfs6L9jjKBd24sBvyCeB9BXpNFAHm7fEbVBezH/hBPFZtVRBGBZpvdj94n5+AOnvWBN8Qb9/EOtMngXxFdX5t44ra0a2UH7MSdzSHdhctuwpOSBXo/ivxEuj/ZLKzjW61vUGMdjaZ++R953x0jUHLH8ByRS+DPDo8O6ZJHNdSXuo3Upub28k+9PM3U47KOAq9AABQBy/wmjvptZ8Y6teaNf6RbX97CbaC+ULIUSFUJwCcDI4ruNVvHhMVtagNeXB2xg8hB3dvYfr0q/UM7QW6yXU5jjCJl5WwMKOeT6daAMy4eLw9owWBDPcMdsafxXEzHP6nJPoAfSrekWKWVu7GKNLm4bzrkxkkNIQMnnnH+eKpaXC+pX39rXaMkagrZQuMFEPWQjqGb07DHfNbdABWP4r1GCx0LUGkmKSCAgCPlwXOxSB1+8RzWxXA2AfxD41vZlgdLCynT/SSoxNsUhY1POVDFnP1XnIxQB1Hh7SzptvtdYw4RIk29o1UAA++ck44ya1qKpazemwsXljjMs7ERwxj+NzwB9O59gaAMxIHu/GEk5lkaGziChdu1Q7ckZ6njBPbnB6VJ4iX7bdafpZZQk8nnTKV3bo48Nt9stt59qu6Jpw02wEO7fM7GWaT/npI3LN+JqvrFjaTSSm6uGt3vYfsIZMBznJwpIPJ5/KgBn2u40nQbu+1eRPOUvLsLjauThIw2Bn+EdM5NZ+v+JJfDvh+z89f7Q1+8HlWlmg2NcTYzjHZVHLN2A9SAa/iPV9OsRC93deVpejq9zdEkZPlgBBk9fmJGOpYACuf0S3v50uPH/iHTv+J7NA6aVpnGbWHbuWJi2AHYgsz5A5xnAoAer/APCH6XK95qfn67dOkmpasYRukkZ/kgjXaQx/gSI4IVs8c1R8D6XcXHiXSdQ1eGK0+yzXUGn6YkpdLKMIuRuJxJISSS4Bx90HAqroNkPEfjrw9q+xo9OCPqUEczKHklIKea56uQDtQHO1R716BYWy2lzkhUcalLtwmz5ZAT7Zzgc80AbmnQGD7TlFXzJ2fgYznHJ/KqumxBNb1iQbMu0WcDnhO9atZel/NqurSBV2GRFDAHJIQA5+h9KAM/TFW88IXlpPJFGUSe2mZsbEPzA556AHmsjxJp1slnpvlo1yWtFhzC+1Xjjw3yHscEsCOcDFdPpEWINQVSmXupT13gZPcZ/Ssu6eXUNH0QzSW1w1xMIpZbVSqFWRwxTOSKAPLNe03V/h5qkM+nPLJ4buCfMhtUMYGR95Sm1hgZPkhlUlty8blXuPBt7pl/qL6hpkUaG43Avb7281YyRvZxuXGT90Hk55NXbrToNRsPDVxqi+a6b7Mqp+UiRdpPHQjYuCOhrz690q7+H+vxWs1oNZ8LiRrqJeDPaFuOFH30BDNsxnqy5wy0Adf4w0228UeMtH07VbffYW9u1wykl1aV32qACBwNhycnr0HWqvxG8J6BqGjiG8tJbczXSwiVH2yxovVogWwS2AOBkhunFJpt6134mn1S6vUbTvsStaz2oMm4FySzJ8yn5RjcPlAY8A9Or19ftEukRFFe2e9jCq4UgqBuDDK8EEYGCCRzk0Acefh/YwW+i6bDYxwXHnyl7gxqzNCx3MVYjKvkJ19xk1v3trpd9ql9pd7qlpLdPdKY7BpNvl4i3CMf3WYHecDoc4qeK8ji8bazIs1mkcP2SBwquzmaUhQH4xu27QMZABy2KhPhS9vdZ8Q3FzdzW1vLqUd7ZxKEKO6WkCJIxwWwsiH5cjOwdjyAbkWimR5VvVie2a2it1jV2O0D7wzwcHA5606G0SHUHghulDq0UwgWba6xBSo3ADJUkHrwcdciuFTwxqT6a0f9k3tpGLe2Se3jmgl+13CMS0rK0m10PAbeVZweR8opV8Ma2weZdOhtNUn0RrKC4t5FRLOYNMRn5yy5V1HybwpzjgA0Adzrun39/ayxRSoAbiJ0XzDGAikFgx2tuzg8Y/Edadb2onutVkhumKzSov7uU5jZAAw/2fpXE2PhS8kjtYGstStrJr+GW5t5JoIUCCGVWKiB+hYxhuct3HU0+98O6n9puDc6XNqVh5l4Le2W4QGNnMXkzfM4AACuM53LngcnAB1/8AYSrqqXEezyDLNJIrkk5kQA7fTkVf0y2ltoY0mMbMsYQso5OCcc+mMVz3hPQLy01i/vtZaSe72wRwzmYlXAt41kYJnC5cNnIBP5V11AHmPxVtfsF/pWtTSXKW0V/AWu4jn7BuDRszL3ifKKwx7nFblujRJ5flSJ5I3tBEd0lvn+OE/wAUR/u8/wBKi+IWnNqBmhRFlklsZI0gI3eaOd3ydHKko23vyO9ZHgnU01Dwzpc9yRGvlB43t8sbRl4cKTy0WQQVPKfdboDQB2FnHLHCr2rRTwPyYsYjk75T+43+yePTFaNu8V0jNEWVwcOGGHT2YH+vas2BhHOPMaKGWf8AiUZt7nvn2Y/n/vVpvao8gw5SVANjr95R6ZP3h7GgCee3inj2SoCB0xwR9COR+FR2UM9uvlyzm4QfdkcAP9DgYP14pi3L26n+0NiKv/LYcIR6n+7+PHvVsEMAVIIPII70ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVjeKfENr4esUmuFee6nfyrS0h5luZSOEQevcnoBkmrWt6nFpNg9zMskjfdiijXLyyH7qKPUniuZ8L+HbttWbxZ4waFtdaHy4II2Jg02E8siZ6uerv36D5QKAINGtp9Dt73xb4yEb+ILpBGLe3/eC3jyTHaw/3mJPJGNzH0Art7SV57WGWSF4HdAzRPjchI6HHcViWEdl4jurDXQJmitfMFoHP7t93HnAd8qPlPoT610FABXNmdfEmoiG3y+j2j5mlH3biUHhFPdVIyT0zgdjTtRtr3XtQezlWW00WBgJjna943XapHKxjuep6Dua34Yo4IUigjSOJAFREGFUDoAB0FAD6KKbLv8p/KCmTadoY4Ge2fagDA8VX1y/l6No0qrqt4M78820OcPMfcdF/2iOwNa+lWFtpenW9jYxrFbW6CNEAxgCqmhaOum+dPcTNd6lckNc3TDBcjoqjoqjoFH45JJOrQAVizyJNrFxNIFeDTYs7AMt5jDcSO33cAfU1tVzjwj+zhbSpJbm9v23ZOG++X/EELj6UAa2jxypp8bXJbz5MyOC5baWOcDPYelUdTk8zXYEeINBZQNdsT3Y5Vdo9QA351t1xuuxapf2fiyDSbhYbyYJa2s8h+WLMa7mH+7udseooAxNJ09tX8ex6jfSXMthpMJtt20pDLeIxd5T6qnmFQehbdxwDUet6g/jPVrXR7KW7htruOS4Z4WKF7FCFOSDgedJwrcNsVuBk52bHSzB8PfsdrMtrp5RV/wBJ+VYLQEb92cnJQNkk9WJyKq/D+wzq9zrLuwuNSdpihjCmOHyohDEeAflTH1JzQB1unW8E/wBhvLdVES24jVcDCgdMccd6g1FFdrt4gpnguIZBkdDheufYmrmgI0WkwQyAiSLMbA+oJHqaiuEKy3wLAb2idcYzjIH9KANWqunQGCObcmwvM8mM5zk9atVl+H12292MEZvJz/5ENAFnTYxGtxt/indv1rIg06PTX0DTI7iZ47fzHBfkybR/Fj/ezWppSBEucSb83Eh+nzdKulQWDEDI6HHSgDm7eNrrw9Mm9ztuyUZsggCYHj9al8WafFdrZyTQrJD5nkz5bbtjf+IEc7gwQgjpyaueHilzoFmzJ8jxhtrD3zzmm+K38vQLqTcy+XtkJUAnCsD3+lAHk+p29z8Ptcmu2he402SZLm/SL5fMjBx9rQL90pkCaMfKyneAOa7q33yDSbmb7BKvmm73RyiMupUkzKCzAjnnnkEcjFbPiS1Gq6HO1lhr2BTLbOuC0cwGQPx6Fe4JB4NeVaJqc3h2e1hmiRtBnnjjsYN+Rp13IB/o5IyPJfdujfBADbMAUAdbBqL3WiI9s9zuk1+GMuszyFsTqXTc2DtADKQMrgHGRWzd+Lvsuq3cMtiRYWl/Fp0115oyJJIo5EITHK/vVUnII64IzjL09nnGjJDY3N3ENTkneS42mS3B3lZH3dOuMDJIIIwK1IvDllb+J7/U7uSSd7q6+2JGzSiOIpbwxAhA2xjhCdxGfmwPu0AZlp8RUuNOlvV0e7aIxRTW4QnMiySLGqsWVVV/nU4DMMZ+binX3izVodWhs4NOhM73kFvJbyyAbA8Mkhw4yCcoOcY69etWtP0XSVlTTls7trdmcBVlmNtD5MqMqqpkKx/MFwFGCFxwBirN9pumXusXkd3bBpnljl3wXLxzBo0UKw2sCOHYZXHHXrQBWn8brbxTXU2nsNPIuxbSrMC0rW4cuCmPlBEblTk9OQvSorrx2bMtBd6aY795IUgiExdXEqSSKWZUJXCwyZAVugxnNO1PSNMWTWTBZb3JEMkbyysn+kMPNKpvCoWDkkrgkkknmreqaFaXOoXSCzRmNvbssiySLIrRs4QqyuCuAzcrg8nJI4oArR+OoTpt7dS6dcxNaWJvJI3+UnEskZAyAcZiJBIGQQcCpLrxdcJqj2ltpQlQX/8AZqytchN03k+aCRtOExwT1z0U1Y1Xwnolxaol3HcONn2Yl7yctKjPu2uQ+ZOSSNxOMnFQ3VtaxHWrkWsSzWF3/aKuxfDS+QAWI3ddmVx074oAINbj1ezsL+CER31vJulgLZZV8xoZArcAjcp544A6ZrE0COJtW1y1sViELXP9o2u1vLaXzSRIenyOsquvv0Oetah0qK11SzWFIk0TUbaW2kjDEsHkLScMSTyWk5GP0FczeyPpevafqUkIZfNNvcxlhGFikZUmO7PzlZljYf8AXY4NAHXWrGCIq4iEEhCssg2wuc8hh/yyf2+6e1b9moSyCKJwFz8kjZdB6Z7+xyfqapCPILFxIhynnsudw6FZV4z9f5d5beKS2jVIcgdRC7ZGAP8Alm358H17CgC7CpkhZJmSZTlSSPvD0Ip1vbxW0eyBdiZyFBOB7Adh7Diq6QsZw+Skp5LjGWHo69PbI9O1XaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACob2ZreznnSGSdo42cRR43SEDO0Z7npU1FAGPpFjcS+Vfa0I5L9HleABQDbRyY/d5HDEAAFu+K0ry2hvbSa1uo1lt5kMciN0ZSMEGpqKAGxRpDEkcSqkaAKqqMAAdAKdRRQAUUUUAFFFFABRRRQAVHNBHM0RlQMYn3oT/AAtgjP5E1JRQAVhX+n3MWiahbwyiSS6nbBWIjYkjgMMAnJCk8/jW7RQBzHjZHOl2OmQXDRHULmOyzxgpy7g8Z5SN16j7xq9pcdq2s6nsRfOt5EQdPkDRJwPTIA/Km6hpr3nivSrxwhgsYZmAL8+Y+0A7fYK3P+0a14p45ZJo0bLwsFcYIwSA348EUAVdIcvBOSc4uJR+Tkf0qvLG15fXyoQDGIo/mzjg788fWn+GpzdaLb3RAH2nM+AuMbiT0yfX1qXTlia5v5oefMm2sc5yVUKfpgjH4UAXicDJ6Vj+Erj7ZoNve7WT7WWudrHld7FsfrT/ABVci08OajLk7zC0cYBwS7fKgz7swH41NNKdM0KSURLm2ti/lghRlVzjPQdOtADdAkM+n/aCSVnkeVM5yFLHHX2xT9dYpoeospYEW8hBXqPlPSpdNj8rT7aPOSsajOc9qbrF0LHSb27aMSi3geUoTgNtUnGecZxQBJYLssbdR0Eaj9BWf4tAbQLlGR3WQxxkJ1wzqDj861IH8yCN9oXcoOB24qnriCTT9rdDLF/Ft/5aL3/zmgCPSFiS91QQAAeeu7Hr5a5rkfEvg8vbtbW1qb3T50uBew5CGSFnDJEnoyFmKHsV6jOa6vw8jBNQeSNUZ72Y5GfmAbAJz7AVBZXEi6lDFHIzQSTXPmZGfmDDAz270AeXfCsT6dNHoZjt3k0y186K9SQma9hmfLXCo33R8qhwckOrDAyCfVxJcLdQmee2+0oFV1CkAqc7ioznkgAbuPl9a89+JukLpmqafeaeGt5pp3ktrt491vZXPDkSkHIgm24cdAwD8HJpmjePUGjXpeKXT9YsLg219pt3KC0U7MDEu4jHluSSGHGwk4JFAHZeHYfth1O5guyZvPuFgZ0B8ne2QR6qQFb3zWraJPb3Ki8zO0Fou65CKN75O7AHzAnaDjp09K5yBLyw8Pw28Ua3NzDHHCFkn2yv95flfILEDewb+LBAro7BdlpdSSiWVpF3eWwHmlQuMH1JwevrQBSKZutSZmG26voUizzkoqZH5o35Vq2gP9oXzHHDIAcdto71zulqt5HaXNvA5ka9a5CMxXEOCqtzx91kOOpye+a3rWNLbUbz99EZJsTygnDKMbV49ML19jQAv2hp4LCVTGfMkBJAOCNrdM4NUmurbTdYvF1KaKKO/mijgD4AkYoRt9ydjdfp6UkUzm70K2d0cNDJOzeb5hJUKAQ3G77/AFqv4hskuL6KBPM3To0W2Rd0QLB3V/Zg6g/ligDOfT5tQ8Hpa2L3MV7o11+5CNhpWgfhcns68dvvVX16DTtb0jUra9uHhtdRt0uYJAv/AB7mQCMkY6/Nhj6FgfQ1teH5p5NRuDOWRb61hugrH5kfbscDtwFU/VqzNJsmg0KwS623f2e5msLoyLx5TuUYKPTcEx7Z4oAr/D/XdQvNPjttZgitNfs2+x3sSt+6klUDv2ZlKup5yrDr27S0eOUMI8qV4eB/4T9O3b2rz65km0LXA95+/g2pp96kkgQSxsT9kuB0AO4+Uzcc47LmurgukkjWdi8sEYwZxxPbHoVkXr+n1HGaAN6SPchGWz2YHDD6H8BSQSb2kXerbDg4GCOM4I+mPzpkE+5FYlXjYZWVOQR/T+VTFFLhyq7wMBscgUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIRaW63r3ggiF28axNMFG8oCSFLdcAsxx7mpFRVZmVVDMcsQOvGOadRQAjMFUsxAUDJJ4AFUtFj2afG2GDSlpmDLtO5yWPB6cnpV6igDM1yV1+wQJarci5ukjbfGXWMAF95HtswD2YrR4ivGs9PQx2y3TzTxW4hboweRVY++FLN/wABrTooAAMDA6VV1WVoNMvJUIDxwu4JGcEKTVqo7qFLm2lgkz5cqFGx1wRg0ANsw4tIPNk82TYu58Abjjk8cVS1t5Vk0xItuyS8USZOPlCs3HvlVrQgj8mCOLez7FC7nOScDGT704gHGQCRyPagChoTCTTlnXAWd3mUD0ZiR+hqhBqD25tVjClbrU5rdt6kEAeaeMe6dT2rZs7aKzto7e2TZDGNqLn7o9KwNLhEV9bQSuzlrm9ulBJ4Pm4/QSEUAaniGza/0S8t441kmKbokY4BkX5kz7bgPb1ryDx54THkaX4k0m4hs5LURzWF5cA+VFnpa3IPW3JYhWPMRYj7vT3Csaxt7bUNCm0y+hjmtmE1pJE/IljVihyPcdfrQB5l4K8Xp4m1qDRb/Rk0vVNPiWTULa4Tc8F1uKxrDknK7RKQRwFkGDkGu81vVBDpUh2RuZ4zapbspJkkbCpGpHLKTvJYHhcntXnt/wCDx9ttVEsjXWnSSRRm0GLqxVVUBoyciWFkkjLQtkAP8vQirY8S6paahYjXEsrSwEMjtrMQLWN5LtCRxlD81u4AJIOPukA/NigD0LTmNqkQjSfyoEKSKZM+WQEAXyxz90Ej8+c1Y1C5SBb95bi2R3C28RUYdWI+VWPPVnBH196z1eLSkVreOFf3B8pghEGRnnf1J2KOvULwe1UbMWsHhSFrm7EAWP7YovJjJtKklPMcgFwpKYH+wACaANry2l8RQxxyqhsoEY7VByr7wyewJRDx/dHrVdpwLhLxW89WEDCcQFTIjyuqru6YUPnHXuetZCXupxaXLqOngSX9ykLvHNEI1Z2QBCx5xuKIhA+5uY84q9dyRtJfSXSxSSxvZ2xZZGYn96pwyHgEO5O4DkEenAA6MJDe6RcPL88d3c2MYPIKMWOPqPKWpbu2iubLxJbW80jyLJ5gjCf6mXy0ddv975sP9TitHXoIzpw2kRFbmGUMuAQ3mqSfx5B+ppdOhs4tX1ZraR3upnjkuFLZCHywqgDt8qg/jQBg6/HBqUXm3IEtpsW1uTFyZradAC3y8jDkEEHgBjTrH7dHOtytpcoImNjKkgVpsIxVJ8rjzEYANg8gHjByKXwSjxtBG6Ijf2TaFiGyd2ZAe3oBS+ILbUNF00appcK32oqkceoTrF+/mhQN86IvDMpYts6sMqDnbQBHpfi3Q7u2XU7e4ls7KbkXMsTJbyZbHJPCuSSMHDZ65rr02kB0bKsMjByD71yNvZ266g7xwxaZqlyG+02pXFtqJIOWxjk88tjfggMDwBr+Ff7OisJLTS7b7EttKyS2fTyHPzbQOgXkFcfLgjHFAGzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzvh60nXWdUmuYZ08p2giklxiQNI8xZOfu4kReg5QjtmuiooAKpWHlC4vUj25jm5UY+XcisfzJzV2mJEiO7oiq8hBYgcsQMc/gKAOWu/Pt/EzXEIVYVvIROTwSksXl8ep3rD+ApYLCLUbGW6iZLW/wDMaC7jkjHk3EittIkQ8ENjgjnDZHWuhvbC2vYJ4biMMs6BHIOCQMkYPYgnIPaqV3oFpc/2hue4T7dEI5SkmPmAwsg9JAAuG/2R6UAcLe+FJdOs5bDSrttIsrhkWWzuQbixeMHDJE2d0JYbzx3IrM8U6trNpc2cOr6fLb2H2URXDti4huN7AsfOx8rL5eVLgD96T2FeprFfpbWsE5gvSWKXEjjZlOcELyCegIom0mBiTESgYksjfNG2RhsqeORx6UAcH4Q12JL4aXHe3VzJJPJcCWRhOVVpDsD4AK537QTx8q44rZtGn1FpJDBdubi6iCsflaOOMmXa+fukNlSp7Edc5rXbwzYPNLcrCLO9mRIpJrM+WWRD8i/QenuRXOXWl6xoenRaZpMlxc7VLR3LIdzy7SN0jLnJ5B+bAOAOgoA6u/ukuNEiuEBVZWhK7uoy64/nUt5cSyW97HpL2wv4mCYnB2byFbDY5+6R0rkbC4srhbSzZXmhspYirQuXUCIYXeg565PoCqnnFaWj69bJYiTWYksbyeVp1hmYbwSflUnoGAKr1xxxxQB0Gj2K6ZpdpZK7S+REsXmN1fAxk/XrVyqdlqVpeWyzwXETIevzjg8cfqKsedFgnzUwOvzDigAuIIriPy7iNJUyDtdcjIOQfwNRW9ja293dXUECJcXRUzyAcyFV2rk+w4qtq+u6Vo0SS6tqNpZxvna00oUHGM4z9R+dWrS+tbu3Se2njkhfO11bg4ODigCxRUU9xDbpuuJo4lzty7BRn05pLa6gulLW0qSqDgshyPzoAmooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAI5oIZ9vnRRybeRvUHFUl0WwS4WaGFoGAxiCR4l/FVIB+uK0aKAMa70FLiUP9vvI8EnA8t8j0JdCce2ail8M2sjXDNK2ZwN3+jwHn+9zHyfrmt6igDLg065teLW8jClskyW6liMdMrtHrzjvStprM+8m0LcjJtQTg9ec1p0UAVbe18k7lW3V8YLJDt4/OkmtJZGJF9cxgn7qCP+q5q3RQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A window is made in the posterior peritoneum allowing the infundibulopelvic ligament to be isolated and clamped.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11157=[""].join("\n");
var outline_f10_57_11157=null;
var title_f10_57_11158="Pulsus paradoxus in pericardial disease";
var content_f10_57_11158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulsus paradoxus in pericardial disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11158/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11158/contributors\">",
"     Barry A Borlaug, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11158/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11158/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11158/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11158/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/57/11158/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic arterial pressure normally falls by less than 10 mmHg during inspiration, but this decline is not palpable at the peripheral pulse. Moderate to severe cardiac tamponade, and occasionally constrictive pericarditis, induce hemodynamic changes that enhance the inspiratory fall in systolic blood pressure. This exaggerated drop in systemic blood pressure during inspiration is termed pulsus paradoxus (",
"    <a class=\"graphic graphic_waveform graphicRef70731 \" href=\"UTD.htm?31/27/32180\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63439 \" href=\"UTD.htm?6/0/6154\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although Kussmaul named this phenomenon pulsus paradoxus, the paradox to which he referred was that the pulse palpated on examination is of variable strength, while precordial activity is regular [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/1\">",
"     1",
"    </a>",
"    ]. The name is somewhat misleading, since the direction of change is the same as in normal subjects and is therefore not paradoxical.",
"   </p>",
"   <p>",
"    Pulsus paradoxus will be discussed here, including its proper measurement, pathophysiology, and clinical conditions in which it may be present. Specific clinical conditions in which pulsus paradoxus may be present are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF PULSUS PARADOXUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe pulsus paradoxus can be palpated in the radial, brachial, or femoral pulses as a weakening or disappearance of the pulse during inspiration (which is best observed by watching or palpating the rise and fall of the chest). However, in most patients pulsus paradoxus is most readily identified while measuring the blood pressure. It may be necessary to have the patient breathe slowly and deeply to elucidate this finding when pulsus paradoxus is not severe.",
"   </p>",
"   <p>",
"    To measure pulsus paradoxus, a manually-operated sphygmomanometer is employed for blood pressure measurement in the standard fashion except that the cuff is deflated more slowly than usual. During deflation, the first Korotkoff sounds are audible only during expiration, but with further deflation, Korotkoff sounds are heard throughout the respiratory cycle. The difference between the systolic pressure at which the first Korotkoff sounds are heard during expiration and the pressure at which they are heard throughout the respiratory cycle quantifies pulsus paradoxus. Pulsus paradoxus can be more sensitively quantified by an invasive arterial measurement, and may also be observed by respirophasic variation of the pulse oximetry waveform (",
"    <a class=\"graphic graphic_waveform graphicRef63439 \" href=\"UTD.htm?6/0/6154\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Change in pulsus severity is a useful parameter to monitor when following a patient with tamponade both before, during, and after pericardial fluid drainage. Monitoring this parameter is also useful when following a patient with pericardial effusion. Since the depth of respiration influences the severity of pulsus, the patient should",
"    <strong>",
"     not",
"    </strong>",
"    be instructed to breathe deeply during this evaluation; any spontaneous change in respiration between observations must be taken into account. The magnitude of respiratory effort-related changes may be exaggerated in obese patients and those with pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PULSUS PARADOXUS IN TAMPONADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of pulsus paradoxus in cardiac tamponade vary widely, with reports ranging from 12 to 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/2\">",
"     2",
"    </a>",
"    ]. Among patients with pericardial effusion, the sensitivity of pulsus paradoxus for cardiac tamponade exceeds 80 percent and is higher than any other single physical finding [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence of a pulsus paradoxus greater than 10 mmHg increases the likelihood of tamponade by 3.3 fold, while its absence greatly lowers the likelihood (likelihood ratio 0.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When pulsus paradoxus is detectable in a patient with a pericardial effusion, cardiac tamponade is at least moderate in severity. On the other hand, pulsus paradoxus is typically absent in low pressure (occult) or regional tamponade. In the case of low pressure tamponade, a moderate size effusion that would not ordinarily cause major decompensation can result in severe hemodynamic compromise, including the appearance of a paradoxical pulse, when there is very marked volume depletion (for example after dialysis or ultrafiltration or with massive hemorrhage due to chest trauma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiac tamponade\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies have shown that pulsus paradoxus appears after modest hypotension and bradycardia and is preceded by right atrial collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/5\">",
"     5",
"    </a>",
"    ]. However, pulsus paradoxus often precedes severe hemodynamic deterioration. Thus, almost all patients with tamponade who have pulsus paradoxus need to have pericardial fluid removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complex mechanisms generate pulsus paradoxus in cardiac tamponade, the most important of which is an amplified interdependence between the right and left sides of the heart inside a restricted pericardial space [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/6\">",
"     6",
"    </a>",
"    ]. Under normal conditions, inspiration increases systemic venous return and right heart volumes increase; the free wall of the right ventricle expands into the unoccupied pericardial space with little impact on left heart volume.",
"   </p>",
"   <p>",
"    When the contents of the pericardial sac acutely increase, due to accumulation of pericardial fluid or with cardiac dilatation, the effective compliance of all chambers becomes that of the tightly-stretched pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/7\">",
"     7",
"    </a>",
"    ]. This is the reason for the observed equalization of diastolic pressures in right and left-sided cardiac chambers during pericardial tamponade (all being equal to intrapericardial pressure). As a result, the increase in right heart filling that occurs during inspiration can only be accommodated by a bowing of the interventricular septum toward the left. This leads to a reduction in left ventricular diastolic volume, a lower stroke volume, and a consequent decrease in systolic pressure during inspiration (",
"    <a class=\"graphic graphic_waveform graphicRef81723 \" href=\"UTD.htm?35/15/36081\">",
"     waveform 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulsus paradoxus can be thought of as a direct result of competition between the right and left sides of the heart for limited space. Cardiac filling becomes a zero-sum game: for the right heart to fill more, the left heart must fill less. This is a situation brought about by powerful enhancement of ventricular interaction and by equalization of the \"effective\" diastolic compliance of all cardiac chambers, which are all equally restricted by the pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other mechanisms make less important contributions to the pulsus paradoxus of cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial and pleural pressure normally fall by approximately the same amount with inspiration; in tamponade, however, the pericardial pressure declines slightly less than does pleural pressure. As a result, pressure in the pulmonary veins, which are intrapleural but extrapericardial, declines more than left ventricular diastolic pressure, decreasing the pressure gradient for left ventricular filling. Left ventricular volume is therefore smaller during inspiration than expiration [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/10\">",
"       10",
"      </a>",
"      ]. As a result, right ventricular stroke volume exceeds that of the left ventricle during inspiration. The opposite events occur during expiration, and the net effect is that pulmonary and systemic arterial pressures increase and decrease with respiration 180 degrees out of phase with one another.",
"     </li>",
"     <li>",
"      Since the left and right heart chambers are arranged in series, the inspiratory increase in right ventricular stroke volume eventually leads to increased left heart filling. Because of the transit time through the pulmonary circulation, this may lead to augmented left atrial filling during the following expiration, contributing to the difference in systolic pressure between inspiration and expiration. In tamponade, when stroke volume is low, the increase in left heart filling is relatively exaggerated. The magnitude of this effect is influenced by both heart rate and respiratory rate. In addition, pulmonary venous pressure exceeds pericardial (and therefore left atrial) pressure during expiration, increasing expiratory left-sided filling and contributing to the respirophasic systolic pressure differential [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another effect of inspiration is to augment the left ventricular transmural pressure (the sum of intracavitary pressure and negative intrathoracic pressure transmitted to the ventricle), which serves to increase left ventricular wall stress and afterload [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/11\">",
"       11",
"      </a>",
"      ]. This factor, which contributes to the inspiratory drop in aortic systolic pressure, is not unique to tamponade, and is more pronounced when the negative inspiratory force is elevated, as occurs in asthma, obesity, obstructive sleep apnea, and chronic pulmonary disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulsus paradoxus without tamponade'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the interaction of multiple forces results in the excessive inspiratory fall in systemic arterial pressure that we call pulsus paradoxus. Competition for room in the artificially fixed pericardial space (enhanced chamber interaction) is by far the principal mechanism. Indeed, in experimental models where inspiratory augmentation in right heart filling is prevented, pulsus paradoxus is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulsus paradoxus primarily reflects the inspiratory decline in left ventricular stroke volume. Thus, when measured via an intraarterial cannula, pulsus paradoxus appears as a decline in both systolic and pulse pressures; the change in diastolic pressure is minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TAMPONADE WITHOUT PULSUS PARADOXUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsus paradoxus does not occur in patients with tamponade if the diastolic pressure in one of the ventricles is greater than that of the pericardial space, or if there is an intracardiac shunt or valvular leak. The most frequent cause is coexisting disease that elevates left ventricular diastolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/7\">",
"     7",
"    </a>",
"    ]. Another cause is cor pulmonale, where the right ventricle is already \"overfilled\" and the interventricular septum cannot bow over further during inspiration to periodically compromise left ventricular filling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/12\">",
"     12",
"    </a>",
"    ]. Finally, pulsus paradoxus may be absent during \"low pressure\" tamponade, as in the presence of dehydration and hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following clinical examples illustrate the settings in which tamponade can occur without pulsus paradoxus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with end-stage renal disease has left ventricular dysfunction with a left ventricular pressure of",
"      <span class=\"nowrap\">",
"       200/25",
"      </span>",
"      mmHg; tamponade occurs in association with uremic pericarditis. The pericardial pressure is 15 mmHg, which causes the right atrial pressure to rise to 15 mmHg. However, the right atrial and pericardial pressures are still 10 mmHg lower than left ventricular diastolic pressure. As a result there is no pressure gradient present to cause bulging of the septum into the left ventricle and thus there is no significant pulsus paradoxus.",
"     </li>",
"     <li>",
"      Atrial septal defect (ASD) and aortic regurgitation prevent pulsus paradoxus by different mechanisms. With an ASD, the right heart fills from two sources: systemic venous return, which varies with respiration; and flow through the intraatrial shunt, which is independent of respiration and usually much larger than the inspiratory increase in venous return [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/14\">",
"       14",
"      </a>",
"      ]. Thus, ASD acts as a buffer; when right atrial filling from systemic venous return increases (with inspiration), the left to right shunt then decreases proportionally, such that right (and thus left) ventricular filling dimensions are unaffected. In aortic regurgitation, the buffering effect comes from the regurgitant flow, but the result is the same: a relatively constant left ventricular end-diastolic volume despite the impact of ventricular interaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PULSUS PARADOXUS WITHOUT TAMPONADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent causes of pulsus paradoxus without pericardial effusion are asthma and chronic obstructive pulmonary disease. In these conditions, the respiratory variation in intrathoracic pressure, which normally ranges from atmospheric pressure at end-expiration to 2 to 5 mmHg below atmospheric pressure at peak inspiration, is greatly amplified and may be as high as 40 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/15\">",
"     15",
"    </a>",
"    ]. When these pressure swings are transmitted to the extrathoracic aorta, pulsus paradoxus can be detected. The same mechanism may cause pulsus paradoxus in patients with obstructive sleep apnea or marked obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition to effects from large changes in intrathoracic pressure, the cardiac fossa may become restricted with marked expansion of the lungs. This in itself may limit epicardial heart volume, which increases the amount of ventricular interdependence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Importantly, when pulsus paradoxus occurs in the settings listed above, diastolic pressure oscillates to the same extent as the systolic pressure and stroke volume is relatively constant. This is in contrast to pulsus paradoxus in tamponade where there is a decline in both systolic and pulse pressures, with minimal change in diastolic pressure.",
"   </p>",
"   <p>",
"    In some cases of chronic lung disease or pulmonary embolism, pulsus paradoxus develops, affecting the systolic but not diastolic arterial pressure (",
"    <a class=\"graphic graphic_waveform graphicRef51766 \" href=\"UTD.htm?9/43/9910\">",
"     waveform 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/19\">",
"     19",
"    </a>",
"    ]. In these cases, Doppler studies have shown true respiratory variation in left and right ventricular stroke volume, comparable to that seen in cardiac tamponade. This may be related to acute or chronic right ventricular dilatation, such that the total heart volume increases, and the enlarged heart directly abuts the rigid pericardium, leading to greater interdependence.",
"   </p>",
"   <p>",
"    Hypovolemic shock can also be associated with pulsus paradoxus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/20\">",
"     20",
"    </a>",
"    ]. The proposed explanation is that pooling in the lung during inspiration accounts for a large proportion of the greatly reduced cardiac output. In tamponade, by comparison, inspiratory pooling of blood in the lungs is only a minor contributor to pulsus paradoxus.",
"   </p>",
"   <p>",
"    Pulsus paradoxus has also been reported in a patient with severe pectus excavatum in whom the pulsus may result from inspiratory impairment of inferior vena caval flow by the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/21\">",
"     21",
"    </a>",
"    ]. Pulsus paradoxus may also occur with other entities, such as bilateral pleural effusion, right atrial mass, right ventricular myocardial infarction, tension pneumothorax, restrictive cardiomyopathy, and extrinsic cardiac compression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PULSUS PARADOXUS AND CONSTRICTIVE PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsus paradoxus is seen in approximately one third of patients with constrictive pericarditis (except in the case of effusive constrictive pericarditis) even though a pronounced inspiratory decline in the velocity of mitral inflow and an increase in tricuspid inflow are characteristic Doppler findings. A significant pulsus paradoxus is more likely to be seen with effusive-constrictive pericarditis variant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H23#H23\">",
"     \"Constrictive pericarditis\", section on 'Effusive constrictive pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for this apparent discrepancy is not universally agreed upon, but it may be because constrictive pericarditis prevents transmission of the inspiratory fall in thoracic pressure into the right atrium, such that preventing inspiration cannot increase venous return to the right heart to the extent seen with tamponade. On the other hand, the drop in left ventricular filling during inspiration is greater than in tamponade because the left ventricle does not see the drop in pleural pressure. The right heart increases in volume solely by ventricular interaction, occurring when the left ventricle is smaller. In tamponade, the septal bulging takes place slowly, favoring pulsus paradoxus, whereas in constriction, the septum bounces rapidly so that the change in the ratio of ventricular volumes takes place abruptly, which does not favor pulsus paradoxus.",
"   </p>",
"   <p>",
"    This particular explanation implicitly suggests that the respiratory variation in ventricular inflow velocities is",
"    <strong>",
"     not",
"    </strong>",
"    an indication of similar changes in the inflow volumes. Support for this explanation comes from the observation that increased respiratory variation in transmitral and transtricuspid blood flow velocities occur in pericardial effusion when the effusion is considered hemodynamically insignificant and long before evidence of tamponade is present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11158/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16289093\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulsus paradoxus is a physical exam finding of an exaggerated drop in systemic blood pressure of greater than 10 mmHg during inspiration. Severe pulsus paradoxus can be palpated in the radial, brachial, or femoral pulses as a weakening or disappearance of the pulse during inspiration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Measurement of pulsus paradoxus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To measure pulsus paradoxus, a manually-operated sphygmomanometer is employed for blood pressure measurement in the standard fashion, except that the cuff is deflated more slowly than usual. The difference between the systolic pressure at which the first Korotkoff sounds are heard during expiration and the pressure at which they are heard throughout the respiratory cycle quantifies pulsus paradoxus. Since the depth of respiration influences the severity of pulsus, the patient should",
"      <strong>",
"       not",
"      </strong>",
"      be instructed to breathe deeply during this evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Measurement of pulsus paradoxus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several complex mechanisms generate pulsus paradoxus in cardiac tamponade, the most important of which is an amplified interdependence between the right and left sides of the heart inside a restricted pericardial space. In addition, pressure in the pulmonary veins, which are intrapleural but extrapericardial, declines more than left ventricular diastolic pressure, decreasing the pressure gradient for left ventricular filling. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulsus paradoxus does not occur in patients with tamponade if the diastolic pressure in one of the ventricles is greater than that of the pericardial space, or if there is an intracardiac shunt or valvular leak. The most frequent situation where this occurs is with a coexisting disease that elevates either left or right ventricular diastolic pressure (eg, systemic hypertension, cor pulmonale). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Tamponade without pulsus paradoxus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent causes of pulsus paradoxus without pericardial effusion or cardiac tamponade are asthma and chronic obstructive pulmonary disease, conditions in which the respiratory variation in intrathoracic pressure is greatly amplified. Other conditions in which pulsus paradoxus may be present without cardiac tamponade include obstructive sleep apnea, marked obesity, pulmonary embolism, hypovolemic shock, severe pectus excavatum, bilateral pleural effusion, right atrial mass, right ventricular myocardial infarction, tension pneumothorax, restrictive cardiomyopathy, and extrinsic cardiac compression. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulsus paradoxus without tamponade'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/1\">",
"      Kussmaul A. &Uuml;ber schwielige Mediastino-Pericarditis und den paradoxen Puls. Berliner Klinische Wochenschrift 1878; 10:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/2\">",
"      Spodick DH. Acute pericarditis: current concepts and practice. JAMA 2003; 289:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/3\">",
"      Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? JAMA 2007; 297:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/4\">",
"      Curtiss EI, Reddy PS, Uretsky BF, Cecchetti AA. Pulsus paradoxus: definition and relation to the severity of cardiac tamponade. Am Heart J 1988; 115:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/5\">",
"      Klopfenstein HS, Schuchard GH, Wann LS, et al. The relative merits of pulsus paradoxus and right ventricular diastolic collapse in the early detection of cardiac tamponade: an experimental echocardiographic study. Circulation 1985; 71:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/6\">",
"      Shabetai R, Fowler NO, Fenton JC, Masangkay M. Pulsus paradoxus. J Clin Invest 1965; 44:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/7\">",
"      Reddy PS, Curtiss EI, O'Toole JD, Shaver JA. Cardiac tamponade: hemodynamic observations in man. Circulation 1978; 58:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/8\">",
"      Santamore WP, Heckman JL, Bove AA. Right and left ventricular pressure-volume response to elevated pericardial pressure. Am Rev Respir Dis 1986; 134:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/9\">",
"      Reddy PS, Curtiss EI, Uretsky BF. Spectrum of hemodynamic changes in cardiac tamponade. Am J Cardiol 1990; 66:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/10\">",
"      GOLINKO RJ, RUDOLPH AM. The mechanism of pulsus paradoxus during acute pericardial tamponade. J Clin Invest 1963; 42:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/11\">",
"      McGregor M. Current concepts: pulsus paradoxus. N Engl J Med 1979; 301:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/12\">",
"      Gollapudi RR, Yeager M, Johnson AD. Left ventricular cardiac tamponade in the setting of cor pulmonale and circumferential pericardial effusion. Case report and review of the literature. Cardiol Rev 2005; 13:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/13\">",
"      Antman EM, Cargill V, Grossman W. Low-pressure cardiac tamponade. Ann Intern Med 1979; 91:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/14\">",
"      Winer HE, Kronzon I. Absence of paradoxical pulse in patients with cardiac tamponade and atrial septal defects. Am J Cardiol 1979; 44:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/15\">",
"      Settle HP Jr, Engel PJ, Fowler NO, et al. Echocardiographic study of the paradoxical arterial pulse in chronic obstructive lung disease. Circulation 1980; 62:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/16\">",
"      Shiomi T, Guilleminault C, Stoohs R, Schnittger I. Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome. Chest 1991; 100:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/17\">",
"      Lee JC, Atwood JE, Lee HJ, et al. Association of pulsus paradoxus with obesity in normal volunteers. J Am Coll Cardiol 2006; 47:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/18\">",
"      Santamore WP, Bartlett R, Van Buren SJ, et al. Ventricular coupling in constrictive pericarditis. Circulation 1986; 74:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/19\">",
"      Cohen SI, Kupersmith J, Aroesty J, Rowe JW. Pulsus paradoxus and Kussmaul's sign in acute pulmonary embolism. Am J Cardiol 1973; 32:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/20\">",
"      Cohn JN, Pinkerson AL, Tristani FE. Mechanism of pulsus paradoxus in clinical shock. J Clin Invest 1967; 46:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/21\">",
"      Yalamanchili K, Summer W, Valentine V. Pectus excavatum with inspiratory inferior vena cava compression: a new presentation of pulsus paradoxus. Am J Med Sci 2005; 329:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/22\">",
"      Swami A, Spodick DH. Pulsus paradoxus in cardiac tamponade: a pathophysiologic continuum. Clin Cardiol 2003; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11158/abstract/23\">",
"      Appleton CP, Hatle LK, Popp RL. Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography. J Am Coll Cardiol 1988; 11:1020.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4936 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11158=[""].join("\n");
var outline_f10_57_11158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16289093\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASUREMENT OF PULSUS PARADOXUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PULSUS PARADOXUS IN TAMPONADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TAMPONADE WITHOUT PULSUS PARADOXUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PULSUS PARADOXUS WITHOUT TAMPONADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PULSUS PARADOXUS AND CONSTRICTIVE PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16289093\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4936\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4936|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/27/32180\" title=\"waveform 1\">",
"      Pulsus alternans and pulsus paradoxus arterial waveforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/0/6154\" title=\"waveform 2\">",
"      Pulsus paradoxus mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?35/15/36081\" title=\"waveform 3\">",
"      M-mode echocardiogram in cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?9/43/9910\" title=\"waveform 4\">",
"      M-mode echocardiogram of pulsus paradoxus in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_57_11159="HLA matching and graft survival in kidney transplantation";
var content_f10_57_11159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HLA matching and graft survival in kidney transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11159/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11159/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11159/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11159/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11159/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11159/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/57/11159/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence that antigens of the HLA system provide the major barrier to acceptance of renal transplants was first obtained with living-related donor transplants. Graft survival was superior in sibling pairs having both the same serologically defined HLA antigens and a nonreactive in vitro mixed lymphocyte proliferative response when compared to randomly matched cadaveric donors treated with the same immunosuppressive drugs, principally",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . (The mixed lymphocyte response [MLR] is an in vitro estimate of incompatibility in which the degree of proliferation of the recipient lymphocytes to donor lymphocytes is measured.) There was an intermediate level of graft survival in haploidentical parent to child or sibling to sibling transplants, in which one but not both of the haplotypes matched.",
"   </p>",
"   <p>",
"    The most valuable databases now in existence are those representing pooling of information from a large number of collaborating centers. Although such pooled data may suffer from variations in protocols and undocumented selection factors, the power of univariate analyses becomes compelling when thousands of patients are included. These large databases include the United Network for Organ Sharing (UNOS), the Collaborative Transplant Study (CTS), Scientific Registry of Transplant Recipients (SRTR), the American Southeast Organ Procurement Foundation (SEOPF), the United Kingdom Transplant Service, Eurotransplant, the Australian New Zealand Data (ANZDATA), and others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELATIVE IMPORTANCE OF HLA-A,-B, AND -DR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simple assumption that each mismatch for HLA antigens has equal weight has not been borne out. The initial CTS analysis showed that the major impact comes from the DR and B antigens, with little additional effect from the A antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The UK Transplant and Eurotransplant data are somewhat similar, with DR matching having a much greater effect than that of B or A [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Another study found that HLA-DR mismatches (and the number of rejection episodes) correlated with poor long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/5\">",
"     5",
"    </a>",
"    ]. Each antigen also appears to exert its effect at different times post-transplant, with the maximal effect of DR and B mismatching occurring within the first six months and two years post-transplant, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/6\">",
"     6",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    A related issue is whether specific HLA mismatch combinations are associated with decreased renal allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A retrospective study addressed this issue by examining 2877 unrelated renal transplants with one mismatch of either HLA-A, -B, or -DR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/7\">",
"     7",
"    </a>",
"    ]. Seven unique combinations (\"taboo\" mismatches) of recipient HLA antigen and donor HLA antigen were associated with significant decreases in graft survival when compared to survival among transplant groups with either no mismatch or one indifferent mismatch. At five years, graft survival among the groups without a mismatch, with one indifferent mismatch, or with one taboo mismatch was 72, 69, and 50 percent, respectively. The mechanism by which \"taboo\" HLA mismatches may result in diminished allograft survival is unknown.",
"   </p>",
"   <p>",
"    When trying to match a donor to a recipient, avoidance of mismatches is used in preference to matching of HLA antigens. This approach maximizes the number of patients offered well-matched grafts because the same antigen may be present twice. As an example, HLA-A2 is a common antigen and homozygosity is frequent. Such a patient can receive a graft with no mismatches; however, he or she cannot be matched for six HLA antigens, since only five are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF EARLY REJECTION EPISODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term graft survival may also be related to the presence or absence of early rejection episodes. Some findings suggest that early rejection increases the risk of future graft failure, which is less likely to occur with reduction in the HLA barrier.",
"   </p>",
"   <p>",
"    It is of interest that the degree of mismatching per se is not directly predictive of early rejection episodes. This raises the issue of whether intrinsic responsiveness of individual patients determines to a large extent the rejection episode rate; once rejecting patients declare themselves, the HLA barrier then becomes an important determinant of graft survival rates. Alternatively, the rejection tempo may be intrinsically more powerful with a higher number of mismatched antigens.",
"   </p>",
"   <p>",
"    Failure to have an early rejection episode, on the other hand, may be determined both by individual susceptibility to immunosuppressive agents and by immunogenetic factors that vary with different donor-recipient combinations. A relatively common example of the latter is the patient doing well with a second transplant after vigorous rejection of a first graft bearing different HLA antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LONG-TERM GRAFT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most transplants that are lost to acute rejection do so within the first year. Later graft loss is primarily due to \"chronic rejection\", a disorder that is not very responsive to current immunosuppressive regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple analyses have demonstrated improved survival in well-matched cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In the 2008 annual report of the Scientific Registry of Transplant Recipients, the five-year deceased non-extended criteria donor allograft survival for zero versus six HLA-mismatched deceased donor kidneys was 75 and 66 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term survival is also best in HLA-identical, particularly living related, kidneys and worst in randomly matched cadaver kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As an example, a report from the same UNOS database evaluated more than 7600 HLA-matched (ie, no mismatches) and 81,000 HLA-mismatched cadaveric renal transplants performed between 1987 and 1999 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/10\">",
"     10",
"    </a>",
"    ]. HLA-matched transplants had longer allograft half-lives (12.5 versus 8.6 years) and increased 10-year survival (52 versus 37 percent). Similar findings have been reported in subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The beneficial effect of HLA matching on long-term survival has come during the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    era, a period in which graft survivals and rejection rates have continued to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/12\">",
"     12",
"    </a>",
"    ]. The benefits of HLA matching have also continued with the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The improved long-term survival observed in well-matched HLA grafts may be less apparent in transplant recipients with a primary glomerular disease. In one report of 60 patients in whom an HLA-identical living related donor transplant had been performed, allograft survival was correlated with the original renal disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/14\">",
"     14",
"    </a>",
"    ]. Among the 33 patients with an underlying glomerulonephritis, the 5, 10, and 20-year graft survival was 88, 70, and 63 percent, respectively; by comparison, no case of graft loss was observed among the remaining patients with nonglomerular renal disease. Recurrent disease appeared to be the principal cause of graft loss.",
"   </p>",
"   <p>",
"    Despite the importance of HLA-DR matching, some seemingly well-matched kidneys are still rejected. These findings in part reflect the incomplete accuracy of routinely used tissue typing methods.",
"   </p>",
"   <p>",
"    A limitation of tissue typing is the difficulty in finding well-matched kidneys. The American UNOS program mandates that six-antigen matched grafts be given priority. Despite the large registered waiting list and relative ease of shipping kidneys around the country, only 13 percent of recipients of deceased donor kidneys are well-matched [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Priority shipping of organs is not limited to six antigen matched grafts as zero mismatching is also given priority. This occurred following two amendments to the original ruling by UNOS; the first to allow donors and recipients that were both homozygous for one antigen to be considered phenotypically matched, and the second to allow for the shipment of zero mismatch kidneys. With zero mismatched kidneys, the donor does not express any antigen different from the recipient, although the recipient may have an antigen that is not expressed by the donor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As of January 2009, only patients with calculated PRAs greater than 20 percent are allowed to be considered for the zero-antigen mismatch program (UNOS) (see",
"    <a class=\"external\" href=\"file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp\">",
"     file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp",
"    </a>",
"    ). This was done based upon the recognition that the expense of transportation and the negative effects of prolonged cold-ischemia mitigate against improved short-term graft survival.",
"   </p>",
"   <p>",
"    Most of the worldwide data on deceased donor transplantation have therefore been based upon random assignment of cases without regard to HLA incompatibility, and the importance of lesser degrees of matching has only been determined after transplantation. A strategy to increase the frequency of partially matched grafts and therefore of transplant survival is regional organ sharing, although the results are less dramatic compared to the six antigen matched cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with greater than 36 hours of cold ischemia time may not benefit from HLA matching. In an analysis of the UNOS data base, recipients of zero HLA mismatched kidneys with less than 36 hours of cold ischemia time had superior five-year graft survival than recipients with one or more mismatches (75 and 67 percent, respectively, p&lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/15\">",
"     15",
"    </a>",
"    ]. However, no survival advantage was observed if zero mismatched kidneys were exposed to more than 36 hours of cold ischemia time.",
"   </p>",
"   <p>",
"    Thus, if there were no cold ischemia time effects, a strategy of national allocation and shipping of all kidneys (not just zero antigen mismatches) to minimize HLA mismatches would generate the largest graft survival improvement and cost savings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/16\">",
"     16",
"    </a>",
"    ]. However, there would be longer preservation times under a national allocation policy, and prolongation of cold ischemia time negatively affects outcome and costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recent trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting evidence exists concerning the current importance of HLA matching and allograft survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, it was noted that the importance of HLA matching for allograft survival may have diminished over the last several years, with non-immunologic factors assuming more relative significance. In this study, the factors underlying allograft survival over the period 1994 to 1998 were noted among over 30,000 transplant recipients of deceased donor kidneys [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/17\">",
"       17",
"      </a>",
"      ]. With each successive year, ever increasing degrees of HLA mismatching were required to have a statistically significant adverse effect upon allograft failure. Thus, increased allograft failure was significantly associated with the following: three to six antigen mismatches in 1995; four to six antigen mismatches in 1996; five and six antigen mismatches in 1997; and six antigen mismatches in 1998. By comparison, peak panel reactive antibody, donor age, sex and cause of death, cold ischemia time, and donor and recipient body size, retained their relative importance for allograft survival over this period. Although the reasons are unclear, the administration of increasingly better immunosuppressive regimens during this period may in part underlie these observations.",
"     </li>",
"     <li>",
"      A second study that compared the effect of HLA compatibility on allograft survival during the years 1985 to 1994, with survival between 2000 and 2004, found that HLA mismatches continued to significantly influence allograft outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/18\">",
"       18",
"      </a>",
"      ]. Compared with three HLA mismatches, for example, the relative risk of allograft survival at five years with two HLA mismatches for the early versus the late period was 0.95 (0.92 to 0.99) and 0.93 (0.89 to 0.97), respectively. Similar findings for the two periods were noted for no to six mismatches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these studies, the weight of overall evidence suggests that HLA matching still has a significant impact on allograft survival. The main effect can be observed between a zero antigen mismatch and a six antigen mismatch. Based upon the 2008 Organ Procurement Transplant",
"    <span class=\"nowrap\">",
"     Network/Scientific",
"    </span>",
"    Registry of Transplant Recipient",
"    <span class=\"nowrap\">",
"     (OPTN/SRTR)",
"    </span>",
"    database, for example, allograft survival at five years for those with zero or six total mismatches was [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      88 and 79 percent for living donor kidneys, respectively",
"     </li>",
"     <li>",
"      75 and 66 percent for deceased non-extended criteria donor kidneys, respectively",
"     </li>",
"     <li>",
"      60 and 55 percent for deceased extended criteria donor kidneys, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMPACT OF DE-EMPHASIS OF HLA MATCHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the de-emphasis of HLA matching in organ allocation may not affect short term results, the above data show that it is likely to affect long-term results. In addition, an analysis of candidates listed in the United States from 1988 to 2007 from the Scientific Renal Transplant Registry (SRTR) database that were relisted after loss of a primary kidney transplant (n=15,980) looked at the change in panel reactive antibody (PRA) from prior to the recipient's initial transplant to the subsequent listing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no appreciable change in PRA for patients receiving a first 0 HLA-A, -B, -DR, or 0 HLA-A, -B-mismatched kidney transplant. However, there was a significant increase in PRA by increasing HLA mismatch of the first transplant. Only 10 percent of patients became sensitized after a 0 HLA-A, -B-mismatched transplant, whereas the proportion rose up to 37 percent with increasing HLA mismatches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HLA AND ORGAN ALLOCATION IN BLACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the distribution of HLA antigens and frequency of deceased donor donation differs among racial groups, thereby affecting organ allocation. Until the 2009 changes in UNOS organ allocation policy, 17 percent of all non-extended criteria deceased donor kidneys were transplanted into fully matched recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/11\">",
"     11",
"    </a>",
"    ], of whom approximately 90 percent were white and only 9 percent black [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/21\">",
"     21",
"    </a>",
"    ]. Between 1987 and 1995, black patients received only 6 percent of fully matched kidneys despite constituting approximately one-third of the national waiting list. Conversely, 30 percent of partially or fully mismatched kidneys go to black recipients, approximating the frequency with which blacks appear on the waiting list.",
"   </p>",
"   <p>",
"    To address this relative inequity, the national allocation policy of the United States was changed to no longer give priority points for fewer HLA-B mismatches. This was derived in part from findings of a study that addressed the effect of eliminating HLA-B matching. Based upon a Cox model analysis in which HLA-DR but not HLA-B matching was utilized, the number of transplants was calculated to decrease by 4.0 percent among whites but increase by 6.3 percent in nonwhites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/22\">",
"     22",
"    </a>",
"    ]; this change was determined to result only in a 2.0 percent increase in graft loss. By comparison, removal of both HLA-B and HLA-DR would result in an 8.0 percent increase in graft loss. A study modeling the impact of this policy demonstrated that it would result in a detrimental effect on Caucasian survival and overall increased costs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LESS SPECIFIC HLA MATCHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, because the distribution of HLAs differs across ethnic groups, African-American and other minority recipients receive a smaller percentage of organs than do their white counterparts. An alternative to allocation based upon HLA specificities is matching by HLA-A and B supertypes, or cross-reactive groups (CREG). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"     \"Organ sharing in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER HISTOCOMPATIBILITY ANTIGENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     MICA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MHC class I-related chain A (MICA) is the product of an HLA-related, polymorphic gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/24\">",
"     24",
"    </a>",
"    ]. MICA is expressed on monocytes, keratinocytes, fibroblasts, and endothelial cells. Although its exact function is unclear, MICA is recognized by a subpopulation of intestinal gamma delta T cells and may play a role in the activation of a subpopulation of natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies directed against MICA may adversely affect allograft function and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. This was shown in the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1920 recipients of kidney transplants, MICA antibodies were detected in 217 (11.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/30\">",
"       30",
"      </a>",
"      ]. Compared to those without antibodies, the presence of MICA antibodies significantly lowered one year allograft survival among all patients (88.3 versus 93.0 percent), recipients of first kidney transplants (87.8 versus 93.5 percent), and recipients who received well-matched kidneys (0 or 1 HLA-A plus HLA-B plus HLA-DR mismatch) (83.2 versus 95.1 percent).",
"     </li>",
"     <li>",
"      As part of the 13th International Histocompatibility Workshop, 1329 patients with functioning transplants were prospectively tested for HLA antibodies in 2002 and followed for four years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/29\">",
"       29",
"      </a>",
"      ]. At four years, allograft survival was significantly higher among those with no identified antibodies (806 deceased-donor recipients) versus those with HLA (158 patients) or MICA antibodies (69 patients) (81 versus 58 and 72 percent, respectively).",
"     </li>",
"     <li>",
"      In a prospective trial of the 14th International Histocompatibility Workshop, one year allograft survival of 1319 deceased-donor recipients and no HLA antibodies was 96 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/29\">",
"       29",
"      </a>",
"      ]. This was significantly higher than that observed for the 344 patients with HLA antibodies (94 percent) and the 33 patients with MICA (83 percent). By comparison, 12 recipients with donor specific antibodies tested by single antigen beads had a one-year graft survival of 64 percent, and 27 patients with non-donor specific 'strong' antibodies had a 66 percent survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials provide strong evidence that HLA and MICA antibodies are associated with graft failure after one and four years post-transplant. Some authors have therefore recommended universal testing of kidney transplant patients for antibodies post-transplantation and careful monitoring of serum creatinine levels if antibodies are detected.",
"   </p>",
"   <p>",
"    However, such testing is not widely performed. We test for such antibodies in select patients with unexplained rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     H-Y antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to reactivity against Y chromosome H-Y encoded gene products, transplants from a male donor to a female recipient, particularly hematopoietic cell transplants, are reportedly associated with an increased risk of rejection. However, the role of such gene products in kidney transplantation is unclear. This was indirectly evaluated in a retrospective cohort study of nearly 200,000 recipients of deceased donor kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/31\">",
"     31",
"    </a>",
"    ]. Compared with all other gender combinations, an increased risk of allograft failure was noted in female recipients of male donor kidneys at one year (hazard ratio 1.08, 95% CI 1.03-1.14) and between 2 and 10 years (hazard ratio 1.06, 95% CI 1.01-1.10). These findings suggest that there may be an association between adverse effects and H-Y encoded products. Further studies are required to better understand this possible association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXPOSURE TO NONINHERITED HLA ALLELES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In utero and while nursing, infants are exposed to maternal antigens that the child has not inherited. There is evidence that such exposure may result in some degree of tolerance. One study of 205 patients evaluated the long-term survival of kidney allografts transplanted from siblings with maternal or paternal HLA alleles not inherited by the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/32\">",
"     32",
"    </a>",
"    ]. Compared to the kidneys donated from siblings with paternal alleles not inherited by the recipient, a higher incidence of survival was significantly observed among the allografts donated from siblings with noninherited maternal alleles at both 5 and 10 years (86 versus 67 percent, and 77 versus 49 percent, respectively). Although many unrecognized factors may be confounding, these results suggest that exposure to donor antigens prior to transplantation may help induce some degree of tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11159/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16468305\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antigens of the HLA system are a major barrier to acceptance of renal transplants. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major impact comes from mismatch of the DR antigen and to a lesser degree, B antigens, with little additional effect from the A antigens. Each antigen appears to exert its effect at different times post-transplant: the maximal effect of DR and B mismatching occurs within the first six months and two years post-transplant, respectively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Relative importance of hla-a,-b, and -dr'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degree of mismatching is associated with long-term graft survival, though not early rejection. Long-term survival is best in HLA-identical, particularly living related, kidneys and worst in randomly matched cadaver kidneys. Despite the importance of HLA-DR matching, some seemingly well-matched kidneys are still rejected, likely reflecting the incomplete accuracy of routinely used tissue typing methods. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-term graft survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with greater than 36 hours of cold ischemia time may not benefit from HLA matching. This is important since if there were no cold ischemia time effects, a strategy of national allocation and shipping of all kidneys (not just zero antigen mismatches) to minimize HLA mismatches would generate the largest graft survival improvement and cost savings. This would result in longer preservation times however and prolongation of cold ischemia time negatively affects outcome and costs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-term graft survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, the distribution of HLA antigens and frequency of deceased donor donation differs among racial groups, thereby affecting organ allocation. Between 1987 and 1995, black patients received only 6 percent of fully matched kidneys despite constituting approximately one-third of the national waiting list. Conversely, 30 percent of partially or fully mismatched kidneys go to black recipients, approximating the frequency with which blacks appear on the waiting list. To address this relative inequity, the national allocation policy of the United States was changed to no longer give priority points for fewer HLA-B mismatches. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hla and organ allocation in blacks'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=see_link\">",
"       \"Organ sharing in kidney transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other histocompatability antigens include the MHC class I-related chain A (MICA) and the H-Y antigen. Antibodies directed against MICA may adversely affect allograft function and survival. Some authors have therefore recommended universal testing of kidney transplant patients for antibodies post-transplantation and careful monitoring of serum creatinine levels if antibodies are detected. However, such testing is not widely performed. We test for such antibodies in select patients with unexplained rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to reactivity against Y chromosome H-Y encoded gene products, transplants from a male donor to a female recipient are reportedly associated with an increased risk of rejection. However, the role of such gene products in kidney transplantation is unclear. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Other histocompatibility antigens'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/1\">",
"      Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 1985; 40:240.",
"     </a>",
"    </li>",
"    <li>",
"     Opelz, G. Collaborative Transplant Study Newsletter 1988; number 3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/3\">",
"      Gilks WR, Bradley BA, Gore SM, Klouda PT. Substantial benefits of tissue matching in renal transplantation. Transplantation 1987; 43:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/4\">",
"      Doxiadis II, de Fijter JW, Mallat MJ, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/5\">",
"      Coupel S, Giral-Classe M, Karam G, et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. Kidney Int 2003; 64:674.",
"     </a>",
"    </li>",
"    <li>",
"     Dialysis and Transplantation. Owen, Pereira, Sayegh (Eds), WB Saunders, Philadelphia 2000. p. 504.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/7\">",
"      Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996; 348:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/8\">",
"      Reisaeter AV, Leivestad T, Vartdal F, et al. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: a single-center study of first cadaveric kidneys to nonsensitized recipients. Transplantation 1998; 66:523.",
"     </a>",
"    </li>",
"    <li>",
"     Cecka, JM and Terasaki, PI. The UNOS Scientific Renal Transplant Registry. In: Clinical Transplants 1993, Terasaki, PI, Cecka, JM (Eds), UCLA Tissue Typing Laboratory, Los Angeles, 1994. p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/10\">",
"      Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343:1078.",
"     </a>",
"    </li>",
"    <li>",
"     The scientific registry of transplant recipients at file://www.ustransplant.org (Accessed 2/2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/12\">",
"      Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/13\">",
"      Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation 2001; 71:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/14\">",
"      Andresdottir MB, Hoitsma AJ, Assmann KJ, et al. The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Transplantation 1999; 68:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/15\">",
"      Lee CM, Carter JT, Alfrey EJ, et al. Prolonged cold ischemia time obviates the benefits of 0 HLA mismatches in renal transplantation. Arch Surg 2000; 135:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/16\">",
"      Schnitzler MA, Hollenbeak CS, Cohen DS, et al. The economic implications of HLA matching in cadaveric renal transplantation. N Engl J Med 1999; 341:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/17\">",
"      Su X, Zenios SA, Chakkera H, et al. Diminishing significance of HLA matching in kidney transplantation. Am J Transplant 2004; 4:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/18\">",
"      Opelz G, D&ouml;hler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007; 84:137.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org/annual-reports, accessed 2/10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/20\">",
"      Meier-Kriesche HU, Scornik JC, Susskind B, et al. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009; 88:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/21\">",
"      Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/22\">",
"      Roberts JP, Wolfe RA, Bragg-Gresham JL, et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/23\">",
"      Mutinga N, Brennan DC, Schnitzler MA. Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation. Am J Transplant 2005; 5:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/24\">",
"      Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1994; 91:6259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/25\">",
"      Zwirner NW, Marcos CY, Mirbaha F, et al. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 2000; 61:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/26\">",
"      Zou Y, Heinemann FM, Grosse-Wilde H, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/27\">",
"      Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/28\">",
"      Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/29\">",
"      Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/30\">",
"      Zou Y, Stastny P, S&uuml;sal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/31\">",
"      Gratwohl A, D&ouml;hler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet 2008; 372:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/32\">",
"      Burlingham WJ, Grailer AP, Heisey DM, et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Engl J Med 1998; 339:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11159/abstract/33\">",
"      Sanfilippo F. Transplantation tolerance--the search continues. N Engl J Med 1998; 339:1700.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7355 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11159=[""].join("\n");
var outline_f10_57_11159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16468305\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELATIVE IMPORTANCE OF HLA-A,-B, AND -DR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMPORTANCE OF EARLY REJECTION EPISODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LONG-TERM GRAFT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recent trends",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMPACT OF DE-EMPHASIS OF HLA MATCHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HLA AND ORGAN ALLOCATION IN BLACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LESS SPECIFIC HLA MATCHING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER HISTOCOMPATIBILITY ANTIGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MICA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      H-Y antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXPOSURE TO NONINHERITED HLA ALLELES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16468305\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/7/5240?source=related_link\">",
"      Organ sharing in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_57_11160="Differential diagnosis and approach to the adolescent with abnormal uterine bleeding";
var content_f10_57_11160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11160/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11160/contributors\">",
"     Nirupama K De Silva, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11160/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11160/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11160/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11160/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/57/11160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual cycles are often irregular in the first months after menarche. According to a study by the World Health Organization, the median length of the first cycle after menarche was 34 days, with 38 percent of the cycles exceeding 40 days and 7 percent occurring less than 20 days apart [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/1\">",
"     1",
"    </a>",
"    ]. Menstrual disorders and abnormal uterine bleeding (AUB) are among the most frequent gynecologic complaints of adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Abnormal uterine bleeding (AUB) refers to bleeding that is excessive or occurs outside of normal cyclic menstruation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/4\">",
"     4",
"    </a>",
"    ]. AUB is described by a variety of terms and may be caused by a number of genital and nongenital tract diseases, systemic disorders, and medications (",
"    <a class=\"graphic graphic_table graphicRef62751 \" href=\"UTD.htm?29/4/29773\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of AUB in adolescents are caused by anovulatory cycles during the first 12 to 18 months after menarche, which is related to immaturity of the hypothalamic-pituitary-ovarian axis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Other common causes include pregnancy, infection, the use of hormonal contraceptives, stress (psychogenic or exercise induced), bleeding disorders, and endocrine disorders (eg, hypothyroidism, polycystic ovary syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment for these disorders ranges from observation to pharmacologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical therapy. Potential sequelae of AUB include anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/6\">",
"     6",
"    </a>",
"    ] and endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. With appropriate management of the underlying problem, these sequelae may be prevented. Thus, it is crucial to establish the correct diagnosis before any therapy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of AUB in adolescents will be discussed here. The management of AUB in adolescents is discussed separately, as is the evaluation of AUB in premenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of genital tract bleeding in adolescents is similar to that in adult women (",
"    <a class=\"graphic graphic_table graphicRef62751 \" href=\"UTD.htm?29/4/29773\">",
"     table 1",
"    </a>",
"    ). However, the most common causes vary according to age (",
"    <a class=\"graphic graphic_table graphicRef61684 \" href=\"UTD.htm?30/12/30924\">",
"     table 2",
"    </a>",
"    ). In adolescents in particular, disorders of pregnancy and the possibility of pelvic infection should be considered early in the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/10\">",
"     10",
"    </a>",
"    ]. It is essential to rule out pregnancy in the adolescent, regardless of the stated sexual history. This is especially important in those adolescents who present with unexplained vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once pregnancy has been excluded, it is helpful to determine whether the bleeding is cyclic (regular) or acyclic (irregular) in nature. The differential diagnosis varies accordingly. As an example, DUB is the most common cause of excessive menstrual flow in adolescents with irregular bleeding, whereas blood dyscrasias and structural anomalies (eg, polyps, fibroids) are more common in those with cyclic bleeding.",
"   </p>",
"   <p>",
"    As a general rule, bleeding that is preceded by premenstrual symptoms (breast tenderness, water weight gain, mood swings, or abnormal cramping) is ovulatory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, heavy bleeding that occurs irregularly is usually anovulatory. However, many patients are between these extremes, and determination of the ovulatory status may be difficult.",
"   </p>",
"   <p>",
"    Common causes of abnormal uterine bleeding in adolescents can be grouped into four patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amenorrhea",
"     </li>",
"     <li>",
"      Irregular bleeding",
"     </li>",
"     <li>",
"      Menorrhagia",
"     </li>",
"     <li>",
"      Breakthrough bleeding due to anatomic defects or medicines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H5#H5\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characterization into one of these patterns may be difficult because of the range of variability in cycles during the first one to two years postmenarche and the difficulty in quantifying volume of flow. In addition, the causative conditions may overlap categories or present atypically. Nevertheless, the categorization scheme is helpful in narrowing the differential diagnosis and directing the additional laboratory evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AMENORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amenorrhea is the absence of menses, which may be primary or secondary. Although there are several unique causes of primary amenorrhea (eg, congenital abnormalities in M&uuml;llerian development or urogenital sinus development), all causes of secondary amenorrhea also can cause primary disease. The most common cause of amenorrhea in a female of reproductive age is pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=see_link&amp;anchor=H3#H3\">",
"     \"Pregnancy in adolescents\", section on 'Diagnosis of pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary amenorrhea is commonly defined as the absence of menarche by age 15 years. The 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for menarche in North America is 14.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The causes, evaluation, and treatment of primary amenorrhea are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14937?source=see_link\">",
"     \"Evaluation of oligomenorrhea in adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary amenorrhea is defined as the absence of menses for more than three cycles or six months in women who previously had menses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/14\">",
"     14",
"    </a>",
"    ]. In adolescents, it is uncommon for girls to remain without their menses for &gt;90 days (the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for cycle length). Thus, adolescents without menses for 90 days warrant an evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/15\">",
"     15",
"    </a>",
"    ]. Once pregnancy is excluded, a step-wise endocrinologic evaluation can be considered. If labs are normal, a progesterone challenge (micronized oral progesterone [200 mg] for 12 days) or a trial of hormonal contraception may be necessary to reestablish menses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14937?source=see_link\">",
"     \"Evaluation of oligomenorrhea in adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IRREGULAR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adolescents, during the first 12 to 18 months after menarche and in the absence of pregnancy, the most common cause of irregular menstrual bleeding is anovulation due to an immature hypothalamic-pituitary-ovarian axis, also called dysfunctional uterine bleeding (DUB) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This condition is a normal finding in the first few years after menarche, but all other pathologic diagnoses must be ruled out (",
"    <a class=\"graphic graphic_table graphicRef78931 \" href=\"UTD.htm?4/40/4748\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link&amp;anchor=H14#H14\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Every young adolescent female is prone to anovulatory cycles in which the endometrium lacks the stabilizing effect of progesterone. In such cycles, the endometrium becomes excessively thickened. It breaks down and sloughs when estrogen is withdrawn (estrogen-withdrawal bleeding) or when it becomes unstable (estrogen-breakthrough bleeding) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Normal menstrual cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescents with regular menses have cyclic estrogen secretion that permits orderly growth and shedding of the endometrium (on account of hormone withdrawal), even in the absence of ovulation. In addition, the secretion of progesterone associated with the occasional ovulatory cycle in these adolescents helps to stabilize endometrial growth and permits more complete shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, adolescents with DUB appear to have delayed maturation of normal negative feedback cyclicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/18\">",
"     18",
"    </a>",
"    ]. In these girls, rising levels of estrogen do not cause suppression of follicle-stimulating hormone (FSH) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/19\">",
"     19",
"    </a>",
"    ]. Estrogen secretion is sustained, and the concentration of FSH is increased relative to that of luteinizing hormone (LH). In these girls with sustained acyclic estrogen secretion, the endometrium proliferates beyond estrogen's ability to maintain its integrity. Bleeding occurs when the endometrium becomes unstable (estrogen-breakthrough bleeding) and continues until estrogen-induced repair takes place [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Episodes of amenorrhea may be followed by sudden and substantial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of irregular menses must be excluded before a diagnosis of DUB can be made. In girls in whom a diagnosis of DUB is considered, additional evaluation may include FSH, LH, thyroid-stimulating hormone (TSH), and prolactin on day three of the menstrual cycle (by convention, the first day of menses is day one of the cycle, even in girls with irregular cycles). Although the concentrations of LH and FSH vary throughout the cycle (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ), they are most reproducible on day three, when they are at their lowest concentrations. If day three happens to fall on a weekend, the blood may be drawn on day four or five. Free and total testosterone and dehydroepiandrosterone sulfate (DHEA sulfate) should be obtained if signs of hyperandrogenism are present (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Polycystic ovary syndrome'",
"    </a>",
"    below). If all pathologic causes are ruled out, and the patient is not bothered by irregular menses, DUB may be managed expectantly for the first few years after menarche.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polycystic ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is a common cause of abnormal bleeding in the adolescent with chronic anovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/19\">",
"     19",
"    </a>",
"    ]. The diagnosis of PCOS is based upon clinical and biochemical criteria. It should be pursued in all adolescents with obesity, menstrual irregularity, insulin resistance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of hyperandrogenism (hirsutism, acne, clitoromegaly) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/20\">",
"     20",
"    </a>",
"    ]. Because signs of hyperandrogenism are not invariably present, PCOS also should be considered in girls with prolonged menstrual irregularity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe DUB, even in the absence of hirsutism or acne. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If PCOS is a consideration, other causes of hyperandrogenism and other causes of irregular menses must be ruled out. These include congenital adrenal hyperplasia (CAH), tumors of the ovary or adrenal gland, Cushing syndrome, hyperprolactinemia, and thyroid dysfunction. The differential diagnosis and evaluation of hyperandrogenism in adolescents is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other hormonal causes of irregular bleeding in adolescents include hypothyroidism and hyperprolactinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/21\">",
"     21",
"    </a>",
"    ]. The causes of hyperprolactinemia are discussed separately but include pituitary tumors and certain medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/10/20645?source=see_link\">",
"     methyldopa",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychologic or exercise-induced stress and eating disorders with large weight loss may cause acute anovulation in adolescents. However, these disorders are typically associated with a hypoestrogenic state and amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, breakthrough bleeding related to bacterial or viral infections of the vulva, vagina, or cervix may give an adolescent the false impression that her menses are \"irregular\". (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Breakthrough bleeding'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MENORRHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menorrhagia is simply defined as heavy menstrual flow. The flow may be excessive in its duration (&gt;7 days) or its volume (&gt;80",
"    <span class=\"nowrap\">",
"     mL/cycle).",
"    </span>",
"    Unfortunately, neither patients nor clinicians can accurately estimate the amount of blood loss. Menorrhagia in the adolescent typically occurs at irregular intervals, indicating that it is anovulatory. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Irregular bleeding'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bleeding disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menorrhagia that occurs at regular intervals or at the onset of menses is often related to a bleeding diathesis and less commonly to systemic illness or structural lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. Inherited bleeding disorders should be considered in the differential diagnosis of all patients presenting with menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/28\">",
"     28",
"    </a>",
"    ]. In retrospective studies, the prevalence of bleeding disorders among adolescents hospitalized for menorrhagia ranges from 5 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/22,24-27\">",
"     22,24-27",
"    </a>",
"    ]. In one series of 59 adolescents who were hospitalized with acute menorrhagia and in whom genital tract pathology had been excluded, an underlying coagulopathy was present in approximately one-fifth overall, one-third of those requiring a transfusion, and one-half presenting at menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coagulation disorders among adolescents with menorrhagia include von Willebrand disease, idiopathic thrombocytopenic purpura, platelet dysfunction, and thrombocytopenia secondary to malignancy or treatment for malignancy (ie, chemotherapy or hematopoietic stem cell transplantation) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. Bleeding diathesis in adolescents also may be related to the use of medications such as anticoagulant or platelet inhibitors. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excessive bleeding should prompt an evaluation of hematologic status. The minimum laboratory evaluation should include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with platelets and examination of the peripheral blood smear and ferritin to detect anemia or thrombocytopenia",
"     </li>",
"     <li>",
"      Coagulation panel (activated partial thromboplastin time (aPTT) and prothrombin time (PT))",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider the diagnosis of a bleeding dyscrasia in adolescents who present with extremely heavy first menses, bleeding requiring blood transfusion, and patients with refractory menorrhagia and concomitant anemia. In such patients, the secondary evaluation also should include a von Willebrand panel (ie, plasma von Willebrand factor (VWF) antigen; plasma VWF activity (ristocetin cofactor activity); and factor VIII activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. It is important that the von Willebrand panel be obtained when the patient is not taking hormones, because exogenous estrogen may elevate VWF into the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, the panel should be obtained at the time of presentation or after exogenous estrogen has been discontinued for seven days. It is also important to obtain blood group typing since blood group O is associated with lower levels of VWF, and to consult with a hematologist if the levels are low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .) If a bleeding disorder is considered, consultation with a hematologist is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common causes of menorrhagia in adolescents include systemic illness, endocrine disorders, and structural lesions. Systemic illness may affect ovarian or liver function, causing abnormalities in ovulation or coagulation, respectively. Examples include diabetes mellitus, systemic lupus erythematosus, renal failure, malignancy, and myelodysplasia. Hypothyroidism and hyperthyroidism may cause heavy menses, as well as anovulatory cycles. Structural lesions that cause menorrhagia in adolescents include cervical polyps and uterine leiomyomas (fibroids). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Irregular bleeding'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adolescents with menorrhagia in whom a bleeding diathesis has been excluded, additional laboratory evaluation may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of serum TSH to exclude hypothyroidism",
"     </li>",
"     <li>",
"      Evaluation for chronic or systemic diseases as warranted by the history and physical examination",
"     </li>",
"     <li>",
"      Pelvic ultrasonography (if it has not already been performed) to exclude structural causes, such as fibroids, polyps, or ovarian tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BREAKTHROUGH BLEEDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exogenous hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous hormone administration (eg, hormonal contraception) is a common cause of abnormal uterine bleeding in adolescents. Breakthrough bleeding is a common side effect of oral contraceptives, depot",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , the contraceptive patch [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/30\">",
"     30",
"    </a>",
"    ], and the ring, implant, and intrauterine devices. Bleeding may occur if these medications are not taken as prescribed or as a side effect of these medications. Thus, it is important to ask detailed questions about how medicines are taken or used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H3#H3\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Breakthrough bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually active adolescents who have a history of acute vaginal bleeding unrelated to menses should be assessed for cervicitis related to sexually transmitted infections. This also applies for girls who have been sexually abused. The prevalence of C. trachomatis in women with AUB is underestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of breakthrough bleeding in adolescents include cervical polyps, ectropion (particularly in girls with cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11160/abstract/10\">",
"     10",
"    </a>",
"    ]), foreign bodies (retained tampons are most common among adolescents), trauma, and certain medications (eg, anticoagulants). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common causes of nonuterine genital tract bleeding in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"       \"Patient information: Absent or irregular periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"       \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of all adolescents with AUB should include exclusion of pregnancy, assessment of hemodynamic status (blood pressure, heart rate), and hemoglobin or hematocrit and platelet count to evaluate the presence of anemia or thrombocytopenia. The additional evaluation depends upon findings from the history and physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to amenorrhea is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anovulatory DUB accounts for the majority of irregular uterine bleeding in adolescents; however, other pathologic causes of bleeding must be excluded (",
"      <a class=\"graphic graphic_table graphicRef78931 \" href=\"UTD.htm?4/40/4748\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Obesity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of hyperandrogenism (eg, hirsutism, acne, clitoromegaly) in girls with AUB should prompt evaluation for PCOS. This typically includes total and free testosterone and DHEA sulfate; additional testing may be necessary to exclude other causes of hyperandrogenism (eg, prolactin, TSH, cortisol). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A progesterone challenge can be performed in girls with chronic anovulatory cycles to evaluate response to endogenous estrogen. In addition, progesterone or hormonal contraception is an important component in the management of prolonged anovulatory bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"       \"Management of abnormal uterine bleeding in adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bleeding disorders should be considered in all adolescents with AUB who present with extremely heavy first menses, bleeding requiring blood transfusion, and patients with refractory menorrhagia and concomitant anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"       \"Approach to the child with bleeding symptoms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sexually transmitted infections and pelvic inflammatory disease should be considered in all sexually active (or sexually abused) adolescents who complain of irregular, breakthrough, or postcoital bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27905338\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Robert Zurawin, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/1\">",
"      World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care 1986; 7:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/2\">",
"      Caufriez A. Menstrual disorders in adolescence: pathophysiology and treatment. Horm Res 1991; 36:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/3\">",
"      Deligeoroglou E, Tsimaris P, Deliveliotou A, et al. Menstrual disorders during adolescence. Pediatr Endocrinol Rev 2006; 3 Suppl 1:150.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/5\">",
"      Lemarchand-B&eacute;raud T, Zufferey MM, Reymond M, Rey I. Maturation of the hypothalamo-pituitary-ovarian axis in adolescent girls. J Clin Endocrinol Metab 1982; 54:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/6\">",
"      Hallberg L, H&ouml;gdahl AM, Nilsson L, Rybo G. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/7\">",
"      Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/8\">",
"      Southam AL, Richart RM. The prognosis for adolescents with menstrual abnormalities. Am J Obstet Gynecol 1966; 94:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/9\">",
"      Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993; 269:1823.",
"     </a>",
"    </li>",
"    <li>",
"     Gray SH, Emans SJ. Abnormal vaginal bleeding in the adolescent. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/11\">",
"      Gray SH, Emans SJ. Abnormal vaginal bleeding in adolescents. Pediatr Rev 2007; 28:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/12\">",
"      Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104:936.",
"     </a>",
"    </li>",
"    <li>",
"     Mitan LA, Slap GB. Dysfunctinal uterine bleeding. In: Adolescent Health Care: a Practical Guide, 4th ed, Neinstein L (Ed), Lippincott Williams &amp; Wilkins, Baltimore 2002. p.966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/14\">",
"      Slap GB. Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 2003; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/15\">",
"      American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, et al. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006; 118:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/16\">",
"      Lavin C. Dysfunctional uterine bleeding in adolescents. Curr Opin Pediatr 1996; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/17\">",
"      Mitan LA, Slap GB. Adolescent menstrual disorders. Update. Med Clin North Am 2000; 84:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/18\">",
"      Aksel S, Jones GS. Etiology and treatment of dysfunctional uterine bleeding. Obstet Gynecol 1974; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/19\">",
"      Bravender T, Emans SJ. Menstrual disorders. Dysfunctional uterine bleeding. Pediatr Clin North Am 1999; 46:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/20\">",
"      Pinola P, Lashen H, Bloigu A, et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod 2012; 27:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/21\">",
"      Minjarez DA. Abnormal bleeding in adolescents. Semin Reprod Med 2003; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/22\">",
"      Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol 1981; 139:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/23\">",
"      Bevan JA, Maloney KW, Hillery CA, et al. Bleeding disorders: A common cause of menorrhagia in adolescents. J Pediatr 2001; 138:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/24\">",
"      Smith YR, Quint EH, Hertzberg RB. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 1998; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/25\">",
"      Falcone T, Desjardins C, Bourque J, et al. Dysfunctional uterine bleeding in adolescents. J Reprod Med 1994; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/26\">",
"      Kanbur NO, Derman O, Kutluk T, G&uuml;rgey A. Coagulation disorders as the cause of menorrhagia in adolescents. Int J Adolesc Med Health 2004; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/27\">",
"      Oral E, Ca��da�� A, Gezer A, et al. Hematological abnormalities in adolescent menorrhagia. Arch Gynecol Obstet 2002; 266:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/28\">",
"      Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/29\">",
"      Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/30\">",
"      Greydanus DE, Patel DR, Rimsza ME. Contraception in the adolescent: an update. Pediatrics 2001; 107:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11160/abstract/31\">",
"      Toth M, Patton DL, Esquenazi B, et al. Association between Chlamydia trachomatis and abnormal uterine bleeding. Am J Reprod Immunol 2007; 57:361.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 114 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-F42F8ABDFE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11160=[""].join("\n");
var outline_f10_57_11160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IRREGULAR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MENORRHAGIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BREAKTHROUGH BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exogenous hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27905338\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/114\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/114|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 1\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/114|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/4/29773\" title=\"table 1\">",
"      Causes abnormal uterine bleeding teen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/12/30924\" title=\"table 2\">",
"      Causes genital bleeding by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/40/4748\" title=\"table 3\">",
"      Causes of anovulatory bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=related_link\">",
"      Definition and evaluation of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14937?source=related_link\">",
"      Evaluation of oligomenorrhea in adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=related_link\">",
"      Pregnancy in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_57_11161="Theophylline use in asthma";
var content_f10_57_11161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Theophylline use in asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Leslie Hendeles, Pharm D",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Miles Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/57/11161/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/57/11161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    to treat asthma has undergone several cycles of enthusiasm and unpopularity over the past 50 years. The dissemination of clinical practice guidelines that list theophylline as a \"not preferred\" alternative, the availability of newer agents, and concerns regarding the risk-benefit ratio of the drug have resulted in infrequent prescribing of theophylline. Nevertheless, its low cost offers an advantage over other long-term maintenance medications that are added to inhaled glucocorticoids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    and long-acting beta agonists.",
"   </p>",
"   <p>",
"    The indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in the treatment of asthma and recommendations for its safe use will be discussed here. Overviews of the treatment of acute and chronic asthma are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Therapeutic actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though traditionally classified as a bronchodilator, the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    to control chronic asthma appears disproportionately greater than is explainable by its modest degree of bronchodilator activity alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Theophylline has antiinflammatory, immunomodulatory, and bronchoprotective effects that potentially contribute to its efficacy as a prophylactic anti-asthma drug [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/7-14\">",
"     7-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    down-regulates inflammatory and immune cell function in vitro and in vivo in animals with airway inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In patients with allergic asthma, it attenuates the late phase increase in airway obstruction and airway responsiveness to histamine, decreases allergen-induced migration of activated eosinophils into the bronchial mucosa, and decreases the sputum eosinophil count [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/8,9,17\">",
"     8,9,17",
"    </a>",
"    ]. Moreover, withdrawal of theophylline from patients with severe chronic asthma receiving high-doses of inhaled glucocorticoid therapy results in increased symptoms of asthma accompanied by an increase in the number of activated cytotoxic T-lymphocytes in the bronchial mucosa and an increase in helper T-lymphocytes in the airway epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/7\">",
"     7",
"    </a>",
"    ]. The reduction in nocturnal worsening of lung function when theophylline is used is associated with both a decrease in the percentage of neutrophils and a decrease in stimulated leukotriene B4 from macrophages in early morning bronchoalveolar lavage fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/18\">",
"     18",
"    </a>",
"    ]. An in depth review of in vitro and in vivo studies demonstrating the immunomodulatory, anti-inflammatory, and glucocorticoid-sparing effects of theophylline has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although several molecular mechanisms have been proposed to explain the actions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , the non-specific inhibition of phosphodiesterase that occurs at clinically relevant drug concentrations appears to be the most important. Theophylline increases the intracellular concentration of cyclic nucleotides in airway smooth muscle and inflammatory cells by inhibiting phosphodiesterase-mediated hydrolysis. However, inhibition of specific isozymes may also be important; inhibition of phosphodiesterase type III and type IV relaxes smooth muscles in pulmonary arteries and in airways [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/20\">",
"     20",
"    </a>",
"    ], while antiinflammatory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunomodulatory actions probably result from inhibition of the type IV isozymes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/16\">",
"     16",
"    </a>",
"    ]. This information has stimulated interest in investigating more specific inhibitors of phosphodiesterase type IV for asthma therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Theophylline also increases histone deacetylase-2 activity, which may increase glucocorticoid responsiveness in patients with glucocorticoid-resistant severe asthma and in patients with asthma who are cigarette smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four clinical circumstances for which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additive maintenance therapy in a patient whose asthma is not adequately controlled with conventional doses of inhaled glucocorticoids, or when addition of a long acting beta agonist either provides no benefit or actually causes worsening of control [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary maintenance therapy in a patient who is more likely to adhere to an oral than an inhaled regimen and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      is not sufficiently effective.",
"     </li>",
"     <li>",
"      Primary maintenance therapy when the administration of an inhaled glucocorticoid is difficult or cumbersome (eg, toddlers and preschool-age children) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      is not effective.",
"     </li>",
"     <li>",
"      Additive acute therapy in the intensive care unit for patients failing to respond to vigorous use of inhaled beta2-selective agonists in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intravenous magnesium and systemically administered glucocorticoids, although evidence for benefit in this situation is lacking. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Additive acute therapy for hospitalized patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Additive maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate and even high doses of inhaled glucocorticoids (inhaled GC or ICS) may provide inadequate control of moderate asthma, despite optimal compliance and technique [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/2,5,7,26-29\">",
"     2,5,7,26-29",
"    </a>",
"    ]. Moreover, high doses of inhaled GC may lead to the risk of systemic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized, double-blind, controlled trials confirm that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    results in better pulmonary function and symptom control than an increased dose of inhaled GC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/2,5,7,28\">",
"     2,5,7,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    .) Representative studies are reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study randomly assigned 62 patients to treatment with 800",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      or the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and 400",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of inhaled budesonide [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/28\">",
"       28",
"      </a>",
"      ]. The doses of theophylline administered were 250 mg or 375 mg, twice daily, for patients weighing &lt;80 kg or &ge;80 kg, respectively. The median serum concentration was 8.7",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      below the commonly-employed therapeutic range (10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL).",
"      </span>",
"      Combination therapy resulted in significantly greater forced expiratory flow in the first second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) and forced vital capacity (FVC), while there were no differences between the groups in terms of beta-agonist use or peak expiratory flow variability. Adverse events were similar in both treatment groups. The high dose budesonide group exhibited suppressed morning serum cortisol levels at the conclusion of the three month study period, but the clinical significance of this finding is unclear. The authors of this report also estimated that the monthly cost of the combination of low dose budesonide and theophylline was markedly lower than the cost of high dose budesonide or budesonide combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Target serum concentration'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Another trial administered placebo or slow-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      (titrated to maintain serum levels of 10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      for four weeks to 21 children with chronic asthma who were all receiving an average dose of inhaled chlorofluorocarbon (CFC)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      of 550",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      (approximately 13",
"      <span class=\"nowrap\">",
"       puffs/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/2\">",
"       2",
"      </a>",
"      ]. Compared with placebo, treatment with theophylline produced more symptom-free days (63 versus 42 percent) as well as significant improvements in spirometry and airway responsiveness to exercise. Placebo treatment resulted in twice the frequency of inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"       metaproterenol",
"      </a>",
"      use and three times the frequency of oral glucocorticoid use (",
"      <a class=\"graphic graphic_figure graphicRef65496 \" href=\"UTD.htm?9/3/9278\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A crossover study evaluated the consequences of discontinuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      in five adolescents with severe asthma treated with both inhaled and oral glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/5\">",
"       5",
"      </a>",
"      ]. There was a marked increase in symptoms, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose, and frequency of beta agonist use beginning within 48 hours of the substitution of placebo for theophylline (",
"      <a class=\"graphic graphic_figure graphicRef75636 \" href=\"UTD.htm?34/35/35390\">",
"       figure 2",
"      </a>",
"      ). Two subjects required intensive care admission during placebo treatment, and the Institutional Review Board therefore terminated the study early.",
"     </li>",
"     <li>",
"      Withdrawal of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      in a double blind fashion from 27 patients with severe chronic asthma, receiving an average dose of 1500",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      (36",
"      <span class=\"nowrap\">",
"       puffs/day)",
"      </span>",
"      of inhaled CFC",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/7\">",
"       7",
"      </a>",
"      ], resulted in a significant increase in asthma symptoms, particularly at night [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/7\">",
"       7",
"      </a>",
"      ]. Theophylline withdrawal was associated with a significant increase in asthma symptoms, particularly at night, and a fall in spirometry and morning peak flow. Withdrawal also resulted in an increase in the number of activated T-lymphocytes in the airway mucosa among the subset of patients who underwent transbronchial biopsy, suggesting that theophylline may have immunomodulatory properties (",
"      <a class=\"graphic graphic_figure graphicRef74336 \" href=\"UTD.htm?32/43/33469\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    to help control chronic asthma in these and other studies has been disproportionate to its relatively mild bronchodilator activity. For this reason, additional mechanisms of theophylline activity have been postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/31\">",
"     31",
"    </a>",
"    ], including antiinflammatory and immunomodulatory effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/7-9,19\">",
"     7-9,19",
"    </a>",
"    ] and decreases in airway reactivity to histamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. The former probably result from inhibition of type IV phosphodiesterase isozymes within inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Compared to other additive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies directly comparing the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    to the addition of other controller therapies (anti-leukotriene agents, long-acting beta-agonists [LABAs]) in patients receiving inhaled GC therapy. Anti-leukotriene agents and theophylline have the \"real-world\" advantage of being orally administered rather than inhaled. Many patients find an oral agent simpler to administer than an additional metered dose inhaler, and compliance is greater, on average, with an oral medication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, only inhaled LABAs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    , have been demonstrated to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in head-to-head studies, although the difference is small, and there are concerns about the safety of LABAs in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/25,33,34\">",
"     25,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double blind, double dummy, parallel group study treated 189 patients with moderate-to-severe asthma with four weeks of either slow-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      (dosed twice daily to a serum level of 10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      or inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      (50 mcg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/34\">",
"       34",
"      </a>",
"      ]. The number of symptom-free nights was significantly greater in the salmeterol group (71 versus 46 percent) although there were no significant differences in daytime symptoms or peak expiratory flow rate (PEFR). Theophylline caused more gastrointestinal symptoms.",
"     </li>",
"     <li>",
"      The differences between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , at therapeutic serum concentrations, and anti-leukotriene agents as additive therapies with inhaled GC, have not been adequately studied. The first head-to-head report found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      to have therapeutic advantages, although the study had important methodologic problems [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/35\">",
"       35",
"      </a>",
"      ]. Furthermore, this result would not be predicted by the relatively greater magnitude of clinical benefit reported from theophylline, when the two agents were studied separately as add-on therapy with inhaled GC [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/5,7,36\">",
"       5,7,36",
"      </a>",
"      ]. In a subsequent randomized, placebo-controlled parallel trial in 489 adults, neither the addition of low-dose theophylline nor montelukast lowered the event rate in patients with poor asthma control taking inhaled GC [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/37\">",
"       37",
"      </a>",
"      ]. In contrast, in patients not taking inhaled GC, theophylline improved asthma symptoms significantly more than montelukast or placebo. Transient gastrointestinal side effects were more frequent with theophylline. The dose of theophylline in this study was only 300 mg of a 12-hour slow-release formulation daily. Therefore, it is not surprising that added benefit was not observed in patients already taking inhaled GC.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      is probably more effective than cromolyn or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      , because unlike theophylline, neither of the chromones has been conclusively shown to provide additional benefit when added to therapy with inhaled GC [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/38-43\">",
"       38-43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Additive maintenance therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link&amp;anchor=H9#H9\">",
"       \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Clinical use'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    may be useful to replace a long-acting beta agonist (LABA) added to an inhaled GC when actual worsening of asthma control occurs from apparent loss of bronchoprotective effect, presumably from down regulation of beta2 adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary maintenance therapy when oral agents are preferred",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled GC are the most effective long-term maintenance medications for chronic asthma, but their inherent efficacy matters little if patients do not take them consistently enough to receive benefit. A once or twice daily slow-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    regimen may produce better health outcomes in certain patients through improved adherence. &nbsp;Theophylline, as slow release beads sprinkled on soft food, can be tried for young children, in whom administration of inhaled glucocorticoids is difficult.",
"   </p>",
"   <p>",
"    Several reports indicate that patients adhere poorly to regimens of inhaled maintenance medications.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    appears to cause less difficulty with compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/32,44\">",
"     32,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study determined adherence to prescribed maintenance therapy among 119 adults and children with asthma in a Health Maintenance Organization in Minneapolis by comparing pharmacy reimbursement claims data and the chart notation of prescribed therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients were on average approximately 50 percent adherent with inhaled glucocorticoid or cromolyn regimens but 79 percent adherent with slow-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      . Adherence with inhaled maintenance medications was particularly low among adolescents (",
"      <a class=\"graphic graphic_figure graphicRef62344 \" href=\"UTD.htm?27/45/28381\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Adherence rates appear to be comparably poor with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      and inhaled GC. In one study, the respective adherence rates were 59 and 56 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anecdotally, we have improved adherence in some patients with moderately severe asthma by treating them with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    and slow-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , each given once daily, instead of twice-a-day inhaled GC regimens. In patients whose asthma is not well-controlled, it is advisable to examine prescription refills by calling the patient's pharmacist as a means of assessing compliance before recommending additional maintenance medication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toddlers and preschool children represent another group in which oral therapy may be advantageous. Inhaled glucocorticoids are the preferred controller medication for children younger than five years with persistent asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/46\">",
"     46",
"    </a>",
"    ]. Inhaled GCs can be administered to young children through a chamber, fitted with a soft mask for the youngest ones. However, many infants and toddlers are uncooperative, making the twice daily administration of medication difficult and the amount of drug delivered to the lungs unreliable.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    has been approved as a nebulizer solution in the United States, but data on long term safety, efficacy, and adherence are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the administration of slow-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    is a more convenient and considerably less expensive alternative to these medications; the drug may be given by sprinkling medication beads on a spoonful of food twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in children with mild chronic asthma has been demonstrated in multiple studies to be at least as great as cromolyn [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/1,49,50\">",
"     1,49,50",
"    </a>",
"    ], and one randomized crossover trial of cromolyn and theophylline in 28 children with more severe chronic asthma found that patients had significantly more symptom-free days while on theophylline (71 versus 59 percent) without significant differences in side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Additive acute therapy for hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, limited benefit is derived by adding intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , in the form of theophylline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    (theophylline with ethylenediamine in an",
"    <span class=\"nowrap\">",
"     80-85/15-20",
"    </span>",
"    percent ratio), to intensely administered inhaled beta agonists and systemic glucocorticoids for patients hospitalized with an acute asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/46\">",
"     46",
"    </a>",
"    ]. More detailed discussions of the use of theophylline in the management of acute exacerbations of asthma in adults and children are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Methylxanthines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute asthma exacerbations in children: Inpatient management\", section on 'Methylxanthines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dosing of IV theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are on chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and unable to take oral medication during an acute exacerbation, the serum level should be assessed and intravenous theophylline administered at a maintenance infusion rate, adjusted if needed to achieve a peak serum concentration of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Additional information about maintenance dosing of intravenous theophylline is provided separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     \"Theophylline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients not previously receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , a single intravenous loading dose of theophylline, 4.6 to 7.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    will provide a peak serum theophylline concentration of about 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and may be justified for patients with severe acute symptoms that do not respond rapidly to routine measures. There is minimal risk for serious toxicity with such a dose, and a maintenance infusion may then be initiated if obvious clinical improvement results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/51\">",
"     51",
"    </a>",
"    ]. Choice of a maintenance infusion rate depends on factors such as age, smoking status, and concomitant medical problems that may alter theophylline clearance. Measurement of serum concentrations is performed one half life after initiation of continuous infusion and then every 12 to 24 hours. Additional information about intravenous administration of theophylline is provided separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     \"Theophylline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SAFE USE OF THEOPHYLLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    has a narrow therapeutic index and wide interpatient variability in clearance. As a result, dosing must be individually titrated to appropriate steady-state serum concentrations in order to achieve maximal benefit and safety. This requires skill and knowledge on the part of the clinician and an ability of patients or parents to follow instructions properly. Failure to adequately monitor theophylline use can lead to potentially fatal drug intoxication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"     \"Theophylline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is well tolerated and there is little risk of serious toxicity when the drug is administered properly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/52\">",
"     52",
"    </a>",
"    ]. As an example, one epidemiologic investigation of 36,000 ambulatory patients who received 225,000 prescriptions for theophylline over a nine year period found that the risk of hospital admission due to complications of chronic theophylline use was less than 1 per 1000 patient-years of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that must be considered to maximize the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    include proper target serum concentration, appropriate dosage titration, the presence of conditions or factors that affect theophylline metabolism, and proper product and dosing interval selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Target serum concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    are closely related to the PEAK serum concentration. In patients receiving theophylline monotherapy, doses providing a PEAK serum concentration of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    <span class=\"nowrap\">",
"     (mcg/mL)",
"    </span>",
"    are best documented to improve symptoms and reduce the need for rescue therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. However, bronchodilatory, antiinflammatory, and immunomodulatory effects of this drug are detectable at levels as low as 5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/7,9,56\">",
"     7,9,56",
"    </a>",
"    ]; in addition, serum concentrations of 5 to 10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    may be adequate for some patients, particularly if they are also receiving inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend titrating dosage to a PEAK concentration of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    formulation and dosing interval that will not result in large fluctuations between the peak and trough levels. A widely quoted guideline recommends a target serum concentration of 5 to 15",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    but does not specify whether this should be a peak or trough level [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/46\">",
"     46",
"    </a>",
"    ]. Such a distinction is important because fluctuations in serum concentration can be sufficient for a trough concentration in the 5 to 15",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    range to result in a peak above 20",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and consequent toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initiating and titrating oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    for maintenance therapy, the initial dose should be sufficiently low to avoid transient caffeine-like side effects such as insomnia and irritability. In non-smoking adults without risk factors for reduced theophylline clearance, a starting dose of 10 mg per kg of body weight per day (up to 300 mg for the initial dose) is appropriate in most cases. In obese patients, ideal body weight is used in this calculation. A sustained release product should be used from the beginning.",
"   </p>",
"   <p>",
"    The dose is then increased, at intervals of three days or more, until the average dose requirements for age are approached (",
"    <a class=\"graphic graphic_table graphicRef53731 \" href=\"UTD.htm?37/55/38780\">",
"     table 1",
"    </a>",
"    ). If a particular dose increase produces unacceptable side effects, the dose should be reduced to that which had been previously tolerated. A single serum concentration measurement is then obtained at the highest tolerated dose, and the final dose is adjusted accordingly (",
"    <a class=\"graphic graphic_table graphicRef53731 \" href=\"UTD.htm?37/55/38780\">",
"     table 1",
"    </a>",
"    ). Fewer than 3 percent of children and 10 percent of adults experience intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    at peak serum concentrations less than 20",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    if a slow titration schedule is used, such as the one listed in the table (",
"    <a class=\"graphic graphic_table graphicRef53731 \" href=\"UTD.htm?37/55/38780\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with risk factors for reduced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    clearance or in whom the serum concentration cannot be measured in a timely fashion, the maximum daily dose should not exceed 10 mg per",
"    <span class=\"nowrap\">",
"     kg/day",
"    </span>",
"    or 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/58\">",
"     58",
"    </a>",
"    ]. In infants six weeks to six months of age, the initial daily dose in",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    can be calculated from the following formula: (0.2 x age in weeks) + 5. Increases beyond the initial dose should be based upon serum theophylline concentration.",
"   </p>",
"   <p>",
"    Generally only one, and uncommonly two, serum concentration measurements are required to achieve a therapeutic peak concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/52\">",
"     52",
"    </a>",
"    ]. The initial measurement is made at the end of the dose titration schedule (",
"    <a class=\"graphic graphic_table graphicRef53731 \" href=\"UTD.htm?37/55/38780\">",
"     table 1",
"    </a>",
"    ). To properly measure the peak concentration, a blood sample should be obtained 3 to 7 hours after a morning dose of preparations indicated for twice-daily administration, or 8 to 12 hours after preparations with sufficiently slow absorption to permit once daily administration (",
"    <a class=\"graphic graphic_table graphicRef75856 \" href=\"UTD.htm?40/5/41051\">",
"     table 2",
"    </a>",
"    ). In the absence of intercurrent illness associated with sustained fever or drug interactions, serum concentrations can be expected to remain relatively stable, and repeat measurement in six months for rapidly growing children or one year in other patients is generally sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Factors affecting metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is metabolized predominately in the liver by the enzyme cytochrome P450 1A2, and to a lesser extent by P450 3A3 and P450 2E1 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/58\">",
"     58",
"    </a>",
"    ]. Genetic factors, concurrent diseases, environmental agents, and other drugs that alter the activity of these isozymes affect the metabolism of theophylline. When the rate of theophylline metabolism is reduced, the total daily dose must be appropriately decreased to prevent excessive accumulation and toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are risk factors for reduced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    clearance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age less than 1 or greater than 60.",
"     </li>",
"     <li>",
"      Concurrent diseases such as acute pulmonary edema, heart failure, cor pulmonale, fever above 38.9&ordm;C (102&ordm;F) for more than 24 hours, hypothyroidism, liver disease, reduced renal function in infants less than three months of age, and sepsis with multiorgan failure.",
"     </li>",
"     <li>",
"      Recent smoking cessation.",
"     </li>",
"     <li>",
"      Pregnancy, particularly during the third trimester. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=see_link\">",
"       \"Management of asthma during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Addition of a drug that inhibits",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      metabolism (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , tacrine) or discontinuation of a concurrently administered drug that enhances theophylline metabolism (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef65611 graphicRef78641 \" href=\"UTD.htm?27/56/28558\">",
"       table 3A-B",
"      </a>",
"      ). Common drugs that do NOT interact with theophylline are also shown (",
"      <a class=\"graphic graphic_table graphicRef66236 \" href=\"UTD.htm?10/27/10685\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians can obtain mean values for half-life and total body clearance for the above factors from the tables, which contain the revised FDA labeling guideline for oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    dosage forms (",
"    <a class=\"graphic graphic_table graphicRef65611 graphicRef78641 \" href=\"UTD.htm?27/56/28558\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Selection of product and dosing interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow-release formulations allow a longer dosing interval than rapid release formulations but vary in their rates and completeness of absorption (",
"    <a class=\"graphic graphic_table graphicRef75856 \" href=\"UTD.htm?40/5/41051\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food caused a precipitous increase in the rate of absorption and peak concentration with the formulation marketed as Theo-24 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/59\">",
"       59",
"      </a>",
"      ], whereas taking the formulation identified as Uniphyl on an empty stomach resulted in a marked decrease in absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/60\">",
"       60",
"      </a>",
"      ]. Only products that are completely and consistently absorbed should be selected. We prefer either United States Federal Drug Administration (FDA) AB-rated generic slow-release tablets or capsules for twice daily dosing, or Uniphyl taken with an evening meal for once daily dosing.",
"     </li>",
"     <li>",
"      Capsule formulations are particularly advantageous for preschool-age children because the capsules can be opened and the beads sprinkled on a teaspoonful of food every 12 hours without affecting pharmacokinetics [",
"      <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with primarily nocturnal symptoms, described strategies have included two-thirds of the total daily dose given in the evening and one-third in the morning, or a single dose given in the evening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The difference between the peak and trough serum concentrations is a function of the rate of absorption of the product, the dosing interval selected by the clinician, and the rate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    metabolism by the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/61\">",
"     61",
"    </a>",
"    ]. In patients with rapid metabolism, such as children, even a formulation as slowly absorbed as Uniphyl is likely to result in a large difference between the peak and trough, whereas administration of the Uniphyl formulation once-nightly in patients with slower metabolism, as in many adults, may provide acceptable fluctuations between the peak and trough concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/57/11161/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial titration of the dose, we suggest checking the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    serum concentration at the estimated peak every 12 months, unless a change in concomitant medications or health status (eg, pregnancy, symptoms of toxicity) dictates a shorter interval. The peak serum concentration varies somewhat with the preparation used, but 4 to 8 hours after a dose is a reasonable estimate for most 12 hour preparations. Products with a claim for 24 hour dosing, taken in the evening, will probably have a peak in the morning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      has bronchodilatory, antiinflammatory, immunomodulating, and bronchoprotective effects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Therapeutic actions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      remains a useful and inexpensive medication for patients with chronic asthma whose symptoms are not controlled with conventional doses of inhaled glucocorticoids, and patients who cannot take or are poorly compliant with inhaled medications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      to inhaled glucocorticoids is more effective than increasing the dose of inhaled glucocorticoids. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Additive maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       Salmeterol",
"      </a>",
"      is more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      when added to inhaled glucocorticoids, although the differences are not large. More studies are needed to evaluate the relative efficacy of therapeutic concentrations of theophylline and anti-leukotriene agents as add-on therapies. In patients in whom the addition of a long-acting beta agonist (LABA) to high dose inhaled glucocorticoid does not seem effective, a trial of substituting theophylline for the LABA may be worthwhile. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Compared to other additive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      is not routinely indicated for the treatment of acute severe asthma in the intensive care unit. Intravenous theophylline (as theophylline or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      ) may be added when patients with severe acute asthma fail to respond to vigorous use of inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      with systemic glucocorticoids, although evidence for this is lacking. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Additive acute therapy for hospitalized patients'",
"      </a>",
"      above and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       \"Theophylline: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Safe use of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      as a maintenance therapy requires initiating treatment at a low dose, measuring a serum concentration to adjust the dose, and reducing the dose in the presence of physiologic states or medications that impair theophylline metabolism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Safe use of theophylline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The absorption characteristics of specific formulations vary considerably, particularly with regards to the effects of food. Familiarity with these details is important. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Selection of product and dosing interval'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/1\">",
"      Hambleton G, Weinberger M, Taylor J, et al. Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study. Lancet 1977; 1:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/2\">",
"      Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981; 304:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/3\">",
"      Dusdieker L, Green M, Smith GD, et al. Comparison of orally administered metaproterenol and theophylline in the control of chronic asthma. J Pediatr 1982; 101:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/4\">",
"      Joad JP, Ahrens RC, Lindgren SD, Weinberger MM. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol 1987; 79:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/5\">",
"      Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/6\">",
"      Rivington RN, Boulet LP, C&ocirc;t&eacute; J, et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995; 151:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/7\">",
"      Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/8\">",
"      Hendeles L, Harman E, Huang D, et al. Theophylline attenuation of airway responses to allergen: comparison with cromolyn metered-dose inhaler. J Allergy Clin Immunol 1995; 95:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/9\">",
"      Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/10\">",
"      Magnussen H, Reuss G, J&ouml;rres R. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987; 136:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/11\">",
"      Koenig JQ, Dumler K, Rebolledo V, et al. Theophylline mitigates the bronchoconstrictor effects of sulfur dioxide in subjects with asthma. J Allergy Clin Immunol 1992; 89:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/12\">",
"      Fabbri LM, Alessandri MV, De Marzo N, et al. Long-lasting protective effect of slow-release theophylline on asthma induced by ultrasonically nebulized distilled water. Ann Allergy 1986; 56:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/13\">",
"      Pollock J, Kiechel F, Cooper D, Weinberger M. Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn. Pediatrics 1977; 60:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/14\">",
"      Chorostowska-Wynimko J, Kus J, Skopi��ska-R&oacute;zewska E. Theophylline inhibits free oxygen radicals production by human monocytes via phosphodiesterase inhibition. J Physiol Pharmacol 2007; 58 Suppl 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/15\">",
"      Scordamaglia A, Ciprandi G, Ruffoni S, et al. Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunopathol 1988; 48:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/16\">",
"      Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am J Respir Crit Care Med 1995; 151:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/17\">",
"      Horiguchi T, Tachikawa S, Kasahara J, et al. Suppression of airway inflammation by theophylline in adult bronchial asthma. Respiration 1999; 66:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/18\">",
"      Kraft M, Torvik JA, Trudeau JB, et al. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996; 97:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/19\">",
"      Markham A, Faulds D. Theophylline. A review of its potential steroid sparing effects in asthma. Drugs 1998; 56:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/20\">",
"      Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/21\">",
"      Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/22\">",
"      Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/23\">",
"      Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     Barnes PJ. Theophylline and phosphodiesterase inhibitors. In: Middleton's Allergy: Principles and Practice, 6th Ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St Louis, MO 2003. p.823.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/25\">",
"      Weinberger M, Abu-Hasan M. Life-threatening asthma during treatment with salmeterol. N Engl J Med 2006; 355:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/26\">",
"      Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen &amp; Hanburys Limited UK Study Group. Lancet 1994; 344:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/27\">",
"      Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/28\">",
"      Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/29\">",
"      Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009; 33:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/30\">",
"      Derom E, Van Schoor J, Verhaeghe W, et al. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999; 160:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/31\">",
"      Vassallo R, Lipsky JJ. Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998; 73:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/32\">",
"      Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/33\">",
"      Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 1998; 92:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/34\">",
"      Paggiaro PL, Giannini D, Di Franco A, Testi R. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Eur Respir J 1996; 9:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/35\">",
"      Shah AR, Sharples LD, Solanki RN, Shah KV. Double-blind, randomised, controlled trial assessing controller medications in asthma. Respiration 2006; 73:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/36\">",
"      Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/37\">",
"      American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/38\">",
"      Toogood JH, Jennings B, Lefcoe NM. A clinical trial of combined cromolyn/beclomethasone treatment for chronic asthma. J Allergy Clin Immunol 1981; 67:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/39\">",
"      Hiller EJ, Milner AD. Betamethasone 17 valerate aerosol and disodium chromoglycate in severe childhood asthma. Br J Dis Chest 1975; 69:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/40\">",
"      Dawood AG, Hendry AT, Walker SR. The combined use of betamethasone valerate and sodium cromoglycate in the treatment of asthma. Clin Allergy 1977; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/41\">",
"      Svendsen UG, J&oslash;rgensen H. Inhaled nedocromil sodium as additional treatment to high dose inhaled corticosteroids in the management of bronchial asthma. Eur Respir J 1991; 4:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/42\">",
"      O'Hickey SP, Rees PJ. High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma. Respir Med 1994; 88:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/43\">",
"      Wong CS, Cooper S, Britton JR, Tattersfield AE. Steroid sparing effect of nedocromil sodium in asthmatic patients on high doses of inhaled steroids. Clin Exp Allergy 1993; 23:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/44\">",
"      Sherman J, Hutson A, Baumstein S, Hendeles L. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions. J Pediatr 2000; 136:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/45\">",
"      Kelloway JS, Wyatt R, DeMarco J, Adlis S. Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids. Ann Allergy Asthma Immunol 2000; 84:324.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/47\">",
"      Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/48\">",
"      Sallent J, Hill M, Stecenko A, et al. Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline. Pediatrics 1988; 81:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/49\">",
"      Newth CJ, Newth CV, Turner JA. Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. Aust N Z J Med 1982; 12:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/50\">",
"      Furukawa CT, Shapiro GG, Bierman CW, et al. A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma. Pediatrics 1984; 74:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/51\">",
"      Hendeles L, Weinberger M, Bighley L. Disposition of theophylline after a single intravenous infusion of aminophylline. Am Rev Respir Dis 1978; 118:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/52\">",
"      Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr 1986; 109:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/53\">",
"      Derby LE, Jick SS, Langlois JC, et al. Hospital admission for xanthine toxicity. Pharmacotherapy 1990; 10:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/54\">",
"      Weinberger MM, Bronsky EA. Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children. J Pediatr 1974; 84:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/55\">",
"      Neijens HJ, Duiverman EJ, Graatsma BH, Kerrebijn KF. Clinical and bronchodilating efficacy of controlled-release theophylline as a function of its serum concentrations in preschool children. J Pediatr 1985; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/56\">",
"      Jenne JW. Reassessing the therapeutic range for theophylline on laboratory report forms: another viewpoint. Pharmacotherapy 1993; 13:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/57\">",
"      Weinberger MM. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24. Pharmacotherapy 1984; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/58\">",
"      Hendeles L, Jenkins J, Temple R. Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy 1995; 15:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/59\">",
"      Hendeles, L, Weinberger, M, Milavetz, G, et al. Food-induced dumping from a \"once-a-day\" theophylline product as a cause of theophylline toxicity. Chest 1985; 87:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/60\">",
"      Milavetz G, Vaughan LM, Weinberger MM, et al. Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing. J Allergy Clin Immunol 1987; 80:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/57/11161/abstract/61\">",
"      Weinberger M, Hendeles L, Wong L. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma. J Pediatr 1981; 99:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 560 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11161=[""].join("\n");
var outline_f10_57_11161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Therapeutic actions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Additive maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Compared to other additive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary maintenance therapy when oral agents are preferred",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Additive acute therapy for hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dosing of IV theophylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SAFE USE OF THEOPHYLLINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Target serum concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initiating and titrating oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Factors affecting metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Selection of product and dosing interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/560|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/3/9278\" title=\"figure 1\">",
"      Theophylline to treat asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/35/35390\" title=\"figure 2\">",
"      Withdraw theophylline in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/43/33469\" title=\"figure 3\">",
"      Effect theophylline withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/45/28381\" title=\"figure 4\">",
"      Adherence to asthma meds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/55/38780\" title=\"table 1\">",
"      Theophylline guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/5/41051\" title=\"table 2\">",
"      Characteristics of theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/38/8813\" title=\"table 3A\">",
"      Drugs interact theophylline I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/23/29053\" title=\"table 3B\">",
"      Drugs interact theophylline II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/27/10685\" title=\"table 4\">",
"      No interaction theophylline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=related_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=related_link\">",
"      Theophylline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_57_11162="Resectoscope parts";
var content_f10_57_11162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69544%7EOBGYN%2F50056%7EOBGYN%2F62804%7EOBGYN%2F75612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69544%7EOBGYN%2F50056%7EOBGYN%2F62804%7EOBGYN%2F75612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: Resectoscope parts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: Resectoscope assembly 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: Resectoscope assembly 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: Resectoscope assembly 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11162=[""].join("\n");
var outline_f10_57_11162=null;
var title_f10_57_11163="Liver test normal pregnancy";
var content_f10_57_11163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Liver tests in normal pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Liver tests affected by pregnancy (these tests are increased or decreased in relation to values in non-pregnant women)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Albuminemia (decreased from the first trimester)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Alkaline phophatase levels (increased in second and third trimester",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bilirubin levels (slightly decreased from the first trimester)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gamma glutamyltransferase levels (slightly decreased in late pregnancy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Liver tests not affected by pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Serum aminotransferase levels (ALT, AST)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prothrombin time",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Serum concentration of total bile acids (fasting state)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11163=[""].join("\n");
var outline_f10_57_11163=null;
var title_f10_57_11164="Abx for meningitis based on Gram stain";
var content_f10_57_11164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for antimicrobial therapy of bacterial meningitis in adults with presumptive pathogen identification by positive Gram stain*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microorganism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternative therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Vancomycin plus a third-generation cephalosporin&bull;&Delta;",
"       </td>",
"       <td>",
"        Fluoroquinolone&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        Third-generation cephalosporin&bull;",
"       </td>",
"       <td>",
"        Chloramphenicol, fluoroquinolone, aztreonam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Ampicillin&sect; or penicillin G&sect;",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"       </td>",
"       <td>",
"        Third-generation cephalosporin&bull;",
"       </td>",
"       <td>",
"        Chloramphenicol, cefepime, meropenem, fluoroquinolone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For recommended dosages, see the table \"Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis\".",
"     <br>",
"      &bull; Ceftriaxone or cefotaxime.",
"      <br>",
"       &Delta; Some experts would add rifampin if dexamethasone is also given.",
"       <br>",
"        &loz; Moxifloxacin is recommended given its excellent CSF penetration and in vitro activity against",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        , although there are no clinical data available. If used, many authorities would combine moxifloxacin with vancomycin or a third-generation cephalosporin (cefotaxime or ceftriaxone).",
"        <br>",
"         &sect; Addition of an aminoglycoside should be considered.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel, AR, Hartman, BJ, Kaplan, SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy;2004 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11164=[""].join("\n");
var outline_f10_57_11164=null;
var title_f10_57_11165="Stages of change";
var content_f10_57_11165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the stages of change",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patient response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Coping tasks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Counseling tasks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Resources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Precontemplation",
"       </td>",
"       <td>",
"        Surprise, ignorance, demoralization",
"       </td>",
"       <td>",
"        Learn, develop awareness",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Give feedback",
"        </p>",
"        <p>",
"         Give advice",
"        </p>",
"        <p>",
"         Inform",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Information media",
"        </p>",
"        <p>",
"         Questionnaires",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Contemplation",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Ambivalence",
"        </p>",
"        <p>",
"         Tells reasons for concern and rationalization for unconcern",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Emotional arousal",
"        </p>",
"        <p>",
"         Self-reevaluation",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Accept ambivalence",
"        </p>",
"        <p>",
"         Avoid argument",
"        </p>",
"        <p>",
"         Develop discrepancy",
"        </p>",
"        <p>",
"         Roll with resistance",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Decision balance",
"        </p>",
"        <p>",
"         Feedback logs",
"        </p>",
"        <p>",
"         Role models",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Preparation",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         I must change",
"        </p>",
"        <p>",
"         I can do it",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Commitment",
"        </p>",
"        <p>",
"         Go public",
"        </p>",
"        <p>",
"         Confidence",
"        </p>",
"        <p>",
"         Design plan",
"        </p>",
"        <p>",
"         Pick date",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Support self-efficacy",
"        </p>",
"        <p>",
"         Design plan",
"        </p>",
"        <p>",
"         Social support",
"        </p>",
"        <p>",
"         Problem solve",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Menu of options",
"        </p>",
"        <p>",
"         Referral",
"        </p>",
"        <p>",
"         Role models",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Action",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         What do I do?",
"        </p>",
"        <p>",
"         Who can help?",
"        </p>",
"        <p>",
"         What problems might occur?",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Take steps to change",
"        </p>",
"        <p>",
"         Manage withdrawal",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Management of cues and consequence",
"        </p>",
"        <p>",
"         Use rewards",
"        </p>",
"       </td>",
"       <td>",
"        Management of withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Maintenance",
"       </td>",
"       <td>",
"        Satisfaction",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Manage cues and consequences",
"        </p>",
"        <p>",
"         Social support",
"        </p>",
"        <p>",
"         Be a role model",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Alert to danger signs and times",
"        </p>",
"        <p>",
"         Teach \"mind games\"",
"        </p>",
"       </td>",
"       <td>",
"        Role model for others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Relapse",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Experience loss of control",
"        </p>",
"        <p>",
"         Demoralization",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Learn antecedents of relapse, and relapse thinking",
"        </p>",
"        <p>",
"         Keep public",
"        </p>",
"        <p>",
"         Call for help",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Relapse is a learning experience",
"        </p>",
"        <p>",
"         Evoke self-efficacy",
"        </p>",
"       </td>",
"       <td>",
"        Same as above",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11165=[""].join("\n");
var outline_f10_57_11165=null;
var title_f10_57_11166="P wave before QRS II";
var content_f10_57_11166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    P wave in front of each QRS complex: P wave and QRS related",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * P wave morphology and PR interval variable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11166=[""].join("\n");
var outline_f10_57_11166=null;
var title_f10_57_11167="Barretts esophagus CPC Endosc";
var content_f10_57_11167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the distal esophagus showing multiple extensions of salmon-colored mucosa above the esophagogastric junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven D. Freedman, MD, PhD and Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_57_11167=[""].join("\n");
var outline_f10_57_11167=null;
